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Brain tumors (BTs) generally have a bad prognosis despite conventional treatment
strategies. Immunotherapy is a relatively novel treatment approach that has shown
benefit for durable treatment of melanoma, and is a promising candidate for different
tumor types including BTs. Immunotherapeutic strategies work by exploiting and/or
enhancing natural anti-tumor immune response, a process that is critically dependent
on adaptive immunity, T cell infiltration and surveillance of tumor. However, little is
known about the dynamics and regulation of T cell surveillance in BTs. Resident
immune cells of the myeloid lineage known as microglia are ubiquitous in the brain
parenchyma while tissue-resident myeloid dendritic cells (DCs) known to activate T
cells are relatively rare in the brain compared to DCs in other organs. Accumulating
evidence indicates that myeloid cells infiltrate and create an immune suppressive
microenvironment in BTs, but the identity of these myeloid cells and their role in the
adaptive immune surveillance of BTs by T cells is unclear. Based on the predominance
of microglia in the brain tissue, studies focused on understanding how BT immune
surveillance is regulated, have been skewed toward microglia. Many conclusions
regarding microglia function have been deduced from in vitro experiments.
Nonetheless, in vivo studies in parallel models such as EAE indicate that DCs are
superior to microglia in antigen presentation to T cells in the brain and to date, there is
vii

no direct in vivo evidence to suggest otherwise. In addition, DCs are well-established
cellular regulators of T cell surveillance in extracranial tumors. Therefore, I
hypothesized that DCs, rather than microglia, play a major role in regulating T cell
surveillance in BTs. To address this hypothesis, I have developed experimental
imaging systems for longitudinal intravital multiphoton microscopy of immune cell
dynamics in BTs in living mice and used this approach to interrogate T cell behavior in
orthotopic glioma and in experimental intracranial metastases in vivo. I found that the
myeloid infiltration of BTs was dominated by CD11c+ DC cells rather than microglia.
Quantitative in situ tissue cell image cytometry further revealed that myeloid-derived
CCR2+ monocytes accumulated in the BT core, CD11c+ DCs at the tumor margin, and
CX3CR1+ microglia outside the tumor. T cells formed clusters around CD11c+ DCs,
but not the microglia. Within these clusters, T cells vigorously interacted directly with
CD11c+ DCs. CD11c+ DCs retained T cells and controlled their motility patterns,
indicating that CD11c+ DCs play a major role in regulating T cell retention and motility
in BT. Corresponding to the preferential distribution of CD11c+ DCs at BT margins was
expression of the neuronal chemokine Fractalkine (CX3CL1). Deficiency of the
Fractalkine receptor CX3CR1 resulted in decreased CD11c+ DC recruitment. In
addition, decreased CD11c+ DC recruitment was accompanied by decreased T cell
recruitment, an increase in the spatial diffusion of the few BT-infiltrating T cells, and
subsequent outgrowth of a fibrosarcoma BT, which spontaneously regresses in the
brain of control wild type mice in a CD8 T cell dependent manner.
In summary, by using novel intravital imaging systems for longitudinal
visualization of BT immune surveillance across several types of cancer, I showed that
the recruitment, migration and retention of tumor infiltrating T cells in the brain is
viii

mediated by incoming CD11c+ DCs rather than by the brain-resident CX3CR1
microglia, and identified the neuronal chemokine Fractalkine as a key molecule that
promotes T cell surveillance in BTs by recruiting CD11c+ DCs.
These findings suggest that the non-microglial tumor-associating CD11c+ myeloid
cells and the fractalkine/CX3CR1 chemokine pathway control T cell surveillance in BT
and represent attractive immunotherapeutic targets that could be modulated for guiding
endogenous or adoptive transfer of T cells to BT sites and for therapeutic modulation to
enhance immunity against BTs.
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CHAPTER 1:
BACKGROUND
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1.1. General Introduction
Mammalian tissues are under constant surveillance by the immune system1,2.
The primary function of the immune system is to protect organisms from environmental
pathogens such as bacteria or viruses that could prove fatal if left unchecked.
Generally, the immune system recognizes molecular aspects of pathogens and mounts
a rapid response in a two-layered manner to resist host organ invasion and damage. In
contrast, nonviral cancer is a more sinister pathological event as it involves intrinsic
mutational changes in an organism’s own cells that may be barely detectable by the
immune system during cancer initiation. These mutations trigger a cascade of events
including cellular transformation, immortalization, unabated proliferation, and a
diminished survival capacity of the host organism. Although cancer cell-intrinsic factors
play key roles in tumor development and progression, and cancerous cells were once
thought to be undetectable by the immune system3-24, it is now established that during
a natural anti-tumor immune response, immune cells are capable of detecting specific
peptide antigens in transformed cancer cells. In addition, immune cells play a major
role in both tumor progression and eradication, and have more recently been shown to
be attractive targets for cancer therapy24-34.
Cancer has been aptly described as “wounds that do not heal35.” This notion is
based on decades of research uncovering striking similarities between chronic wounds
and cancer. Importantly, both disease conditions are usually characterized by rich
immune cell infiltrates and abundant immune cell-derived molecular signals, and
epidemiological and mechanistic studies have linked chronic inflammation to cancer
progression, indicating a pro-tumorigenic effect of immune cell infiltrates36-42. However,
the significance of the immune system as a key antagonist of cancer growth has been
2

recognized due to better understanding of the immune system through finely-tuned
molecular mechanistic studies and immunotherapeutic applications43-45. More than a
decade ago, in a landmark review, Hanahan and Weinberg condensed the multitude of
research data elaborating the mechanistic underpinnings of the cellular and molecular
aspects of cancer progression into a handful of principles known as the “Hallmarks of
Cancer.” These hallmarks include self-sufficiency in growth signals, insensitivity to antigrowth

signals,

evading

apoptosis,

limitless

replicative

potential,

sustained

angiogenesis, and tissue invasion and metastasis46. This extensive review excluded
the role of the immune system because there was only weak mechanistic evidence
available to support the hypothesis of tumor immune surveillance proposed by Burnet
and Thomas in 1957. More recently, however, the inflammatory and immune evasive
properties of cancer have been included as part of cancer hallmarks based on
mounting evidence that the immune system can in fact detect and eliminate cancer
cells, and paradoxically also aid in cancer progression24,47,48. While each of the initially
prescribed hallmarks were viewed from a mostly cancer cell-intrinsic angle, myriad
studies have been extensively reviewed in the updated version of the “Hallmarks of
Cancer,” emphasizing that tumor immune infiltrates and immune-derived molecules
play either major or supporting roles in almost all of the initially described hallmarks of
cancer47,49-55.
A reinvigorated interest in the historically controversial field of cancer
immunology is due to a better understanding of molecular immunology and the
accepted role of immunotherapy in the care of the cancer patient.

56-60

Nonetheless, a

significant proportion of patients receiving immunotherapy do not respond. Therefore,
to increase the efficacy of immunotherapy, it is pertinent to answer key questions
3

pertaining to why some tumors elicit robust immune responses while others do not. For
example, it was hypothesized that differences in tumor neoantigenic load could explain
differences in response to immunotherapy in different tumor types, and advances are
already being made in understanding the impact of tumor mutational load and as a
consequence, neo-antigens in response to T cell immunotherapy61-64. It is also known
that immune cell compositions in different tissues are distinct in steady state and in
cancer progression65-67, and this may play a role in determining the extent to which an
adaptive T cell immune response to cancer works to eradicate cancer cells. A
deepening of our understanding on immune response to tumors in the context of the
complex biological milieu in which they might exist is essential for a better grasp of
immune surveillance in specific tumor types.
The brain is one such complex environment that presents a challenge for proper
understanding of an immune response to tumors because of its distinct anatomy and
immunological makeup. I will address brain tumors (BTs), the immunological
composition of the brain, its anatomical barriers (blood brain barrier and CNS
lymphatic), and the concept of brain immune privilege in different sections below. In this
thesis, I have sought to investigate the extent to which BTs are infiltrated by T cells, the
dynamics of potentially-infiltrated T cells in BTs, and the mechanisms by which T cell
surveillance in BT is regulated. A comprehensive understanding of the mechanisms
guiding T cell immune surveillance in BTs may reveal strategies that may be important
for the development of potent immunotherapy for BT treatment and may pave the way
for an organ-specific approach to immunotherapy application in cancer.

4

1.2. A brief historical perspective on brain tumor immunology research:
Brain tumors constitute one of the most deadly types of cancer. Relative to other
tumor types, BTs are one of the less well-understood in the context of tumor
immunology. On the basis of research conducted by Medawar more than half a century
ago, the brain was claimed to be an immune privileged site68,69. About the same time,
the inability to identify classical lymphatic vessels in the brain, which were known to be
present in other mammalian tissues and organs and critical for immune cell trafficking,
lent credence to the notion of brain immune privilege. Subsequent studies conducted a
few decades after Medawar’s findings revealed no role for the immune system in
controlling BTs in athymic immune-deficient nude mice and further bolstered the idea of
brain immune privilege70,71. These findings led to the erroneous conclusion that the
brain is shielded from surveillance by adaptive immune cells such as T cells, and likely
has impeded progress in understanding the mechanisms of T cell surveillance of BTs.
However, the idea of an immune-privileged brain was first challenged in observational
studies showing the presence of dural lymphatic-like vessels and subsequent findings
in which fluorescent tracers injected directly into mouse brain parenchyma were
identified within non-vascular pathways in the olfactory lobe region, which were
traceable to the cervical lymph nodes72. In the absence of a conventional channel for
drainage of brain interstitial fluid (ISF) to the cervical lymph nodes, non-vascular tracks
were proposed to serve as substitutes for lymphatics. Since then, studies have
documented the presence of brain-derived myelin antigen-specific T cells in the
parenchyma, brain meninges, and cervical lymph nodes in mouse models of multiple
sclerosis and brain infections73-79. The latter studies suggested a model in which
antigens in the brain can be transported to the cervical lymph nodes for potential
5

activation of naïve T cells

72,80

. In support of this model, recent studies confirmed and

extended these previous observations by identifying and describing distinct networks of
lymphatic channels that drain directly into the cervical lymph nodes, indicating that
lymphatic drainage of the brain is similar to extracranial peripheral tissues. In addition,
it suggested that the brain is not sequestered from immune cell surveillance. Based on
this, there is more impetus in the field of neuroimmunology to investigate the dynamics
of antigen presenting cells and T cells in various brain pathologies.
Historically, BTs have been classified according to histological appearance and
studied as separate entities, and treatments have been applied differently according to
the histological diagnosis81. In the section below, I will be discussing BT types and
examine how immune infiltrates in such tumors could serve as a predictive/prognostic
tool in patient survival. 82-88.

1.3. Brain Tumors
Brain tumors are heterogeneous and are classified into two main types
according to the organ of origin. Primary BTs arise from within the brain tissue and
secondary BTs or brain metastases originate from extracranial organs.
I will briefly elaborate on the complexity in BTs types and subtypes based on the World
Health Organization (WHO) and The Cancer Genome Atlas (TCGA) classifications5,89.

1.3.1. Primary brain tumors
Primary BTs arise within distinct anatomical brain regions in the pediatric patient
relative to the adult patient. BTs in pediatric patients frequently develop in the
infratentorial (brainstem) region, while they are mostly supratentorial (cerebral
6

hemispheres) in adults. However, the cell-specific origin for such tumors is not well
understood90-94. Because of similar marker expression with several precursor or
differentiated cell types, primary BTs are thought to originate from poorly differentiated
glial cells such as oligodendrocytes, astrocytes, neural progenitor cells, and ependymal
cells. For instance, astrocytomas share glial fibrillary acid protein (GFAP) expression
with astrocytes and oligodendrogliomas stain for myelin basic protein (MBP), an
oligodendrocyte marker. Based on aggressive histological characteristics and rapid
patient mortality, a deadly type commonly known as glioblastoma multiforme (GBM)
has become well-recognized among the multitude of primary BTs types and is thought
to arise from astrocytes as it characteristically has GFAP expression. Recent studies
based on gene-expression from TCGA dataset has further classified GBMs according
to molecular characteristics95. Differential gene-expression and somatic molecular
characteristics delineate GBM into four recognized subtypes including pro-neural,
classical, and mesenchymal, thus indicating distinct molecular subtypes within the
GBM

histological

subtype

with

associated

differences

in

the

inflammatory

responses95,96. In this new classification, it is now recognized that in both primary and
recurrent GBM, the mesenchymal subtype has the highest immune signature,
characteristically infiltrated by neutrophils, both pro-inflammatory “M1” and immune
suppressive “M2” macrophages, but reduced presence of activated natural killer T
(NKT) cells in comparison with other molecular subtypes96. The proneural subtype has
decreased resting memory CD4 T cells and the classical subtype has increased
dendritic cell signature96. Despite the differences in the composition of immune
infiltrates, in recurrent GBM of all subtypes, there is increased infiltration by regulatory
T cells. Patients with primary or recurrent GBM of the mesenchymal subtype have the
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worst overall or progression-free survival while the proneural subtype has the best96. In
sum, differences in immune cell presence may be exploited for effective
immunotherapy in different GBM molecular subtypes. However, as these studies were
nonfunctional, mechanistic work is required for better understanding of immune
surveillance in BTs and could provide new knowledge for developing novel immune
therapeutic strategies to improve patient survival.

1.3.2. Brain metastases
In contrast to primary BTs, brain metastases originate from cancers of
extracranial tissues97. The epithelial to mesenchymal transition (EMT) process enables
conditions favorable for cancer cells to migrate and penetrate the tissue basement
membrane and gain access into the circulation98,99. Subsequently, disseminated cancer
cells undergo a cascade of events that end with successful engraftment and growth of
cancer cells in peripheral organs including brain tissue27,100. Brain metastasis is an
event that can potentially occur during the progression of any malignant primary cancer
type100. In the United States alone, it is estimated that approximately 170,000 new
patients will be diagnosed with brain metastases annually, a number 10 times higher
than in primary BTs101. Primary cancer types such as lung cancer, breast cancer, and
melanoma have a high propensity to metastasize to the brain102 (Table 1). In contrast,
brain metastases derived from soft tissue fibrosarcoma, cervical, prostate, and liver
cancers are relatively rare103-106. Patients who develop brain metastases have very
poor prognosis with a median overall survival ranging from a few weeks to months100.
Present treatment strategies such as surgical resection, radiation therapy, and
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chemotherapy have shown only modest benefit in extending survival of patients with
brain metastases107,108.
In comparison with GBM, the link between the immune system and brain
metastases is even less well-understood despite its high incidence. Although there is
no comprehensive comparison of immune cell infiltrates between distinct brain
metastases types, recent characterization of patient brain metastases aggregated
regardless of tissue of origin demonstrated that T cells can infiltrate brain metastases
generally109,110. Further, it was shown that the density of T cells infiltrating brain
metastases foci ranged from sparse to very dense109. In addition, T cell localization was
found to correlate with “peritumoral edema” as defined by the flare region in preoperative magnetic resonance imaging, and higher T cell infiltration into brain
metastases correlated with better overall survival time of patients109. These
observations and associations are potentially translatable as they could serve as
prognostic or predictive tools for patient outcome; however, the extent to which T cells
infiltrate brain metastases foci originating from distinct primary tumor types is unclear.
In addition, how T cells localize and are organized in BT and what mechanisms
regulate T cell localization in the tumor and their interaction with other cells in the BT
microenvironment remain unknown. These are questions that I will be probing in
chapters 3 and 4 of this thesis. In sum, a better understanding of T cell surveillance in
brain metastases is urgently needed. The knowledge gained may provide new insights
into the development of novel immunotherapeutic strategies for brain metastases.
Overall, the brain tissue is a common denominator for growth of both primary BTs such
as GBM and brain metastases. Therefore, knowledge of immune response gained from
studying one cancer type may be relevant for the other and vice versa.
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Adapted by permission from Macmillan Publishers Ltd: [Nat Rev Cancer] (Nguyen DX
et al., Metastasis: from dissemination to organ-specific colonization 2009. Apr;
9(4):274-84. Copyright Clearance Center.

1.4. Mechanisms of tumor immune surveillance in the brain
1.4.1 An overview of the immune system and anti-tumor immune surveillance
The immune system is divided into two arms—innate and adaptive (Figure 1).
The innate arm of the immune system is naturally wired with evolutionary conserved
receptors that can sense conserved structures on pathogens and sterile tissues such
as pathogen associated molecular patterns (PAMPs) and danger associated molecular
patterns (DAMPs), respectively111-114. Innate immunity functions as the first line of
defense during an immune response and responds rapidly relative to the adaptive
immune system; however, this response is generally non-specific. In contrast, the
adaptive arm of the immune system takes several days to respond during an immune
10

response, but its actions are highly specific. The specificity of adaptive immune cells is
determined by an incredible capacity to recombine their receptors to recognize different
antigens in a major histocompatibility complex (MHC)-restricted manner. Upon
resolution of a disease, the adaptive immune cells can evolve a memory phenotype.
Due to their intrinsic cellular properties, antigen-specific memory adaptive immune cells
are capable of initiating very strong and rapid adaptive recall responses in the event of
a re-encounter of the same antigen1,115,116. Innate immune responses are executed by
myeloid

cells

including

macrophages,

microglia,

monocytes,

dendritic

cells;

granulocytes such as neutrophils, eosinophils, basophils, and mast cells; γδ-TCR T
cells; and natural killer (NK) cells. On the other hand, adaptive immune cells include
αβ-TCR T cells and B cells. For the purpose of this thesis, I will be focusing on how
innate myeloid cells including microglia, monocytes, macrophages, and dendritic cells,
and the adaptive T cells interact in BTs.
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Figure 1. Classification of cells in innate and adaptive immunity. Cells that
participate in innate and adaptive immunity are illustrated within the bright lavender
(left) and pink (right) colored circles, respectively. Natural killer (NK) and γδ T cells
have characteristics that overlap between innate and adaptive immunity and are
represented within the overlapping segment between both circles. Adapted by
permission from Macmillan Publishers Ltd: [Nat Rev Cancer] (Glenn Dranoff, Cytokines
in cancer pathogenesis and cancer therapy 2004. Jan; 4(1):11-22. Copyright Clearance
Center.

Immune surveillance of a tumor is based on the fact that immune cells are highly
dynamic and can detect and recognize tumor-specific antigens (TSA) and/or tumorassociated antigens (TAA). Tumors are composed of highly mutated cells that may
provide a plethora of antigenic materials that are potentially ingested by antigen
presenting cells such as dendritic cells (DCs) and macrophages, and transported via
tumor-draining lymphatics to secondary lymphoid tissues for presentation to naïve T
cells (Figure 2). Following T cell recognition of TSA/TAA displayed by DCs, T cells
become activated, egress from the lymph node, and potentially migrate to the target
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organ invaded by cancer to perform effector functions including an attempt to eradicate
the tumor.

Afferent lymphatic

Efferent lymphatic

Figure 2. Illustration of the dynamics of antitumor immune surveillance.
Dendritic cells (green) engulf antigens from the tumor; process it, and present
processed antigens to naïve T cells in the tumor-draining lymph node. Effective antigen
presentation involves 3 signals (1. Peptide-MHC complex; 2. costimulatory molecules;
and 3. cytokines), which lead to T cell activation, differentiation and proliferation of
effector T cell that then migrate to the tumor (tumor infiltrating lymphocytes; TIL) to
perform effector functions. In the absence of costimulation, T cells become anergic.
Several cellular [myeloid derived suppressor cells (MDSCs) and regulatory T cells
(Tregs)] and molecular (PD-1/PD-L1) regulatory mechanisms are present in the tumor
or the lymph node to maintain tight control of this process and may cause immune
suppression through a variety of mechanisms leading to T cell exhaustion.
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The idea of tumor immune surveillance was first hypothesized by Thomas and
Burnet in 1957 based on observations made in organ transplantation and subsequent
studies in tumor graft transplantation24,117. Essentially, it was discovered at that time
that following transplantation in rabbits, a donor tissue such as skin was frequently met
with vigorous rejection by the recipient’s immune system118,119. In tumor transplantation
experiments, it was observed that tumor transplantation into a non-syngeneic host
resulted in tumor rejection, indicating that the recipient’s immune system was capable
of recognizing what was likely a tumor antigen. Therefore, it was postulated that the
infrequency of cancer occurrence in humans could be explained by an immune
surveillance mechanism that continuously prevents the outgrowth of cancerous
cells117,120. However, this idea was controversial because there was no mechanistic
insight into how the immune system could recognize and eliminate a tumor, which was
believed to express self-antigens as it originates from aberrant host cells117,121,122. Also,
spontaneously arising tumors were rarely rejected despite the induction of an immune
response123. Subsequent experiments by Osias Stutman revealed no difference in the
development of tumor in immune-deficient athymic nude mice in comparison with
control immune-competent mice, suggesting that the immune system played no role in
the control of tumor progression, and discredited the immunosurveillance concept71.
Despite these early setbacks, the first tumor antigen was eventually identified in
1991124, athymic nude mice are now known to be “leaky” and not absolutely immunecompromised125-128, and robust concrete evidence has accumulated in support of tumor
immune surveillance in both animal models and humans leading to renewed
enthusiasm for the immune surveillance hypothesis24,129-132. With advancements in the
field of molecular biology and the availability of new tools including knockout (KO) mice,
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the immune surveillance hypothesis has been overwhelmingly supported by
observations from studies conducted in the laboratory of Robert Schreiber and
others24,133-140. For example, sarcomas that were induced by a chemical carcinogen in
recombination activation gene (Rag)-KO mice, which unlike nude mice completely lack
adaptive immune cells, showed significant outgrowth in comparison with wild type mice,
indicating that tumor growth is controlled by the adaptive immune system. Similar
results were obtained in interferon-gamma receptor (IFNyR)-KO mice, STAT1-KO
(lacking the gene responsible for IFNy signaling), perforin-KO, αβ T cell KO (lacking the
TCR β-chain), and γδ T cell KO (lacking the TCR δ-chain) mice, all indicating that
components of the immune system are involved in controlling tumor growth24,133-140 .
Although the immune system plays a tumor surveillance role, spontaneous tumors tend
to progress lethally from presumably immune-resistant cancer cell clones. In a set of
experiments to test the role of the immune system in the development of tumor
resistance clones, transplantation of a carcinogen-induced tumor from a primary wild
type host to a secondary wild type recipient resulted in lethally progressive tumor. In
contrast, transplantation of a similar tumor from a primary immune-deficient Rag-KO
host to a secondary wild type recipient showed significant decrease in tumor growth.
Together, these results suggested that the intact immune system in the primary
immune-competent wild type host provided selective pressure for development of less
immunogenic and resistant tumor clones while the lack of immune selective pressure in
the primary immune-deficient RagKO host was necessary for the retention of tumor
immunogenicity. This phenomenon of tumor sculpting by the immune system was
conceptualized

as

the

process

of

cancer

immunoediting.

132,141-143

.

Cancer

immunoediting is a process that includes three phases including elimination,
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equilibrium, and escape (Figure 3). In effect, this concept includes tumor
immunosurveillance during which tumor eradication occurs (elimination phase),
immunological sculpting of the tumor leading to selection for resistant cancer cell
clones, which are potentially less immunogenic or have acquired mechanisms of
immune evasion or suppression (equilibrium phase), and subsequent uninhibited tumor
progression (escape phase)24,130,144.
Despite our present understanding of cancer immune surveillance and aspects
of immunoediting, most of the data is borrowed from research conducted in extracranial
organs. In the brain, however, the mechanisms regulating immune surveillance in
tumors remain unclear partly due to the idea of brain immune privilege. This idea first
came to light following an experiment by Medawar69. He observed that skin to skin
transplantation in rabbits caused the recipient rabbit to mount strong immune response
with subsequent rejection of the transplanted tissue. However, when the same tissue
was transplanted into recipient rabbit brain, the tissue was not rejected. In contrast,
when he first transplanted donor skin tissue into the skin of recipient rabbits and waited
a few days before transplanting similar donor skin tissue into the brain of the same
recipient rabbits, the transplanted tissue in the brain was rejected69. This suggested
that the brain is immunologically quiescent or privileged in comparison with peripheral
tissues. Since then, in support of an immune-privileged brain, countless studies have
demonstrated unique features of the brain that could prevent the development of robust
immune response within the brain tissue68,145-148.
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Figure 3. The process of cancer immunoediting.
Cancer immunoediting encompasses three processes. (a) Elimination corresponds to
immunosurveillance (b) Equilibrium represents the process by which the immune
system iteratively selects and/or promotes the generation of tumor cell variants with
increasing capacities to survive immune attack. (c) Escape is the process wherein the
immunologically sculpted tumor expands in an uncontrolled manner in
immunocompetent host. In a and b, developing tumor cells (blue), tumor cell variants
(red) and underlying stroma and nontransformed cells (gray) are shown; in c,
additional tumor variants (orange) that have formed as a result of the equilibrium
process are shown. Different lymphocyte populations are as marked. The small orange
circles represent cytokines and the white flashes represent cytotoxic activity of
lymphocytes against tumor cells. Reprinted by permission from Macmillan Publishers
Ltd: [Nature Immunology] (Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer
immunoediting: from immunosurveillance to tumor escape. 2002;3:991-8); Copyright
(2002). Copyright Clearance Center.

1.4.2. The Blood-Brain Barrier (BBB) in steady state and inflammation
The BBB has been pivotal in the debate on brain immune privilege and is
believed to play a critical role in regulating interactions between the brain and immune
cells in extracranial peripheral tissues. The BBB serves to tightly regulate the influx of
molecules or cells from the circulation into the brain tissue in normal homeostatic
conditions146,149,150. Unlike fenestrated capillaries in the extracranial peripheral tissues,
the BBB is made up of endothelial cells that are bound together by tight junctions. This
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basic endothelial structure is further reinforced by pericytes, astrocytic foot processes,
and smooth muscle cells151. BBB tight junctions and efflux pumps are mechanisms that
prevent small molecules from penetrating the brain parenchyma152-155. Consequently,
delivery of small molecules such as kinase inhibitors and targeted therapy to treat brain
pathologies such as brain tumors has been shown to be inefficient154. In contrast,
systemic immune cells such as memory T cells have been found to be present in the
brain at steady state156-158; however, only very small numbers of these cells have been
identified in comparison with extracranial peripheral tissues147,158159. Furthermore,
transmigration of T cells via the BBB into the brain parenchyma frequently occurs in
diseases such as multiple sclerosis and viral encephalitis in humans74,79,160,161, or
experimental acute encephalomyelitis (EAE) in mice79,162,163.
As an early model system to understand how immune cells breach the BBB and
penetrate into the brain parenchyma, several mechanisms have been proposed as to
how the initiation of EAE occurs. Activated or encephalitogenic T cells, but not resting T
cells were found to be able to penetrate the BBB after intravenous injection in
rats164,165. This event was found to be independent of antigen recognition or MHC
compatibility, but dependent on the activation and the blast stage of the T cell,
indicating that T cell activation alone was sufficient for T cells to breach the BBB166.
Subsequent studies showed that this process is dependent on P-selectin to access the
leptomeningeal vascular endothelium, and lymphocyte function-associated antigen 1
(LFA-1) and α4-integrins to penetrate the BBB167. Additionally, based on the
constitutive expression of CCL19 in CNS endothelia, a CCR7/CCL19-chemokinedependent mechanism has been proposed for CCR7-expressing T cells to cross the
BBB via the leptomeninges162,164,168,169. In another study, entry of T helper-17 cells into
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the CNS via the choroid plexus into the brain ventricles was found to be a
CCR6/CCL20-dependent process, required for the initiation of EAE170. Cumulatively,
these data indicate that encephalitogenic T cells can access multiple brain interface
sites to penetrate the BBB and induce neuroinflammation. Although the prior studies
were based on a model in which autoreactive T cells are constantly circulating in the
bloodstream and are able to directly penetrate the BBB, a recent study showed that
circulating T cell blasts lack the capacity to penetrate the BBB and initiate EAE in a rat
model unless they are first licensed in the lungs171. In fact, after local stimulation of
resting myelin-reactive memory T cells in the lungs of rats, those cells proliferated
profoundly, migrated to the CNS, and caused paralysis in the rats171. This indicated
that the lung is a site of reactivation for autoaggressive T cells prior to induction of EAE.
More recently, another study detailed the events that occur after the BBB has
been breached following induction of EAE163. Shortly after cerebral vessel disruption
following EAE induction with subcutaneous injection of myelin oligodendrocyte
glycoprotein (MOG) peptide, Incomplete Freund’s Adjuvant (IFA), and intraperitoneal
injection of pertussis toxin, microglia become activated, and this was followed by
infiltration of DCs and T cells163. This latter study suggested a model in which activated
microglia are the primary initiators of autoaggressive T cell entry into the CNS.
However, only the green fluorescent protein-tagged receptor CX3CR1, which is broadly
expressed by microglia, macrophages, and some DCs, was used to identify
microglia163. In addition, the mechanisms by which T cells accumulate and are retained
at sites of EAE remain unknown. In sum, there appear to be different mechanisms
involved in the initiation of EAE. Whether the various mechanisms involved in EAE
initiation are interconnected or work separately is an important question that is still
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being dissected. Importantly, whether similar mechanisms are operational in brain
tumors is being investigated.
In patient GBM tissues, studies conducted in the 1970s and 1980s revealed high
numbers of infiltrated microglia and macrophages, but rare infiltrating T cells. In
addition, GBM patients were found to be highly lymphopenic, bearing resemblance to
patients with immune-deficient disorders172-175. On one hand, it was believed that GBM
patients were generally lymphopenic and on the other, due to the prevailing idea of
brain immune privilege, it was thought that antigen presenting cells such as DCs and
adaptive immune T cells were likely restricted from being present within these tumors.
Regulatory T cells have been found in high numbers in peripheral blood and tumor
tissue in patients with GBM, and have been suggested as an immune suppressive
mechanism in GBM patients176-179. Hence, it is unlikely that the BBB preferentially
restricts effector T cells from migrating into GBM tumor tissue. Alternatively, it was
thought that inefficient or lack of antigen presentation to naïve T cells could explain the
limited number of effector T cells in GBM tissue180-189. This latter theory seemed
plausible partly due to the fact that classical lymphatics in the CNS had not been
identified at the time190-192. As it would turn out, there is now evidence to support the
idea of inefficient or lack of antigen presentation in GBM, and CNS lymphatics have
been identified62,63,82. Thus, by using appropriate models in which antigen presentation
is operational, one could address several important questions pertaining to the
dynamics of T cell migration into BT, potential local proliferation in the tumor, and
interaction with antigen presenting cells in the tumor microenvironment. These are
questions that I will probe in chapter 3 of this thesis.
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1.4.3. The role of CNS Lymphatics in immune response to brain tumor
Lymphatics are critical in the generation of an immune response during tumor
progression. Conventional lymphatic vessels are made up of endothelial cells that are
identified by the expression of Prox1, CD31, LYVE-1, podoplanin, VEGFR3, and
CCL2182,193,194. Similar to peripheral tissue capillaries, lymphatics are generally
permeable, allowing for ISF, macromolecules, and cellular entry195. Anatomically, there
are two types of lymphatics, including afferent and efferent lymphatics; the afferent
lymphatic channel transports lymph and cells from the tissue to the draining lymph
node while cells exit the efferent lymphatic into the bloodstream to a potential target
tissue (Figure 2). Functionally, lymphatic vessels are classified into initial and collecting
vessels195-198. Importantly, the collecting vessels possess bi-leaflet valves to allow for
unidirectional flow of lymph. Antigen presentation generally involves the migration of
antigen presenting cells such as DCs via the afferent lymphatic vessel to the tissuedraining lymph node where antigen presentation to naïve T cells occurs. The efferent
lymphatic vessel serves as a conduit for activated effector T cells exit the lymph node
into the bloodstream and migrate to a target tissue.
In the brain, the mechanism of antigen transport is still been unraveled. In the
1960s, lymphatic vessels were described to be present at the base of the skull
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Subsequently, dural lymphatics were described in rats200. It was in the 1980/ 1990s that
Cserr H.F. et al. first showed using functional experiments that tracer dyes that were
directly injected into the CSF or brain parenchyma could be traced from beneath the
olfactory lobe to the nasal lymphatics and the cervical lymph nodes72,80 (Figure 4).
Recently, mechanistic studies have confirmed earlier findings and demonstrated that
brain parenchymal ISF drains into cerebral perivascular spaces, termed “glymphatics”,
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and that both ISF and cerebrospinal fluid (CSF) eventually drain into a recently
described perisinusoidal conventional lymphatic network in the mouse meninges82,194
(Figure 5a &b). In addition, a direct connection between the meningeal lymphatics and
the cervical lymph node has been demonstrated. In light of these findings, the routes of
antigen-presentation in EAE that I elaborated on in the BBB section are being
reexamined193,201,202.
In BTs, prior studies showed that vaccination of BT-bearing mice and GBM
patients in the flank region with dendritic cells loaded with tumor antigen can induce
antigen presentation in the inguinal lymph node and result in BT eradication86,203,204.
This supported the idea that antigen presentation is likely defective in GBM patients. It
also suggests a model in which antigen-presentation in a distal secondary lymphoid
tissue from the brain can elicit robust immune response to BT. In addition, in a recent
study, Dunn G.P. et al., identified the presence of neoantigens in GBM mouse tumor
models including GL26163. Interestingly, these mouse tumor models were found to
contain very high mutational load of up to 26, 000 compared to less than 100 in GBM
tissues22,63. Following direct inoculation of mice with cancer cells into the brain, antigenspecific T cells for the same previously identified neoantigens were recovered with
tetramers from both the tumor mass and the cervical lymph node. These findings
suggest a model in which BT antigens are transported from the brain parenchyma to
the cervical lymph node likely via the “glymphatic” and meningeal lymphatic routes
described above. Whether BT antigen-presentation occurs at multiple sites other than
the cervical lymph node or whether the extent of BT antigen presentation varies in
different lymphoid tissues remains to be elucidated. In sum, the brain appears to be
open to surveillance by immune cells such as T cells. This gives further support for the
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questions I aim to answer pertaining to T cell surveillance in BTs. In the next few
sections I will go into details into the key cells involved in tumor immune surveillance,
the distinct immune cells found in the brain, and the roles they might play in BT
surveillance.

Figure 4. Prior view of CNS lymphatics. Schematic showing the drainage paths of
lymphatics in a rat brain (Black arrows). Adapted by permission from John Wiley
&Sons, Inc.: [Neuropathol Appl Neurobiol.] (Kida, S., CSF drains directly from the
subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and
immunological significance 1993 Dec; 19(6):480-8.). Copyright Clearance Center.
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a

b

Figure 5. New view of CNS lymphatics.
a. Schematic showing the drainage paths of lymphatics in a mouse brain (Green
arrows). The blue and orange arrows show the flow of CSF and ISF, respectively.
Adapted by permission from Elsevier: [Neuron] (Louveau A., Lymphatics in
Neurological Disorders: A Neuro-Lympho-Vascular Component of Multiple Sclerosis
and Alzheimer’s Disease? 2016 Sep 7;91(5):957-73.). Copyright Clearance Center.
b. Schematic depiction of the glymphatic pathway. In this brain-wide pathway, CSF
enters the brain along para-arterial routes, whereas ISF is cleared from the brain along
paravenous routes. From here, solutes and fluid may be dispersed into the
subarachnoid CSF, enter the bloodstream across the postcapillary vasculature, or
follow the walls of the draining veins to reach the cervical lymphatics. “From [Iliff,
Jeffrey J. et al. “A Paravascular Pathway Facilitates CSF Flow Through the Brain
Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid Β.” Science
translational medicine 4.147 (2012): 147ra111. PMC. Web. 11 Mar. 2017.]” Reprinted
with permission from AAAS. Copyright Clearance Center.
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1.4.4 Myeloid cells
Macrophages
Macrophages are critical in regulating tissue homeostasis, and controlling tissue
inflammation involving pathogens and cancer53,205. Macrophages originate from the
yolk sac during embryogenesis in mice and migrate into tissues to become tissue
resident cells such as Kuppfer cells in the liver, microglia in the brain, Langerhan cell in
the dermis, and alveolar macrophages in the lungs. During inflammatory conditions,
macrophages presumably originate from circulating monocytes, which are derived from
the bone marrow common macrophage dendritic precursor (MDP) cells206. However,
the specific population of blood monocytes that differentiates into macrophages in
tissue is yet to be identified. Within different tissues, the mechanisms by which
macrophages are sustained vary. In general, macrophages are able to self-renew in
tissue by local proliferation while a portion of tissue-resident macrophages are
replenished from the circulation by blood monocytes207. Macrophages in mice and
humans can be identified by a combination of surface markers including CD11b
(mouse/human), F4/80 (mouse), CD68 (mouse/human), CSF1R (mouse/human),
MAC2 (mouse/human), CD11c (mouse/human), Ly6G (mouse), Ly6C (mouse), IL4Ralpha (mouse/human), and CD163 (human)208. Importantly, there is no single
marker that defines macrophages exclusively and typically a combination of high
CD11b, F4/80, and low CD11c (enriched in DCs), Ly6G (enriched in granulocytes), and
Ly6C (enriched in monocytes) are used to identify them. In addition, other surface
markers such as CX3CR1 and Iba1 together with cellular morphology are utilized for
identifying specialized tissue macrophages such as microglia and other CNS
macrophages residing at brain interfaces209,210.
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Microglia and CNS macrophages
In the adult steady state brain, microglia make up the highest number of resident
myeloid cells in the brain parenchyma 75,211,212 (Figure 6). Microglia play critical roles
during neural development and in maintaining tissue homeostasis in the adult brain by
pruning developing neurons and engulfing cellular debris, respectively211,213. In steady
state, microglia soma are fixed, and they rely on highly motile cell processes that
continuously extend and retract to survey the surrounding brain region for potential
dead cells214. In a recent finding, TAM (named after receptor tyrosine kinases Tyro3,
Axl, and Mer) receptor tyrosine kinases Mer and Axl, and corresponding ligands Gas6
and protein S, which are known regulators of innate immune response, were found to
control phagocytic functions of microglia at steady state215. However, in the presence
of inflammatory signals such as IL6, TNFalpha, and nitric oxide (NO), microglia become
sensitized to neural-derived factors such as adenosine triphosphate (ATP), glutamate,
and the chemokine fractalkine (CX3CL1)216-219. They then become activated, transform
into an amoeboid form, and subsequently migrate to areas of perturbation to prevent
further damage to the brain tissue or, in some cases, exacerbate the inflammation215.
For a long time, microglia were thought to arise from bone marrow progenitor cells,
which give rise to some tissue macrophages220-223. Fate mapping studies in mice,
however, have revealed a colonization of the brain by microglia during only
embryogenesis224 (Figure 7). Around embryonic day 9.5 (E9.5), yolk sac myeloid cells
migrate to the brain to become the brain microglia. It was also believed that circulating
monocytes could replenish microglia in an adult brain221. However, numerous studies
have now shown that microglia in an adult brain are not replenished by peripheral
myeloid cells, indicating that microglia self-renew and that resident microglia and
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Figure 6. Organization of innate myeloid cells in the healthy brain. Microglia are
present within the parenchyma of the brain in steady state. Other myeloid cells are
named according to location occupied in the cranial compartment including choroid
plexus macrophages (location: choroid plexus in the ventricles); perivascular
macrophage (location: perivascular space); meningeal macrophage (location:
meninges); and dendritic cells (location: meninges and perivascular space). Adapted by
permission from Macmillan Publishers Ltd: [Nat Rev Neuroscience] (Marco Prinz and
Josef Priller, Microglia and brain macrophages in the molecular age: from origin to
neuropsychiatric disease 2014 May; 15(5):300-12. Copyright Clearance Center.

infiltrating monocytes/macrophages derived from the circulation may play distinct roles
in steady state and pathological conditions206. However, the radioresistant nature of
microglia as well as the quick regenerative properties of monocytes/macrophages have
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made it technically challenging in delineating the distinct roles played by each of these
subsets in chronic diseases such as cancer225,226.
Apart from microglia which are the resident intraparenchymal myeloid cells of
the CNS, there are other resident macrophages that reside within specific niches at
brain parenchyma interfaces including meningeal (mMF), perivascular (pMF), and
choroid plexus macrophages (cpMF). Recent studies have provided a better
understanding of the relationship between these cell types209. Despite the believe that
other CNS macrophage subsets originate from the fetal liver and can be replenished by
circulating bone marrow-derived monocytes, recent findings indicate that CNS
macrophages and microglia are actually ontogenically related209 (Table 2). Apart from
cpMFs which originate from both the yolk sac and fetal liver myeloid precursor cells and
can be replenished by circulating Ly6C+ monocytes in a CCR2 dependent manner,
mMFs and pMFs were demonstrated to originate from only the yolk sac and migrate
into their distinct niches in the brain at similar times with microglia209. And both mMFs
and pMFs are not replenished by circulating monocytes in similarity to microglia. At the
transcriptional level, CNS macrophage subsets and microglia depend on the
transcription factor PU.1, but not Myb, Batf3, and Nr4a1. In addition, they share surface
expression of CX3CR1, CSF1R, and Iba1. Notwithstanding, all CNS macrophage
subsets showed higher expression of Ptprc (CD45) at both the mRNA and protein level
when compared with microglia, while perivascular macrophages were enriched for
Mrc1 (CD206) and CD36 in addition to CD45209. Furthermore, CNS meningeal and
perivascular macrophage development was shown to be independent of Flt3+
multipotent hematopoietic precursors in the BM, indicating that CNS macrophages are
distinct from BM derived cells.
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Table 2. Characteristics of resident myeloid cells in the brain parenchyma and at
central nervous system interfaces

In fact, it was demonstrated that previous observations of BM-derived cells infiltrating
the brain interfaces in chimera experiments was due to irradiation-induced CNS tissue
inflammation, which could damage the BBB and artificially attract BM cells to the
brain221. Morphologically, microglia are ramified, meningeal macrophages are
amoeboid, and perivascular macrophages are elongated in alignment with proximal
blood vessels. Therefore, they can be distinguished by imaging studies. In addition,
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intravital imaging has shown that microglia and CNS macrophages extend and retract
cell protrusions differently209. However, whether CNS macrophage subsets play distinct
roles from bone marrow-derived macrophages or microglia is not yet known. In sum,
different myeloid cell subsets have to be taken into consideration when investigating
the role of myeloid cells in BTs.

Figure 7. Myeloid cell colonization of the brain from embryonic to adult life in
mice. At embryonic day 9.5 (E9.5), Yolk-sac (YS)-derived macrophages gain access
into the circulation, migrate, and localize in the embryonic brain to give rise to microglia.
Other brain macrophages depicted in Figure 6 differentiate from YS and fetal liverderived monocytes, and the bone marrow becomes a major source of monocytes in
adult steady state or inflamed brain. Adapted from Frontiers open-access publisher:
[Front Cell Neurosci.] (Ginhoux F, Origin and differentiation of microglia 2013 Apr
17;7:45.)
Role of Macrophages and Microglia in brain tumors
In the context of cancer, macrophages constitute a widely researched population
in the tumor microenvironment termed tumor-associated macrophages (TAMs)227-231.
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Early investigations into immune response to BTs revealed that BTs are largely
infiltrated by classical macrophages and the brain resident microglia205,232. Since then,
there has been immense interest in understanding macrophage plasticity and its role in
BT progression. Based on the availability of certain molecular factors such as IFNgamma, IL-1, and TNF-α, TAMs can be skewed to an “M1” anti-tumor or “classical”
phenotype, while immune suppressive cytokines such as IL-4, TGF-beta, and IL10,
tend to skew TAMs to an “M2” pro-tumor or “alternative” phenotype233,234. However,
most of these studies are in vitro and may not rigidly translate in vivo as represented by
a recent study that found that these macrophage phenotypes do not exist at polar ends
of a spectrum but rather in continuum, with more resemblance of an unpolarized “M0”
phenotype235. Depletion of presumably “M2” TAMs by various strategies including small
molecule inhibitors such as colony stimulating factor 1 receptor (CSF1R) inhibitors in
vivo has shown reversal in tumor growth, and this is presently an area of intense
research as CSF1R inhibitors are currently being tested in clinical trials236-239.
However, the origin of TAMs in brain tumor remains very controversial.
Experiments in mice have shown that TAMs are mostly composed of infiltrating cells
from peripheral tissues such as the bone marrow; however, a recent study claims that
TAMs in BT are composed of mainly microglia and not circulating monocytes, and that
microglia drive BTs progression240. In the latter study, head-shielded mice were
irradiated, leading to eradication of only bone marrow hematopoietic cells and
circulating cells in the periphery but not the cranial compartment. Microglia but not
blood-derived macrophages or monocytes were found to be diffusely infiltrating the
tumors. Conflicting with other investigators, the authors claimed that microglia have
high expression of CD45 (a marker that has been shown to be strikingly low in
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microglia and used as a separation marker for microglia and CD45hi-expressing
macrophages)240 and suggested that the literature on microglia should be reevaluated.
Furthermore, the authors failed to consider CNS macrophage subsets at brain
interfaces, skull bone marrow myeloid cells, and brain dendritic cells that were not
eliminated with irradiation

209,212,241

. In fact, a more recent study showed that

macrophages residing at CNS interfaces express high levels of CD45 at both the
mRNA and protein levels, in contrast to microglia, and may play a crucial role in neurooncologic diseases209. As such, the composition of myeloid cells in BTs is still unclear
and deserves thorough scrutiny. In this thesis, I have generated a novel reporter mouse
model and developed a new method of analysis in an attempt to better characterize
myeloid cell subsets in BTs.
For a long time, there has been uncertainty as to whether DCs could play a
major role in antigen presentation in BTs since only very small numbers have been
detected in BT tissue242. Due the predominance of microglia and macrophages, which
have been estimated to make up about 30% of BT tissue, it has been suggested that
these are the cells that play a major role in regulating immune surveillance in BT
progression. In studying immune regulators in BTs, microglia and macrophages are
commonly lumped together due to the difficulty in distinguishing between both cell
types. Thus, it is unclear as to whether both cell types play distinct roles in immune
response to BTs. Nevertheless, glioma-infiltrating microglia/macrophages show high
expression of TLRs, but are inefficient at producing inflammatory cytokines such as
TNF-α, IL-1, and IL-6. In addition, despite showing high expression of MHC-II, they lack
expression of costimulatory molecules CD80 and CD86242,243. This would suggest that
they are likely ineffective at presenting antigens to T cells. Interestingly, in vivo
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stimulation of glioma-infiltrating microglia/macrophages in rats by intratumoral injection
of CpG-containing oligonucleotides, which engage TLRs, in glioma-bearing rats
resulted in increased glioma growth and a reduction in cytotoxic T cell tumor lysis
capacity244. This indicates that attempts at stimulating glioma-infiltrated
microglia/macrophages, at least with CpG-containing oligonucleotides, may be
ineffective in activating adaptive T cells and could be deleterious. In BT-bearing mice,
microglia have been shown to express Fas ligand, a molecule involved in cell-mediated
apoptosis. Inhibition of Fas ligand activity resulted in increased infiltration of leukocytes
into the tumor mass. Thus, glioma-infiltrating microglia/macrophages are thought to be
polarized to an “M2” tumor-promoting phenotype, in which form they suppress effective
immune surveillance of BT245. Importantly, interventions aimed at skewing presumable
“M2” macrophages to an “M1” proinflammatory or anti-tumor phenotype or depleting
glioma-infiltrating microglia/macrophages have resulted in extended survival in tumorbearing mice235,236,246 247. However, it is still unknown whether depletion by CSF-1R
inhibitors actually acts on distinct “M2” macrophages since “M1/M2” macrophages are
now known to be closely related and bear semblance to an unpolarized “M0”
phenotype at least in human glioma, which may extend in a similar manner in mice.
Nonetheless, the results indicate that glioma-infiltrating microglia/macrophages have an
immune suppressive role in BTs, but does not reflect on their capacity to directly control
T cell surveillance in BTs. In addition, depleting glioma-infiltrating
microglia/macrophages is inefficient as tumors recur frequently237.
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Monocytes
Monocytes play key roles in tumor progression248. They are thought to differentiate and
replenish macrophages or DCs in tissue249,250. Monocytes originate from a common
macrophage dendritic cell precursor (MDP) in the bone marrow250 (Figure 8), and are
classified into Ly6C+ classical monocytes (CM) and Ly6C- patrolling monocytes
(PM)250.

Figure 8. Monocyte derivatives in peripheral tissues in health and disease.
Resident monocytes express high levels of CX3CR1 which, upon interaction with
fractalkine, facilitates extravasation into tissues, where these cells give rise to
specialized cell types. Inflammatory monocytes express lower levels of CX3CR1 but
have high levels of other receptors like CCR2 that respond to inflammatory
chemokines, resulting in migration of the cells to sites of inflammation, where they
subsequently differentiate into dendritic cells (DCs) or macrophage/myeloid derived
suppressor cells. Monocytes with no expression of CX3CR1 give rise to interferon
producing cells (IPC) also called plasmacytoid DCs (PDC). Adapted by permission from
Macmillan Publishers Ltd: [Immunity] (Geissmann F. et al., Blood Monocytes Consist of
Two Principal Subsets with Distinct Migratory Properties 2003 Jul;19(1):7182.) Copyright Clearance Center.
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Several transcription factors including PU.1, JunB, C/EBP-a, C/EBP-b and IRF8 play
key roles in the development of myeloid cells in general and especially in CM. In
contrast, development of hematopoietic cells into PM has only been recently shown to
be dependent on Nuclear Receptor Subfamily 4 Group A Member 1 (NR4A1)
expression251,252. Although it was previously believed that CMs differentiate into PM, it
is now known that CM and PM utilize distinct and independent pathways during
development and likely perform different functions252. The CM subset is identified by
the surface expression of Ly6C+ CCR2+ CX3CR1lo CD62L+. Functionally, CMs migrate
to tissues invaded by infectious agents or into inflamed tissues, and can differentiate
into antigen presenting DCs and potentially mediate acute pathogen clearance or
differentiate into monocytic myeloid derived suppressor cells (MDSC), in which case
they contribute to immune tolerance in chronic disease states253. Importantly, CMs
have also been shown to robustly migrate and infiltrate tumors, where they contribute
to an immune suppressive population of monocytic cells also referred to as Ly6C+
CD11b+ Gr1+ CCR2+ monocytic MDSC as opposed to the neutrophilic population of
Ly6G+ CD11b+ Gr+ granulocytic MDSCs. Both populations promote tumor growth and
there is active research in this area to gain better understanding about their
regulation254,255. Despite the availability of more evidence skewed toward revealing CM
as pro-tumorigenic cells, some studies have also demonstrated an anti-tumor role for
CM in the control of cancer cell metastasis, reminiscent of its capacity to also serve as
precursor for antigen presenting DCs in infection and indicative of a dual role during
inflammation256-258.
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Table 3. Classification and characteristics of monocytes

In contrast, patrolling monocytes, which are identified by the surface expression
of Ly6C- CCR2lo CX3CR1+ CD62L-, were known for long a long time to only survey
healthy vasculature for potential damage259,260; however, recent intravital imaging
studies in a model of lung tumor revealed a new role for PMs in preventing the
adhesion of circulating cancer cells to lung tissue vasculature. In situations where
cancer cells succeeded in engrafting into the lung tissue, PMs were found to be
capable of transmigrating through the pulmonary vascular endothelium and infiltrating
the established tumor. In addition, signaling via the Fractalkine chemokine receptor
CX3CR1 was found to be required by PM to inhibit lung tumor initiation261. However,
the extent to which CMs and PMs infiltrate brain tumor and their organization in the
tumor microenvironment is unknown. In this thesis, I have attempted to analyze the
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extent to which CMs and PMs are prevalent in BT. Nevertheless, it will be crucial to
distinguish the functions of these monocyte subsets in BT progression.

Dendritic cells
Dendritic cells (DCs) are professional antigen presenting cells (APCs) and serve
as a major link between the innate and the adaptive arms of the immune system212,262265

. DCs utilize a diverse repertoire of receptors expressed on the cell surface to scan

and recognize PAMPs in microbial infections266-273 Consequently, they endocytose and
process such infectious microbial agents into peptides that are eventually presented to
naïve T cells in the lymph node via peptide-MHC complexes I and II (pMHC-I and
pMHC-II)274-276. Precisely, the engulfed tumor materials are processed through complex
intracellular machinery such as the proteasome into distinct peptide antigens, which are
then loaded unto MHCs in the endoplasmic reticulum, and eventually routed through
the golgi apparatus and displayed on the surface of DCs277. During this process, DCs
migrate through afferent lymphatic channels to the tumor-draining lymph node
paracortical regions, where they encounter naïve T cells.
Importantly, unlike other APCs such as macrophages, after phagocytosis of
antigens, the acidic milieu in DCs is tightly regulated by NOX2 to prevent destruction of
potential peptide antigens necessary for T cell activation278. In addition, DCs have an
extensive capacity to process and present/cross-present antigens from both
intracellular and extracellular pathways via pMHC I and II278. Further, in contrast to
other APCs, DCs express costimulatory ligands CD80 and CD86 that are necessary for
T cell priming. Regardless, a clear distinction between DCs and macrophages still
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remains controversial as there is no specific marker that delineates these two
described cell types.
DCs are recognized by their expression of a combination of several surface
markers, including CD45+ CD11chi MHC-II+ CD11b+. Although CD11b is widely
shared by myeloid cells including DCs and macrophages, CD11c is highly expressed
on all subsets of DCs in mice in contrast to a low expression on macrophages (which
have high expression of F4/80), while CD11b is expressed by only a few subsets of
DCs. Therefore, CD11c expression has become almost interchangeable with the
presence of DCs; however, care must be taken in interpreting results using this marker.
CD11c is an integrin also referred to as integrin gamma X (ITGAX) and its functional
role is unknown. Fluorescent transgene encoded by the CD11c promoter has been
used to create a reporter mouse that has helped dissect the myeloid lineage within in
vitro studies and has played a major role in increasing our understanding and
appreciation of dynamic interactions between DCs and T cells in in vivo imaging
studies.
Two subsets of DCs have been recognized based on differences in phenotype
and function. They include CD8α+ and CD8α- DC subsets. CD8α+ DCs are found in
the spleen of mice279 and are critical in the activation of CD8+ cytotoxic T cells (CTLs).
In peripheral tissues, however, similar DCs do not classically express CD8α. Instead,
they are recognized by the expression of CD103280. Importantly, CD8α+/CD103+ DCs
are efficient at engulfing and processing apoptotic cell bodies at sites of infection or
cancer, and subsequently cross-present the peptide product of apoptotic cells to CD8+
T cells within the same vicinity281,282. Thus, it is likely that efficient T cell surveillance of
BT will involve interactions between DCs, such as CD8α+ DCs, and T cells in the tumor
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microenvironment. CD8α+/CD103+ DCs rely on several transcription factors for
development including Batf3, IRF8, and Zbtb46283. In Batf3 knockout mice in which
CD8α+ DCs are absent, there is poor control of infections such as Toxoplasma gondii,
and enhanced growth of tumor in cancer models284-286. This would suggest a possible
role for CD8α+ DCs in BT control. The second subset of DCs identified as CD8α- DCs
are delineated by other surface markers including CD11b+ and CD4+. Importantly, they
are involved in the activation of CD4+ T cells. CD8α- DCs are required in Th2 T cell
responses in allergic diseases279,287. Apart from these latter DC subsets, a small
population of resident DCs has been found to reside in certain regions of the brain
involved in neurogenesis212. Based on marker expression such as CD115, Gr-1, and
Ly-6C, it is thought that they are mucosal and monocyte-derived288. In addition, they
can be identified by expression of CD11c, but some populations express CD11b and
CD103. Interestingly, brain DCs can proliferate under the influence of IFN-gamma, can
upregulate MHC-II, and can stimulate naïve CD8 T cells241,289. However, they are
known to be largely radioresistant, in similarity to microglia, and their role in BTs needs
to be determined. In sum, DCs are likely to play a major role in controlling T cell
surveillance in BT. In the next section, I will discuss T cells and the mechanisms by
which DCs prime T cells during an immune response.

1.4.5 T cell biology, T cell priming, and role of T cell subsets in cancer
T cells are the main effectors of the adaptive arm of the immune system involved
in cell-mediated immunity1. For T cells to function effectively, they must recognize
antigens presented as peptides on MHCs via the T cell receptor (TCR). The TCR is a
heterodimeric protein in the T cell membrane that consists of an alpha and a beta chain
39

(αβ-T cells); however, in a different type of T cells, the TCR is made up of a gamma
and a delta chain (γδ T cells). Within the scope of this thesis, I will be focusing strictly
on the role of αβ-T cells in BT surveillance. Developmentally, T cell precursors, which
originate from the bone marrow, migrate to the thymus where they rearrange alpha and
beta TCR chains and undergo positive and negative selection in the thymic cortical and
medullary regions, respectively. During this selection process, T cells that bind strongly
to self-antigens are clonally deleted290. T cells that are not deleted undergo clonal
diversion to become regulatory T cells (Tregs), which play crucial roles in both
autoimmunity and cancer progression. Following completion of T cell selection, mature
CD4 and CD8 T cells exit the thymus into the systemic circulation and eventually
localize and reside in secondary lymphoid organs such as lymph nodes (SLOs) and
spleen291. Within SLOs such as lymph nodes, T cells continuously scan for cognate
antigens in the para-cortical region. However, for efficient antigen presentation, pMHCDCs rely on chemokine receptors like CCR7 to migrate to paracortical T cell areas in
the draining lymph node over a CCL19/CCL21 chemokine gradient78,292,293.
Correspondingly, naïve T cells also utilize CCR7 in addition to DC-CK1 (a DCexpressed chemokine, which preferentially attracts naïve T cells294) to scan for pMHCbearing DCs. Upon making contact with pMHC-bearing DCs, a three-signal model of T
cell activation ensues295-298.
The first step in T cell activation involves the engagement of T cells with the
pMHC on DCs via the TCR. The avidity and affinity of the TCR for cognate pMHC
determines the strength of the signaling cascade downstream of the TCR299,300. This
TCR signaling can be monitored by use of transgenic mouse models such as nuclear
factor of activated T cells (NFAT) or NR4A1-GFP reporter mice301-303, in which the
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green fluorescent protein (GFP) transgene is expressed under the orphan nuclear
receptor NR4A1/Nurr77 promoter. By using a reporter mouse such as NR4A1-GFP
transgenic mouse, early T cell activation involving only the ligation of the TCR can be
detected in the form of GFP accumulation in the T cell nucleus. The mechanism behind
this involves TCR ligation to pMHC complex, which leads to translocation of the NR4A1
transcription factor from the cytoplasm to the nucleus where it binds to DNA cassettes
to promote further downstream signaling.
Following TCR ligation, cell-cell contact between the T cell and pMHCexpressing DCs initiate the second signal299,304; this is mediated by binding of
constitutively-expressed CD28 on T cells to costimulatory molecules on pMHC-DC
including CD80 (B7-H1) and CD86 (B7-H2). Efficient binding of CD28 to CD80/86, is a
necessary step in T cell activation without which T cells become anergic305. This step
also helps to amplify the TCR signal strength. In some situations, very high TCR signal
strengths that could be deleterious to the host are potentially possible and could cause
T cells to function in an auto-reactive manner. To prevent this from occurring,
peripheral tolerance regulatory mechanisms involving the upregulation of co-inhibitory
molecules such as CTLA-4 on the surface of T cells, which has a high affinity for
B7/H1 and B7/H2, competitively bind to and work to out-compete CD28 for the same
cognate receptors, preventing cell cycle progression306. Furthermore, the programmed
death receptor receptor (PD-1), which is upregulated by chronically activated or
exhausted T cells and binds to its cognate ligands (PDL1 and PDL2) on tolerogenic
DCs, inhibits T cell activation by recruiting SHP1/2 to the TCR. SHP1/2
dephosphorylate early downstream signaling events307-311. Cancers appropriate the
upregulation of these natural homeostatic mechanisms of immunity to prevent
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immunological clearance. In addition to the immune checkpoints, cellular (Tregs and
MDSCs) and other molecular factors including T cell Fas/Fas-ligand interaction,
transforming growth factor-beta (TGF-b), IL-10, and indoleamine 2,3-dioxygenase 1
(IDO1), and immune suppressive cytokines contribute to peripheral tolerance
mechanisms in physiologic or pathologic states312,313. These factors are known to be
involved in inhibiting T cell activation. This would imply that in situations such as viral
diseases and cancer, the inhibition of T cells by upregulation of these factors could
subdue effector functions of T cells including interferon-gamma (IFN-γ), perforins, and
granzymes139. In fact, a number of studies have revealed the utility of blocking these
inhibitory signals in the tumor microenvironment in preclinical models of a diverse type
of cancers including BTs314. The results from those studies showed that inhibition of
such inhibitory signals slows the rate of tumor progression and is associated with
increased presence of cytotoxic effector T cells314-319.
The third signal includes a variety of stimulating cytokines including type 1
interferon (IFN-I) and IL-12. Mechanistically, IFN-I and IL-12 enhance T cell response
to basal IL-2 by prolonging the surface expression of IL-2 high-affinity receptor, CD25,
thereby activating downstream phosphoinositol-3-kinase (PI3K) pathway and cell cycle
progression genes via FoxM1320. As such, the third signal maintains long-term T cell
proliferation.

CD4 effector T cells
A subset of CD4 T helper cells enhance the activation of CD8 cytotoxic T cells
and also perform effector functions such as tumor killing. The Th1 subset of CD4
effector T cells is induced by IL-12 and IFN-γ and is identified by the expression of the
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Tbet transcription factor and production of cytokines including IFN-γ, IL-2, and TNFɑ321. This subset is involved in cell-mediated immunity and inflammatory conditions,
elimination of intracellular pathogens, and autoimmunity. Importantly, during T cell
activation, inhibition of the co-inhibitory molecules such as CTLA-4 resulted in a Th1mediated control of tumor322.
The Th2 subset is induced by a cytokine milieu in which IL-4 and IL-2
predominate323,324. Such T cells are identified by the expression of GATA-3
transcription factor and the production of IL-4, IL-5, IL-6, IL-10, and IL-13. This subset
is primarily involved in the production of antibodies by B cells, in elimination of
extracellular pathogens, and in allergic diseases such as asthma.
In chronic diseases, a different subset known as Th17 is induced by TGF-beta and IL6, and identified by the expression of RORγt and production of IL-17, IL-21, and IL-22.
Th17 cells play a role in the exacerbation of autoimmune conditions such as Crohn’s
disease and in the elimination of extracellular pathogens and fungal infections325.
Although their function remains controversial, elimination of Th17 cells resulted in
decreased tumor-bearing mouse survival326,327.

CD4 Regulatory T cells (Tregs)
CD4 regulatory T cells are a subpopulation of T cells that are usually
characterized by FoxP3 expression. In steady state, Tregs maintain immune tolerance
to self-antigens. Within inflammatory diseases, Tregs suppress T cell activation328-332.
Tregs are similar to other T cells in that they originate from the same lymphoid
precursor that populates the thymus. However, Tregs only acquire a distinct signature
during the later stages of T cell development in the medullary region of the thymus by
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binding to intermediate levels of self-antigen presented by autoimmune regulator
(AIRE+)-expressing medullary thymic epithelial cells333,334. In addition, before exiting
the thymus, they begin expressing high levels of the forkhead box P3 transcription
factor (FoxP3)335, a hallmark feature of functional regulatory T cells (Tregs). Deficiency
of Tregs in mice and humans leads to the rapidly fatal autoimmune condition known as
immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX)336,337,
demonstrating the key role of Treg cells in the maintenance of immune tolerance. The
thymus-derived Tregs are termed natural Tregs and are best defined by the expression
of CD4+, CD25+, and FoxP3+338. In addition, an inducible form of Tregs, which can be
identified with a similar set of markers, are potentially generated from effector T cells in
disease microenvironment such as cancer due to abundant immune suppressive and
differentiation cytokines such as TGF-beta339,340. Importantly, Tregs are highly enriched
in tumors and play an immune suppressive role by producing cytokines such as IL-10
and TGF-b305,334,341-343. Previous work showed that Tregs accumulate preferentially in
high-grade human gliomas, such as GBMs, altered effector function of non-Treg T cell
fraction in vitro, but there was no impact of Treg presence on patient survival179,344,345.
However, following similar observations in glioma-bearing mice, depletion of Tregs with
anti-CD25 antibody resulted in prolonged mouse survival indicating that Tregs play an
immune

suppressive

role

in

the

glioma

microenvironment178,179,318,319,346.

Mechanistically, the CCL2/CCR4 chemokine axis has been implicated in the
recruitment of Tregs in human glioma and strategies have been tested to modulate this
pathway347. In addition, small molecule inhibitors acting on pathways utilized by Tregs
such as the signal transduction and activation of transcription 3 (STAT3) pathway have
been shown to deplete Tregs and are about to be tested in clinical trials348,349.
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Furthermore, checkpoint blockade therapies including CTLA4, which have been shown
to alter the CD4 T cell compartment and prolong survival in glioma-bearing mice, are
already in clinical trials315. Thus, there is great interest in understanding immune
suppressive mechanisms that might be utilized by Tregs to subvert immune-eradication
of cancer and potentially resist these promising treatment strategies. However, it is
unknown how Tregs are regulated by DCs in brain tumor. This thesis will address how
Treg dynamics might be regulated in the BT microenvironment.

CD8 T cells
CD8 T cells are crucial in the elimination of viral infectious agents and in
controlling cancerous growths341,350-355. Depletion of CD8 T cells with monoclonal
antibodies is known to result in increased tumor growth and decreased mouse
survival356,357. CD8 T cell engagement with cancer cells in vitro results in the
polarization of cytolytic granules including perforins and granzymes toward the contact
area if effector function is maintained358. Perforins are released and contribute to cell
killing, in part, by creating pores in the target cell membrane thereby enabling the
penetration of granzymes and subsequent target cell lysis359,360. Because CD8 T cells
are effective in eliminating cancer during cancer immunotherapy, CD8 T cell proportion
in tumor has been applied clinically, to some extent, as a surrogate for response to
treatment361-367. Following the clearance of cancer cells or pathogens, CD8 T cells
contract and form a memory pool that can be rapidly recalled upon secondary
challenge by the same cancer or pathogen.
Memory CD8 T cells are also an attractive target in immunotherapy especially in
formulating anti-tumor vaccines because of its potential to prevent tumor occurrence or
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recurrence after successful treatment. An active area of tumor immunology research is
trying to understand how endogenous or exogenous transferred CD8 T cells can be
retained in tumor to promote tumor cell killing. Some survival molecules that are being
investigated include cytokines such as IL-2, IL-7, IL-15, and IL-21368,369, because they
are critical in both naïve T cell function and in maintaining memory CD8 T cell pool. In
the brain, CD8 T cells have been shown to form a tissue-resident memory pool after
the elimination of a model virus pathogen in mice370. This memory pool correlated with
the presence of a subset of CD11c+ DCs371, indicating that memory T cells may require
CD11c+ DCs after resolution of an infection, at least in the brain. In general, however,
how T cells interact with DCs and may be retained in BTs is unknown. I will be
investigating the retention and interaction dynamics of T cells in this thesis.

1.4.6. Dynamics of DCs and T cells in anti-tumor immune surveillance
Anti-tumor immune surveillance is a very dynamic process. For this to occur
during a natural anti-tumor immune response there must be cell-to-cell interaction
between myeloid cells and T cells, and between T cells and the tumor372-375. Classical
immunological techniques such as flow cytometry, immunohistochemistry, and animal
cell transfers or chimera experiments have been used to establish a basis for immune
cell infiltration and interactions in tissue; however, they have limited primary utility, but a
significant complementary role in dissecting, understanding, and defining distinct real
time cell dynamics and interactions within the immune circuit. Recent advances in
intravital confocal and two photon microscopy have played a major role in the
investigation of cell interactions in various organs and tissues including the eye, skin,
lung, liver, intestine, brain, and lymph nodes376. While this technical application has
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advanced our understanding of immune cell interactions especially in the lymph
node295,377-379, it has only been recently deployed to study immune surveillance of
tumors in peripheral organs including the lungs, skin, brain, mammary fat pad, and
abdomen374,380.
Through intravital multiphoton microscopy and complementary in vitro live cell
studies of mostly infectious diseases373,379,381-383, it has been established that naïve T
cells in the lymph node are highly motile. Naïve T cells display high average velocities
of between 10-15μm/min, show non-directed random motility, and high instantaneous
speeds of up to 25μm/min. However, upon making contact with antigen-loaded DCs, T
cells show reduced velocity and instantaneous speed and persist in long-lived
contacts384. Thus, the exceptionally high speeds displayed by T cells in the lymph
node have been explained as a mechanism to enhance the scanning efficiency of
naïve T cells for peptide-loaded DCs.
Super-resolved in vitro microscopy studies of peptide-loaded DCs and T cells
have enhanced our understanding of immune synapse formation between cytotoxic T
cells (CTLs) and DCs385-393. This highly dynamic process involves a feedback
mechanism between CTL actin cytoskeleton polarization and TCR signaling. The
mechanism entails the polarization of CTL actin cytoskeleton toward the immune
synapse, upregulation of adhesive molecules such ICAM-1 and LFA-1, ligation of the
TCR to the pMHC-DCs, and subsequent TCR downstream signaling that eventually
results in the activation of the CTLs. Calcium imaging studies and model antigens such
as ovalbumin have also enhanced the appreciation of the level of strength of T cell
activation during such interactions394-396. In addition to the TCR ligation, the expression
of co-stimulatory ligands such as CD28 and its interaction with its cognate B7-H1/B747

H2 receptors on DCs has been detailed296,306,397. As these processes are critical for T
cell function, it will be important to study these processes in the BT microenvironment,
as there may be differences in how T cells interact with DCs in vivo.
In the tumor, the dynamics of immune cells in general are less wellunderstood398,399. Nevertheless, in time-lapse movies, antigen-experienced T cells
engage cancer cells and potentially a myriad other immune and stromal cells. Although
it was predicted that an activated T cell could make sequential one to one contacts to
kill cancer cells as had been observed in vitro, it has become apparent that this is a
more complicated process in vivo400. For example, intravital imaging has shown that it
takes approximately 6 hours for one cytotoxic T cell to kill one cancer cell372. This
indicates that cancer killing, in vivo, is a very slow process, and supports the idea that
large numbers of cytotoxic T cells are required to make any meaningful impact in tumor
progression. However, possibly due to antigen recognition, T cells display a variety of
migration patterns in vivo such as maintaining prolonged interactions, less prolonged
interactions (“kiss and run”), or no interaction401. Therefore, it is likely that given a
certain number of cytotoxic T cells in the tumor, only a proportion of those T cells may
be involved in active killing of cancer cells. Despite these potential limitations, valuable
knowledge has been obtained by direct visualization of T cell surveillance in tumor. For
example, in a a model of subcutaneous tumor, OVA-expressing EG7 thymoma cells
were implanted in mice and subsequently infused with exogenous TCR transgenic OTI-CTLs.Tumor-antigen specific CTLs infiltrated the tumor and show high expression of
CD69 and IFN-y, indicating T cell activation. They exhibited reduced velocity, their
migratory pattern became more confined, and they showed increased arrest in the
tumor relative to non-OT-I-expressing CTLs372,402,403. Recent studies in mammary fat
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pad of mice also utilizing the model OVA-antigen have shown that exogenously
transferred OT-I-CTLs can persist in prolonged contact with DCs at the margin of the
tumor, where they undergo reactivation375. These findings indicate that T cells must
recognize cancer antigens in order to engage in prolonged interactions in the tumor
microenvironment, potentially with cells such as DCs, macrophages, and/or tumor. It
must be recognized that despite the ease of using model antigens in mouse studies to
simplify our understanding of anti-tumor immune response, parallel studies in human
tissues require analysis of highly polymorphic MHCs expressing a vast array of tumor
associated-antigens, and variably recombined TCRs may have different reactivity to T
cell epitopes404. A more recent study utilizing intravital imaging within a subcutaneous
tumor suggested that during tumor progression, DCs “trap” CTLs; however, little is
known about the role of DCs in the regulation of T cell surveillance in tumor.
Specifically, much less is known within BT. Therefore, I will be devoting chapter 3 of
this thesis to comprehensively address some questions pertaining to the role of DCs in
BT immune surveillance and their interaction with T cells.

1.4.7. Role of chemokines in immune cell recruitment and surveillance in brain
tumors
For immune cells to establish cell to cell contact, they must first migrate to the
tissue of interest. Immune cells are highly dynamic and can migrate over long and short
distances405,406. Myeloid cells such as DCs are generally generated from monocytes
that migrate from the bone marrow and seed tissues while adaptive T cells egress from
lymph nodes to tissue after undergoing priming. Chemokines are cytokines involved in
the chemoattraction of cells in normal homeostatic conditions and at sites of
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inflammation407. Several chemokines have been identified and they are grouped into
four subfamilies including C-, CC-, CXC-, and CX3C- based on the number and
spacing of cysteines.
During inflammation, chemokines may be expressed at tissue endothelial
surfaces in a bound form or released as a soluble form into serum. Importantly,
immune cells migrate over chemokine gradients and utilize adhesion molecules such
as integrins to bind to endothelial-bound chemokines in order to transmigrate into
tissues via the vasculature408,409. Interestingly, DCs have been shown to exhibit
differential migration patterns depending on the form of chemokine available. For
example, surface-immobilized CCL21 was found to induce random migration of DCs,
whereas a soluble CCL21 induced a directional motility pattern408. Although the
repertoire of chemokines necessary for myeloid and T cell migration is vast, the
specifics of how immune cells migrate and organize themselves in BT remains unclear
and the regulation of this process is largely unknown.
In the brain, several factors have been implicated in immune cell recruitment
during inflammation including chemokines, neurotransmitters, molecules of the
complement pathway, and ATP216. In BTs, glioma cells have been shown to produce a
host of chemoattractants, which have been implicated in the recruitment of TAMs.
including

CSF-1,

monocyte

chemoattractant

protein-3

(MCP-3),

monocyte

chemoattractant protein-1 (MCP-1/CCL2), hepatocyte growth factor and scatter factor
(HGF/SF), fractalkine (CX3CL1), glial cell-derived neurotrophic factor (GDNF), CXCL12
(SDF-1), and granulocyte macrophage-colony stimulating factor (GM-CSF). This
indicates that there are a multitude of chemoattractants that can mediate immune cell
recruitment in BTs. However, many of these studies have been conducted in vitro using
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microglia cell lines, and in vivo studies on the importance of some chemoattractants
such as MCP-1 have been challenged216. Out of all these, fractalkine is a particularly
compelling candidate since it is highly expressed at steady state in brain tissue in
comparison with other organs and has been termed the “neuronal chemokine.” Yet, its
role in BT immune surveillance is unknown.
Fractalkine is constitutively expressed in a membrane-bound form by neurons in
a healthy brain and can be subsequently cleaved into a soluble form by
metalloproteinases (MMPs) such as ADAM10 and 17 following tissue damage210. In the
membrane-bound form, fractalkine exists as a 373 amino acid with an extracellular
domain and mucin-like stalk, a transmembrane domain, and a cytoplasmic tail410.
Following MMP cleavage, however, the soluble form acts as a chemokine that has an
extracellular domain and the mucin-like stalk. Thus, fractalkine can serve both adhesive
and chemotactic functions depending on the state of the tissue411,412.
Fractalkine acts on and signals via its only known receptor, CX3CR1413,414.
CX3CR1 is a G-protein coupled receptor413. CX3CR1 has been studied extensively
with respect to microglia and macrophages in the context of cellular adhesion,
apoptosis, and migration (Figure 9) but CX3CR1 is also expressed on the surface
membrane of monocytes, and some DCs as such CX3CR1 may mediate DC and
monocyte

migration

and

function

in

both

physiological

and

pathological

conditions210,409-411,414,415. In steady state, CX3CR1 is ubiquitously expressed by
microglia in the brain parenchyma.
The expression of both fractalkine and CX3CR1 has been intensively studied in
neurogenesis, neurodegenerative diseases such as Alzheimer’s, and in brain
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tumors213,416. The disruption of CX3CR1 has been shown to affect neural pruning,
suggesting that microglia is critical in brain development211,213. In addition, CX3CR1
deficiency may or may not have a role in mediating microglia function duringplaque
removal and neuronal damage in models of Alzheimers417,418. Recently, CX3CR1
deficiency was found to be associated with Ly6C+ classical monocytes infiltration in
BTs and reduced survival in BT-bearing mice; however, DCs and T cells were not
studied419. In addition, this process was determined to be orchestrated by IL-1 since
fractalkine showed very low expression in mouse or human GBM cells/tumor mass,
where the monocytes/macrophages were localized.419. However, it seems unlikely that
fractalkine that is constitutively and highly expressed in healthy neuronal cells and a
major chemokine would be dormant during an inflammatory process involving tumorinduced tissue stress/damage and immune cell recruitment237. In the brain, it is
possible that aggressively progressing tumors damage neurons and induce of the
release of soluble fractalkine, which is an ideal candidate to regulate the dynamics of
anti-tumor immune surveillance.
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Figure 9. Role of Fractalkine/CX3CR1 chemokine pathway.
The roles of Fractalkine are illustrated in the figure. It shows membrane bound and
soluble Fractalkine (cleaved by metalloproteinases) participating in cellular adhesion
and survival anti-apoptosis/migration, respectively.

1.5. Specific aims
Based on the information in this chapter, my central hypothesis is that brain
antitumor immune surveillance by T cells is regulated by extracranial myeloid cells,
such as BM-derived DCs through the neuronal chemokine fractalkine. I will present
results from the investigation of this hypothesis in two specific aims:

1. Determine the role of antigen presenting cells in the recruitment and
dynamics of T cells in brain tumor microenvironment by employing real time
imaging techniques
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2. Determine the role of fractalkine/CX3CR1 signaling pathway in the dynamics
of immune response to brain tumors by utilizing genetic knockout mouse
models and intravital microscopy.

The work in this thesis is aimed at determining the identity and composition of
myeloid cells infiltrating BT and understanding the fundamental cellular mechanisms
regulating anti-tumor T cell immune surveillance. In addition, I have examined a
molecular mechanism involving how a local chemokine produced in the brain tissue
governs immune response to BTs. The results obtained from the experiments
conducted in this thesis will increase our understanding of BT immune surveillance and
will be relevant in developing strategies to enhance conventional immunotherapy.

1.6. Overall approach and rationale
The studies conducted in this thesis will help in constructing a brain tumor
landscape of immune cellular localization, migration, and interaction. For this to be
accomplished, appropriate tumor models will be used. Genetically engineered mouse
models of spontaneously developing tumors (GEMMs) are the gold standard for
studying tumor progression in preclinical settings. However, these models are driven by
mostly oncogenic mutations and lack the endogenous passenger mutational load that
may be relevant for proper antigenic immune cell recognition and function. Similarly,
cancer cells derived from human BTs contain genetic mutations that may be closest to
those detected in human patients with cancer; however, they have to be grown within
immune deficient mice to prevent rejection. Thus immune response to such tumors
cannot be adequately studied. In contrast, experimental tumor models derived from cell
cultures of carcinogen-induced cancer types from different tissues including the brain,
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lungs, skin, and soft tissues can potentially develop in immune-competent syngeneic
animals when re-implanted. Importantly, it has been shown that tumors derived from
such cancer cell types possess high mutational loads63 and are strongly
immunogenic117,139, suggesting that there is likely to be endogenous immune reactivity
when implanted in vivo in immune competent mice and as such help in the
understanding of T cell surveillance in tumor. Therefore, to investigate the dynamics
and regulation of endogenous immune cells in BTs, I have employed longitudinal
intravital multiphoton microscopy of immune cells in experimental BT models including
GL261 glioma, Lewis lung carcinoma (LLC), B16 melanoma, and MCA fibrosarcoma
brain metastases. The rationale for employing intravital two-photon microscopy is to
provide high spatiotemporal 3-dimensional resolution time-lapse images to better
understand T cell surveillance in BTs in a dynamic fashion.

Two-photon microscopy:
Two-photon microscopy is a powerful imaging technique in biological research.
In contrast to a confocal microscope that generates single high-energy photons from
ultraviolet lasers to excite molecules in a volume of tissue, a 2-photon microscope
works by simultaneously directing two separate low-energy photons of long
wavelengths generated by ultra-fast femto-pulsed infrared lasers at a molecule. In
confocal microscopy, excitation works linearly, while it is non-linear in 2-photon
microscopy, meaning that, theoretically, image resolution is better with confocal
microscopy; however, practical adjustments can be made in 2-photon microscopy to
produce confocal-like resolution images.
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Figure 10. Illustration of tissue excitation and emission in confocal and 2-photon
microscopy. The green region represents the volume of tissue excited by photons.
The green sphere at the intersection of the inverted cones represents the volume of
tissue at the focal plane of interest. The region within the inverted cones represents
the volume of tissue above and below the focal region of interest.

It is worth noting that low-energy photons are significantly less absorbed by
molecules such as fluorophores than high-energy photons. Based on this principle,
several advantages of using a 2-photon microscope become apparent. First, in contrast
to confocal microscopy in which high-energy photons excite molecules above and
below the focal plane in a volume of tissue illuminated (Figure 10), the low-energy
photons of a 2-photon microscope only excite molecules in a focal plane, where the
probability of two separate photons converging on a single molecule is highest. Further,
because a large volume of tissue is excited during confocal microscopy, there is a lot of
light scattering that occurs from out-of-focus planes leading to a blurred image. Hence
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a pinhole is required to prevent the collection of out-of-focus scattered light. In contrast,
since a 2-photon microscope restricts excitation of a molecule to a single plane,
scattering from out-of-focus planes is greatly diminished and a pinhole is therefore not
required. This enables deeper penetration of more low-energy photons into the brain
tissue, resulting in better signal-to-noise. Interestingly, a very good example of a tissue
that is highly light-scattering is the brain. In addition, exposure of large volumes of
tissue to excitation in confocal imaging can potentially lead to
photobleaching/photodamage and possible loss in tissue viability, while
photobleaching/photodamage are limited to the focal plane of interest in 2-photon
imaging and as such better preserves tissue viability. Especially relevant to brain
imaging, low-energy photons in 2-photon microscopy can penetrate deeper into
biological tissues to depths of up to 600um to 1mm420-425, while confocal imaging is
usually limited to the surface of tissues to a depth of about 100um from the surface.
Apart from the advantages above, 2-photon imaging also has the capacity to produce
signals from unlabeled tissue samples such as collagen and muscle based on secondharmonic generation (SHG). In this thesis, SHG will be used during imaging to visualize
skull and meninges without any labeling, which will enable differentiation from the
underlying brain cortex.
Despite the advantages of 2-photon microscopes, the image resolution is usually
lower than with confocal imaging. This is immediately understandable because a
microscope’s scale resolution is inversely proportional to the wavelength of light
used420. As such, 2-photon imaging requires expensive objectives with high numerical
apertures. In addition, thermal damage arises during imaging of pigmented specimen
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and could be potentially problematic during imaging of pigmented tumors such as
melanoma.
The use of intravital two photon microscopy here is innovative because it has not
been used previously to the extent of its application in the studies conducted in this
thesis. In addition, it will reveal information such as real time in vivo single cell-cell
interactions in a multidimensional manner that cannot be accessed otherwise.

Tumor models
The tumor types that will be utilized include fluorescent-labelled syngeneic
GL261 glioma, Lewis Lung Carcinoma (LLC), MCA-fibrosarcoma, and B16-F10
melanoma. I have selected these cancer types because they recapitulate the most
prevalent and deadly of patient primary BT and brain metastases to a certain extent, at
least in an experimental setting. Importantly, as described earlier, each of these models
is syngeneic to the immune competent hosts in which they will be studied, and thus can
implanted to be studied in an orthotopic or heterotopic manner. To visualize tumor
growth by intravital imaging, the cancer cells have been made fluorescent. As it is likely
that fluorescent cancer cells may have higher immunogenicity due to the fluorescent
proteins, appropriate controls have been used for proper interpretation of the data.

Experimental strategies
To visualize immune cell interaction with tumor, a broad range of multi-color
reporter mice have been used to visualize distinct groups of immune cell populations
including microglia, monocytes, DCs, T cells, and Tregs. For further visualization of T
cell subsets and important molecules involved in T cell interaction, cells have been
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stained by tissue immunofluorescence. To increase the robustness of the investigations
in this thesis, genetic knockout mice, cell-specific in vivo depletion experiments such as
in cell-specific diphtheria-toxin receptor mice, and bone marrow transfer studies have
been conducted. In addition, to ascertain relevance to human patients with brain
tumors, selected studies have been conducted on human tumors. It is hoped that the
studies completed here will reveal relevant mechanisms underpinning anti-tumor T cell
surveillance in the brain and provide new insight into how to optimize immunotherapies
for brain tumor patients.
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CHAPTER 2:
MATERIALS AND METHOD
Cell lines
MCA-205 fibrosarcoma cell line was obtained from Dr. Xiao-Feng Qin (The
University of Texas MD Anderson Cancer Center (UTMDACC)) B16-F10 was obtained
from Dr. Willem Overwijk (UTMDACC), LLC was obtained from Dr. Limo Chen
(UTMDACC), and GL261 was purchased from American Type Culture Collection
(ATCC). Cell lines were confirmed to be mycoplasma free. Cancer cells were
maintained in RPMI culture medium containing 5% fetal bovine serum (FBS), 1%
Penicillin/Streptomycin (P/S), 1% beta-mercaptoethanol or in DMEM/high glucose
media containing 10% FBS and 1% P/S. Cells in culture were stored in incubators at
370C and 5% CO2. To render the cells fluorescent for intravital microscopy, MCA-205
fibrosarcoma, B16-F10 melanoma, Lewis-lung carcinoma (LLC), and GL261 glioma cell
lines were transduced with VECTOR DESCRIPTION encoding the mCerulean
fluorescent protein as previously described.426

Animals
Use of animals was approved by the institutional use and care committee
(IACUC) under protocol number 00000878-RN01. All animals were on the C57Bl/6
background and bred in-house or commercially purchased. C57Bl/6 wild type (WT),
Rag1-/-, CX3CR1-GFP, and CCR2-RFP mice were purchased from the Jackson
Laboratories (Bar Harbor, ME). Additional C57Bl/6 WT mice were purchased from the
Radiation Oncology Department at UTMDACC. CD11c-EYFP mice were obtained from
Dr. Michel Nussenzweig, The Rockefeller University, New York, NY; hCD2-DsRed mice
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were from Dr. Dimitris Kioussis, The National Institute for Medical Research, Mill Hill,
London, U.K.; and ROSAmT/mG mice were obtained from Dr. M. Konopleva, Dept. of
Leukemia, UTMDACC. Various combinations of these strains were generated by
interbreeding and genotyping. For experiments, mice of both sexes were used at ~1.5
to 6 months old and euthanized by CO2 inhalation and cervical dislocation in line with
the IACUC guidelines.

Brain Tumor Models
To generate tumors in mouse brain, cancer cells were prepared and injected
either directly by intracranial injections or indirectly via the internal carotid artery.
Cancer cells were harvested from 10 cm cell culture dishes at logarithmic growth phase
by washing with 1x PBS and trypsinizing with 2ml of 0.05% trypsin for about 2 minutes
and detaching the cells by gentle agitation of the dish, followed by trypsin neutralization
with 8 ml media and cell concentration by centrifuging at 1,350rpm, 40C, for 10
minutes, repeated for a second wash in HBSS. Cell concentration was measured with a
hemocytometer and adjusted for injections as described later. Cells were kept on ice
throughout the length of the injection procedure.

Preparation of intravital thinned skull windows
To create skull window for longitudinal imaging, the mouse was anesthetized
with a loading dose of 10µl/g mouse of 10mg/mL ketamine and 1mg/mL xylazine
cocktail intraperitoneally, followed by 50µl of same concentration every 15-20 minutes
to maintain anesthesia until completion of surgery. Fur was depilated from the cranial
vault, which extended to the nasal bridge anteriorly, the temporal skull regions laterally,
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and the occipital region posteriorly. The skin was then decontaminated using swabs of
betadine and 70% alcohol. The skin overlying the cranium was excised and the
pericranium was gently detached from the underlying skull bone. Mouse was restrained
with tapes on a surgical stage and warmed with a heating blanket for the entire length
of the surgery. A 5-6 mm diameter parietal skull region to be thinned was marked using
a pen 1-mm lateral to the sagittal suture and 1-mm posterior to the coronal suture.
Vetbond glue was then applied on the dry skull except within the region marked with a
pen. The marked skull region was thinned to about 10-20 μm in thickness using a highspeed diamond drill with saline cooling. Specifically, the outer table or cortical bone and
spongy medullary cavity of the mouse skull were surgically shaved off, leaving an intact
inner table. Further shaving was done with cone-shaped drill bits to increase the optical
quality of the inner table. Thereafter, the thinned skull was reinforced with a 5mmdiameter/1mm-thickness round cover glass that was lightly attached to the inner table
to prevent indentation of the thinned skull into the cranial compartment. Further
strengthening of the window preparation was done using dental cement.

Internal carotid artery injection for metastasis models
Brain tumors were induced by injection of cancer cells into the internal carotid
artery (ICA). Specifically, the mice were anesthetized, the fur was depilated on the
anterior region of the neck, and the exposed skin was decontaminated with betadine
and 70% alcohol. After this, a 1 cm midline incision was made on the anterior aspect of
the neck, followed by exposure of the common, external, and internal carotid arteries.
The common carotid and external carotid arteries were ligated and 1 x 105 cancer cells
in 0.1 ml volume of saline were infused via the patent part of the common carotid artery
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into the internal carotid artery, which supplies the brain. Infusion of cancer cells was
done slowly over 30 seconds to 1 minute. After this, the patent part of the common
carotid artery was then ligated, and skin was closed using surgical staples.

Orthotopic cancer injection for the GL261 glioma model
For direct intracranial injection, the mice were anesthetized, the fur was
depilated on the head, and the exposed skin was decontaminated with betadine and
70% alcohol. A 5-6 mm burr hole was placed in the parietal skull while preventing
damage to the dura mater. 2 x 104 cancer cells were implanted using a glass pipette
attached to a micromanipulator system (Sutter, Novato, CA). The glass pipette was
stereotactically oriented at the center of the exposed brain region and inserted to a
depth of 200-250 μm. Cancer cells were injected in 2 μl volume of phosphate-buffered
saline (PBS) over a period of 2 to 5 minutes and the pipette was then withdrawn slowly
over a period of 15 to 20 minutes. An air-brain interface was created by applying PBS
or artificial CSF427,428 on the exposed brain. This was followed by closure of the brain
by use of a glass coverslip that was adhered with Vetbond glue to the adjacent skull
and further reinforced with dental cement.

Tail vein injection
For tail vein injection, cells were harvested with trypsin and washed twice in
PBS. 105 cells were injected via the tail vein into mice.
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In vivo depletion of CD8 T cells
For CD8 T cell depletions, mice were injected with 100 mg/ml anti-CD8ɑ
antibody (Clone #53-6.72, BioXcell, San Diego, CA) intraperitoneally, either one day
before or on day 5 after injection of cancer cells and then every other day until the
experiment was terminated at day 20 after cancer cell injection. Control animals were
injected with PBS. Depletion was verified by flow cytometry analysis of CD8 T cell
levels in mouse peripheral blood.

Depletion of CD11c-YFP cells
Mouse expressing both YFP and diphtheria toxin receptor (DTR) under the CD11c
promoter was used for depletion of CD11c cells in longitudinal imaging studies.
Specifically, CD11c cells were depleted by consecutive injections of100ng/day of
diphtheria toxin (DT) on days 11 and 12 after a baseline time-lapse movie of CD11cYFP cells in the tumor had been acquired. Depletion of CD11c-YFP cells was
confirmed by in vivo visualization of CD11c-YFP cells in the tumor on day 13.

Bone marrow transfer studies
CD11c-EYFP/hCD2-DsRed and CX3CR1GFP/GFP mice were used as donor and
recipient, respectively. Bone marrow (BM) was harvested from CD11c-EYFP/hCD2DsRed mice, resuspended in RPMI media, and injected intravenously via the tail vein
into unirradiated CX3CR1GFP/GFP mice (7 x 106 cells/mouse). BM infusion was done
either one day before cancer cells were injected into mice via the ICA or five days after
ICA cancer cell injection. Brains of recipient mice were harvested, and brain tumors
were analyzed at day 20 after ICA cancer cell injection.
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Immunofluorescence
Brain tissue was embedded in optimal cutting temperature (OCT) medium and
stored at -800C immediately after mice were euthanized. Embedded brain tissues were
cryotome sectioned into 5-8 μm thin sections. Sectioned fresh brain tissues were
stained with various antibodies, either alone or in combinations including, anti-mouse
MHC-II biotin conjugated antibody (1:100; Clone M5/114.15.2; eBioscience) as a
primary and APC streptavidin (1:500; Cat.#554067; BD Pharmingen) as secondary;
and purified rabbit anti-mouse fractalkine (1:100; Cat.#TP233; Torrey Pines Biolabs
Inc.) as the primary and Alexafluor-647 goat anti-rabbit (1:500; Cat.#A31633; Invitrogen
Molecular Probes) as the secondary. Antibodies were used in a 1:100 dilution ratio in
blocking buffer. Specifically, frozen tissues were first washed with PBS to get rid of the
OCT. After this, the tissues were incubated with blocking buffer (SuperBlock blocking
buffer; Thermo scientific; #37517) for 30 minutes. Subsequently, tissue samples were
washed twice in PBS, and then incubated with antibodies overnight as described.
Finally, the antibody was washed off of tissues by using PBS. For fresh tissue sections,
the specimens were immediately incubated in blocking buffer for 30 minutes to 1 hr
before proceeding through similar steps as with the frozen sections. Tissues were
mounted with Prolong Gold (Invitrogen) and imaged using a Leica SP8 confocal laser
scanning microscope (Leica Microsystems, Buffalo Grove, IL).

In vivo dynamic microscopy
Intravital microscopy was performed using a customized two-photon confocal
SP5 laser scanning microscope (Leica Microsystems, Buffalo Grove, IL) with four
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channel non-descanned detectors, including two hybrid (HyD) detectors, and two
femtosecond lasers (Spectra-Physics). The system was operated in a fast resonant
scanning mode with frame averaging or in a conventional galvo-scanning mode. Mice
were anesthetized as earlier described. After confirming complete anesthesia, mice
were head-immobilized with a custom-made stereotactic holder on a heated motorized
microscope stage maintained at 370C throughout the entire imaging procedure. To
highlight the vasculature, TRITC-dextran; 155kD (10mg/ml; Sigma Aldrich; #T128750MG) was diluted at a concentration of 1:5 in PBS and 50μl injected via the tail vein or
retro-orbital route. Time-lapse stacks of images were acquired using Nikon objectives
(16X, NA = 0.8 or 25X, NA = 1.1), at a distance of 5 μm between Z-planes and a 20 to
30 seconds inter-stack interval, for a period of 30 minutes to 2 hours. Interline
sequential excitation at two femtosecond-pulsed wavelengths was used to enhance
channel separation as follows: 840 nm excitation: CFP, GFP and TRITC emission; 990
nm excitation: SHG, YFP and DsRed emission. Typical image format was 512 x 512
pixels. Some sequences were acquired in 1024 x 1024 pixel format. For longitudinal
studies, imaging was repeated on the same area using the vasculature as landmark at
set time points after cancer cell implantation until about 30 days.

Ex vivo imaging
For ex vivo imaging, brain was harvested after mouse circulation fixation with
4% paraformaldehyde under anesthesia. The brain was sectioned into 4-5 equal thick
coronal sections (~2mm each) with a sharp blade, sections were overlaid with a PBSmoistened cover glass and imaged through a 2X and 4X objectives (Olympus), or a
16X NA = 0.8 objective (Nikon).
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Image processing
Prior to analysis, acquired images were subjected to processing using the Leica
Application Suite version 1.7.0 build 1240 (Leica Microsystems). Images were parsed
through several stages. For example, if images were noisy, filtering was performed by
applying a median filter width of 3. Next, crosstalk correction was performed on each
channel to eliminate channel bleed-through. Subsequently, images were analyzed in
xy-2-dimension maximum intensity projections created from all images, xyz-3dimension images, or xyzt-4-dimension time-lapse images.

Image analysis: cell tracking
For three-dimensional cell tracking and contextual analyses, Leica Image
Format (lif) files were opened using Bitplane Imaris analysis software versions 7 to
8.3.1 (Bitplane AG, Saint Paul, MN). Voxel dimensions were specified according to the
objective used for image acquisition. If drift was present, it was corrected based on
averaged landmark features such as cancer cell groups. T cell motility was analyzed by
tracking individual T cells using the spot and surface tools of Imaris. For time-lapse
images obtained from the open skull window experiments, cells at a depth of >100 μm
below the cover glass were analyzed to avoid potential confounding surface tissue
artifacts. Cells were tracked by initial automated spot detection followed by
autoregressive spot tracking and manual tracking. Quantitative analyses were done on
all tracks with a duration > 10 min. Contextual analyses, which involves determining the
behavior of cells in context of other cells or anatomical structures, were based on
surface detection followed by distance transformation.

67

Image analysis: static analyses
Large area imaging by image stitching
For gross analysis of the brain, multiple images were acquired and stitched.
Each individual image was generated from a z-stack by projecting in 2-dimensions
using maximum intensity projection in Leica processing software. Image stitching (tile
alignment) was done in Photoshop CS6. Line intensity profiles were generated from
images using the Line tool on Slidebook version 5/6 or ImageJ.
Cells were counted using the spot function in Imaris. If direct counting of cells
was not possible due to dense cellular clustering and insufficient image resolution in
the image of the data set, then cell counts were obtained using a volumetric approach
implemented in Imaris software429,430. Thus, volumes of either CD11c-EYFP or hCD2DsRed T cell objects were delineated in 3-dimensions by thresholding. Cell numbers
were calculated by dividing each volume by the average calculated volume of a given
cell type, which was calibrated in the same data set based on averaging individually
measured volumes of multiple well-isolated single cells (10-20 cells). Overall cell
densities were calculated by dividing the number of cells by the z-stack volume.
Sphericity is the extent to which the shape of a cell closely approaches that of a
mathematically perfect sphere. It is calculated by using the surface tool in Imaris to
represent a cell, and the software models the cell’s shape and does calculations to
determine the extent of sphericity, which ranges from 0 to 1.

Cell-cell spatial correlation
To analyze the degree of spatial correlation between cell types, each primary
image was divided into nine equal sub-fields. In each sub-field, total areas of each cell
68

type were obtained by segmentation of images in respective channels. Resulting paired
values (measured in pixels) were analyzed for correlation using GraphPad Prism
Software.

Contextual image analyses
Proximity of T cells to DC or cancer cells.
For calculating cellular densities inside and outside tumors, and at tumor
margins, each of these regions was determined using the surface tool and distance
transformation, followed by splitting the DC and T cell volumes (or spots) in each
measured tumor region volume. Distances of T cell to CD11c-YFP DC was generated
after converting T cells to spot objects by using the spot tool and CD11c-YFP cells to
surface object by using the surface tool. Imaris Distance Transformation function was
then used to create certain threshold distances outside CD11c-YFP cell surface
objects. Finally T cell distance to CD11c-YFP cells was generated using the Filter and
distance threshold functions.

Analysis of myeloid cell subset numbers and densities within the tumor, at the margin,
and within the extratumoral region or brain parenchyma.
To identify all highlighted myeloid cells, CX3CR1+/GFP/CD11c-YFP/CCR2-RFP
channels were all normalized and added together by using the Arithmetic processing
function on Imaris to create a single “myeloid” channel. Each cell in the “myeloid”
channel was then represented as a spot by using the spot tool. The Surface tool was
then used to create tumor surface object, and the Distance Transformation tool/Filter
and Distance threshold functions were used to generate distances from outside or
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inside the edge of the tumor surface object and used to segregate spots (CX3CR1+/GFP
/CD11c-YFP/CCR2-RFP) into different compartments (tumor outside, tumor margin,
and tumor core) from the “myeloid” spot population.

Human Samples
Human GBM tissue and blood samples were obtained by Dr. A. Heimberger
under approval from the Institutional Review Board of UTMDACC LAB03-0687.
Informed consent was obtained from each participant. Patients’ tumors were graded
pathologically as newly diagnosed glioblastoma (glioblastoma, n = 11) by a
neuropathologist according to the World Health Organization (WHO)
classification. Peripheral blood was drawn from the patients intra-operatively or healthy
donors (n=11). Control CD14+ cells [a general marker of monocytes and monocytederived macrophages 431 (n = 4, age range of 26-35) from intractable epilepsy brain
tissue was provided by Prof. Jack P. Antel (Montreal Neurological Institute). CD11b+
cells from postmortem brain tissue (n = 4, age 67 and 78, gray and white matter, post
mortem delay 7-9 h) were obtained from The Netherlands Brain Bank (NBB),
Netherlands Institute for Neuroscience, Amsterdam (open access: www.brainbank.nl).
All Material has been collected from donors who provided a written informed consent
for a brain autopsy and the use of the material and clinical information for research
purposes obtained by the NBB. Human glioma or CNS tissue was digested with
Liberase TM enzyme which contains highly purified collagenase I and II. This approach
significantly improves cell isolation when compared with standard collagenase
digestion.432 After enzymatic digestion, the myelin was removed by centrifugation using
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a Percoll gradient which has previously been shown to result in the highest viability of
CD11b+ cells.433

Statistics
GraphPad Prism version 6.00 (GraphPad Software), Microsoft Excel (Microsoft
office package), and statistical software R v3.3.1 with packages nestedRanksTest v0.2
and nlme v3.1-128 were used for statistical analyses. Student t-test was used to
analyze normal-distributed data while the non-parametric Mann-Whitney test (twogroup comparison) was used to analyze non-normal distributed data. When
appropriate, non-normal-distributed data were transformed by logarithm for the
parametric analysis. For data including several mice in which T cells were followed
longitudinally in the same mouse, the mixed effects regression model was applied to
account for variability in T cell behavior and heterogeneity between mice. The mixed
effects regression model434 was employed to examine the change of T cell velocity
after CD11c-DC depletion. Each observation of velocity was first normalized using
logarithmic transformation. T cell arrest coefficients were arranged in [0,1] with
significantly inflated 0s and 1s, with 0 and 1 representing T cell values pre- and postCD11c-DC depletion, respectively.
For the mixed effects regression model:
Suppose yij is the velocity of jth T cell from the ith mouse. APij takes value of either 0 or 1, where
1 indicates that the jth T cell from the ith mouse is after depletion, 0 before depletion. β i0 and

β i1 are between-mouse random effects for intercept and slope. To examine the change of T cell
velocity after depletion, we test whether H0: α1=0 against H0: α1!=0.
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This can be mathematically represented as follows:
log(yij) = α0 + β i0 + (α1 + β i1)*APij + εij

β i0 ~ N(0, σ02)
β i1 ~ N(0, σ12)
ε i1 ~ N(0, σε2)

Since we failed to transform arrest coefficient values to fit a Gaussian distribution, we
applied non-parametric nested Mann-Whitney-Wilcoxon Test435 to make comparison
before and after CD11c-DC depletion.
Horizontal bars represent the means, and vertical bars represent +/- Standard
Deviation (SD). P values of less than 0.05 were considered statistically significant
(*p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001).
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CHAPTER 3: LONGITUDINAL INTRAVITAL VISUALIZATION OF ENDOGENOUS
INNATE AND ADAPTIVE IMMUNE SURVEILLANCE IN BRAIN TUMORS
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Part I: Development of an intravital imaging system to investigate immune
response to brain tumors.
Introduction
Multiple physiological mechanisms exist to protect the brain from immunemediated neuronal damage150. However, these same protective mechanisms make it
challenging to tease apart physiological responses of brain immune cells in intravital BT
imaging as traumatic brain preparations are involved. From the exterior; the
pericranium, skull, dura, arachnoid and pia maters, and vascular barriers prevent the
accessibility of the brain parenchyma to environmental pathogens, blood-borne
infectious agents, molecules, and antibodies. Such barriers include the blood-brain
barrier and the blood-CSF barrier68,145,146,148,149,152,155,436-439. In addition to these exterior
deterrents, in the event that the brain vasculature is breached, there is rapid migration
of microglia to the site of vascular damage, and is a process that is not clearly
understood in the context of brain metastases initiation76,214. Recent studies have also
shown in intravital movies how the brain vasculature is immediately repaired by
macrophages, which are required to “glue” breached endothelial tips together440. All of
these support a model in which the homeostatic state of brain resident immune cell
populations changes rapidly upon direct mechanical manipulation of the brain.
Multiphoton intravital imaging has provided unprecedented direct visualization of
immune cell dynamics in various organs and tissues including the brain214,380. Despite
the application of thinned and open skull imaging windows to answer fundamental
questions214,428,441, studying the initial immune response to tumors in a physiological
state is nearly impossible due to the surgical procedures involved. For example,
mechanical trauma to the dura or arachnoid initiates a strong response by the resident
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immune cells including the microglia and potentially the peripheral innate and adaptive
immune cells214. Although it was previously thought that immune cells isolated from
BTs in mice and humans were mostly microglia, recent understanding of broadly
shared surface markers between microglia and peripheral immune monocytes and
macrophages blurs the lines of distinction209. Thus, making conclusions about the
contribution of immune cell populations to brain tumor immune surveillance during the
various stages of tumor progression could be confounded by traumatic events during
cancer cell implantation. Progress in intravital imaging has been made by the use of
sliced brain organotypic cultures419; however, this isolates the brain from the systemic
circulation and traumatizes the tissue as well. Recent methods now enable intravital
imaging of tumors in intact brain tissue in living mice, but the studies still involve
significant traumatic preparations and have been mostly limited to immune-deficient
nude and subacute combined immune-deficient (SCID) mice441-449. Intravital imaging in
immune competent mice has been conducted, but in some cases mice have been
treated with immune suppressants such as dexamethasone, which prevents immune
cell proliferation and effector functions441. To overcome these technical limitations in
brain tumor imaging, which conventionally involves 1) brain trauma due to full-thickness
skull bone removal and 2) cancer cell deposition by direct intracranial injection, I have
developed a novel experimental model of intravital imaging of in vivo brain tumor
immune surveillance. This system consists of a thinned skull window that is combined
with internal carotid cancer cell injection. Thinned skull window preparations have been
used in the past to study multiple physiological processes involving neurons, microglia,
and the cerebral vasculature in pathological conditions such as Alzheimers and
stroke417,450. Likewise, internal carotid injections have been conducted in previous
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studies to answer a variety of questions related to the process of brain metastasis and
stem cell biology100. Both techniques, when done separately, do not involve mechanical
trauma to the brain parenchyma. Therefore, a combined system involving both
techniques was developed for visualization of immune cells in brain metastases.This
method was selected because it does not inflict mechanical injury to the brain tissue,
when performed with appropriate expertise. I present data that reveals this approach
does not produce artefactual immunological activation and specifically, cancer cells
engraft and grow from within the vasculature into the brain tissue beginning from single
cancer cells closely recapitulating the clinical scenario. As a read-out of brain tissue
injury, morphological response of microglia has been visualized in CX3CR1+/GFP mice
as microglia are known to respond rapidly to regions of brain parenchyma or
vasculature injury211,214. In addition, I have compared the behavior of microglia in
response to cancer cells between models in which tumor is initiated by delivery via the
internal carotid artery relative to cerebral injection. The experiments conducted here
were focused on early tumor time points ending at day 7, which represents a phase in
which acute mechanical trauma is potentially most detectable.
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Results
3.1a. Intravital imaging experimental setup
To verify that skull thinning does not inflict mechanical trauma to the brain,
CX3CR1+/GFP/hCD2-DsRed mice were used. In this mouse strain, GFP reporter gene
has been knocked into the CX3CR1 locus encoding CX3CR1 protein expression and
DsRed is expressed under the CD2 promoter; CX3CR1 is expressed by all microglia,
and T cells can be visualized by the expression of Ds-Red. Importantly, the
CX3CR1+/GFP reporter mouse strain faithfully reports very rapid reaction of microglia to
injury within very brief time periods214. The CD2-DsRed mice have been used to show
the influx of T cells into the brain parenchyma during stroke450.
To first visualize microglia in the steady state brain, mice with thinned skull
windows that were not injected with cancer cells were head-restrained with a customdesigned mouse skull frame and stabilized on a heated custom-made motorized
imaging stage. Imaging was performed transcranially via the glass window 5 to 10
minutes after thinning of mouse skull, by using multiphoton microscopy settings as
described in the methods section. Mouse body temperature and anesthesia was
maintained throughout imaging, as described in the methods. A schema demonstrating
this process is shown in Figure 11a.
Second harmonic generation (SHG) was applied during multiphoton imaging to
differentiate the thinned bone and underlying meninges from the underlying brain
cortex. This is possible because biological structures such as collagen, which constitute
skull and meninges, exhibit inversion asymmetry and a structural arrangement that
show a second order non-linear optical property451-453. This property can be harnessed
during photonic molecular polarization to generate fluorescent signals from such
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endogenous tissues without prior dye labeling and is known as SHG. Within the brain
cortex, microglia were observed to be discretely distributed in both two-dimensional
orientation and three-dimensional optical sections, with multiple dendrites extending
from each cell soma (Figure 12a & movie 1). The soma and dendrites of some of the
microglia appeared to be in direct contact with the cerebral vasculature. Time-lapse
imaging revealed motile microglia dendrites around the relatively sessile soma,
scanning the brain especially around vessels and presumably other adjacent brain
structures such as neurons and astrocytes, as previously described214 (Figure 12b and
movie 1). This observation was consistent with previous studies that have investigated
the dynamics of microglia in healthy in vivo brain tissue214,215. Importantly, T cells were
observed to travel within the lumina of microglia-associated blood vessels, but not
extraluminally. This observation is similar to those made in sham controls in a previous
study of T cell influx into the brains of mice with stroke450. Overall, these findings
indicate that the proposed model does not cause changes in microglia dynamics and
perturb the blood-brain barrier in mice.
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Figure 11

New: Thinned skull window + internal carotid artery inj. expt. setup

Conventional method 1: Thinned skull window + intracranial inj. expt. setup

c

Conventional method 2: Open skull window + intracranial inj. expt. setup

Figure 11. Schematic diagram of skull window experimental systems for intravital
imaging of brain metastases.
a. A schematic of a new system combining thinned skull window and ICA injection. The
model consists of thinning a 5-6mm diameter of a mouse skull leaving an eggshell
osteotomy, followed by bonding of a cover glass to the edges of intact calvaria. Cancer
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cells are then injected to the brain via the ICA, and non-survival or longitudinal survival
intravital imaging is performed.
b. A schematic of a conventional system for intravital imaging system of brain tumor
through a thinned mouse skull. A 5-6mm diameter of mouse skull is thinned as in (a),
but cancer cells are implanted directly into the brain through the thinned skull at a depth
of ~200-250μm by using an automated glass pipette, then the thinned skull window is
secured with cover glass as in (a). Non-survival or longitudinal survival intravital
imaging is performed.
c. A schematic depicting open skull window imaging of brain tumor. Craniotomy is
performed to completely excise a 5-6mm diameter piece of mouse skull unlike in (b)
where an eggshell osteotomy is left. In similarity to (b), cancer cells are injected directly
into the brain at a depth of ~200-250μm below the dura mater by using an automated
glass pipette. Artificial CSF or PBS is applied to the exposed brain, and a round glass
coverslip is used to protect the brain tissue from dehydration and reinforced with
Vetbond glue and dental cement on the edges. Intravital imaging can be done through
the window to obtain time-lapse images longitudinally, and tumor size can be followed
by acquiring tumor mosaics.
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Figure 12

a.

b.

hMW-TRITC-dextran CX3CR1+/GFP hCD2-DsRed
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Figure 12. Intravital imaging of healthy mouse brain.
a. Representative image from z-stack imaging of healthy mouse brain showing
meninges (white) in the xz/yz axes, distribution of microglia (CX3CR1+/GFP; green)
within the brain cortex, and brain vasculature (cyan) in a three-dimensional xyz space.
High molecular weight TRITC dextran dye was injected intravenously via the tail vein to
visualize the vasculature. Imaging depth is up to 200µm (Movie 1).
b. Representative still image from intravital time-lapse imaging of healthy mouse brain
showing motility of microglia (CX3CR1+/GFP; green) and T cells (hCD2-DsRed), and
brain vasculature (hMW-TRITC-Dextran; White). Inset represents zoomed-in region
showing close-up structure (white lines; thick line represent microglia soma, dotted
lines represents the dendrites) and motility of microglia dendrites (Movie 1)
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3.2a. Internal carotid artery injection is a more physiologically relevant method than
intracranial injection for studying the immune response to brain tumors from a single
cancer cell level
Direct implantation of cancer cells in mouse brain confounds the understanding
of microglia dynamics in response to brain tumor initiation.

To test the extent of

microglia reactivity to BTs beginning at a single cell level and without local mechanical
trauma, the new model was used in syngeneic CX3CR1+/GFP mice on the C57BL6
background (Figure 11a). In these reporter mice, microglia can be visualized in a
healthy brain based on morphological characteristics (Figure 12a) while CX3CR1+/GFP
monocytes from extracranial tissues are absent in the healthy brain. CX3CR1+/GFP
monocytes are present in the brain only after trauma, in which case their morphology is
ameboidal (Figure 13a & movie 2).
In the new model, within two days after mice wereinfused with cancer cells
derived from methylcholanthrene (MCA)-induced fibrosarcomas by internal carotid
artery injection, single cancer cells were found to be lodgedwithin cerebral
microvasculature and the microglia mostly retained their typical ramified morphology as
in Figure 12a & b. Seven days after ICA-inj., I could still visualize features of resting
microglia including relatively immobile microglia soma as well as arrays of highly
dynamic dendritic extensions. In contrast, in the conventional model (Figure 11b), mice
receiving cancer cells directly into the brain showed CX3CR1+/GFP cell accumulation
around the site of the injection and lost the typical microglia morphology, and the BBB
appeared to have been breached as indicated by dye leakage from vessels in the brain
parenchyma (Figure 13a & movie 2). At day 7 after cancer cell injection by intracranial
(ICr) injection in the conventional model, I could not identify any distinct morphological
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features of CX3CR1+/GFP cells resembling that of resting microglia, and analysis of
CX3CR1+/GFP cell sphericity became technically challenging as the cells appeared to
have clustered into “bee hive” formations. Quantitatively, the density of CX3CR1+/GFP
cells in the imaging field of view increased after direct ICr-inj. while there was no
observable change after indirect ICA-inj. of cancer cells to mice brain in comparison
with healthy brain (Figure 13c). In addition, CX3CR1+/GFP cells in ICr-injected mice
increased in sphericity as opposed to cells in ICA-injected mice and in steady-state,
indicative

of

the

potential

activation

status

of

microglia

and/or

infiltrating

monocytes/macrophages following ICr injection. (Figure 13d). Importantly, it is
impossible to distinguish activated microglia from infiltrating monocytes/macrophages
in an inflamed brain as they both appear amoeboid in shape. Together, these results
suggest that ICA injection of cancer cells coupled with transcranial intravital imaging via
thinned skull window provides a better physiological platform than direct ICr injection
for studying the initial events of immune response to BTs.

3.3a. CX3CR1+/GFP cells become motile after ICr (conventional model) but not ICAinduced (new model) cancer cell injection.
To determine the motility pattern of CX3CR1+/GFP cells in both systems, I tracked
individual CX3CR1+/GFP cells two days after cancer cell injection (Figure 14a). In mice
that were injected with cancer cells via ICr-inj., multiple elongated time color-coded
tracks of varying lengths were found to be present around the site of cancer cell
injection suggesting CX3CR1+/GFP cell motility. In contrast, after ICA-induced cancer cell
injection or in the healthy brain, only dots of single colors were observed indicating that
no CX3CR1+/GFP cell displacement had occurred (Figure 14a). Further, CX3CR1+/GFP
84

cells in the conventional model had significantly increased average velocity in
comparison with the relatively immotile cells in the new model or steady-state microglia
(Figure 14b). We were unable, however, to quantify the motility of distinct
CX3CR1+/GFP cells seven days after ICr-inj. due to the extensive infiltration, cluster
formation of the CX3CR1+/GFP cells around the injection site, and extremely blurred
morphological features of individual cells (Figure 14b). Again, this indicates that the
new model is a better system than the conventional model at least in terms of
maintenance of CX3CR1+/GFP cell motility behavior as in the healthy steady state brain.
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Figure 13

b

hMW-TRITC-dextran Microglia/CX3CR1+/GFP hCD2-DsRed

C

d

86

Figure 13. Intravital imaging of brain tumor within the New Vs Conventional
murine model systems.
a. Representative still image from intravital time-lapse imaging of MCA brain tumorbearing mouse in the conventional model showing MCA cancer cells/tumor (blue),
microglia/monocytes (CX3CR1+/GFP; green), and brain vasculature (hMW-TRITCdextran; cyan), 2 and 7 days after cancer cell injection by intracranial injection via a
thinned skull window. The day 7 panel shows abnormally tortuous vasculature, and
“bee hives” of CX3CR1+/GFP cells. Scale bar represents 100μm.
b. Representative still image from intravital time-lapse imaging of MCA brain tumorbearing mouse in the new model showing MCA cancer cell/tumor (blue), microglia
(CX3CR1+/GFP), and brain vasculature (hMW-TRITC-dextran; cyan), 2 and 7 days after
cancer cell injection by the ICA injection method. The top panel shows MCA cancer cell
trapped in brain vasculature, and microglia (based on morphology), 2 days after ICA
cancer cell injection The right panel shows MCA cancer cell(s), brain vasculature, and
microglia (based on morphology), 7 days after ICA cancer cell injection. Scale bar
represents 100μm.
c. Density of CX3CR1+/GFP cells in healthy brain and in MCA brain tumor-bearing mice
2 days after ICr- or ICA-induced MCA tumor (n = 3 from 2 separate experiments; each
dot represents the density of all cells in a field of view in a mouse brain; data analysis
was done by unpaired t test; *P < 0.05).
d. Sphericity of CX3CR1+/GFP cells in healthy brain and in MCA brain tumor-bearing
mice 2 days after ICr- or ICA-induced tumor (Representative of 3 animals from 2
separate experiments).
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Figure 14

Healthy brain

ICA D2

+/GFP

Spot rendering of microglia/CX3CR1

cells

ICr D2

b

Figure 14. Window-located CX3CR1+/GFP cells become highly motile after IC
injection, but not after ICA injection.
a. Representative still images from Imaris cell tracking of CX3CR1+/GFP cells in mice
brain in intravital time-lapse movies. The left and middle panels show green spots,
which represent the positions of microglia over the duration of 9 min and 45 min,
respectively. The right panel shows the positions of CX3CR1+/GFP cells (green spots)
and their migratory tracks (time-scale color-coded lines) over 40min. Scale bar
represents 40μm.
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b. Mean velocity of CX3CR1+/GFP cells in the imaging field of view within the skull
window region in healthy brain and MCA tumor-bearing mouse brain after ICA- and ICrinduction of BT (n = 2 from 2 separate experiments; the average velocity of individual
CX3CR1+/GFP cells acquired over 20min to >1 hr of time-lapse movies were
accumulated for comparison by using the non-linear mixed effects regression model;
****P < 0.0001).

89

Discussion
In this study, I successfully developed an experimental setup to study the
immune response to BTs in near-physiological brain tissue in living mice and showed
that ICA injection combined with thinned skull window imaging is better than the ICr
injection approach with regards to non-specific immune cell motility. While the
combination of open skull windows and ICr injection is conceptually superior to the
thinned skull window technique because it enables direct penetration of photons into
the brain tissue and ultimately enhances better imaging and visualization of cells
located in deep remote brain regions, it is a more traumatic alternative. In general, a
unique advantage of the conventional thinned skull approach is that it aids relatively
easy manipulation and cancer cell implantation454. In addition, it enables better
predictability of tumor growth location, which potentially increases the extent of
experimental reproducibility in terms of imaging different animals at similar time points,
in longitudinal experiments. However, it carries an attendant risk of causing brain
parenchymal damage before cancer cells engraft in the tissue and is associated with
artifacts of early immune cell activation and response, with the disruption of the BBB.
The study by Zhang L. et al. supports the conclusion above, in that following ICr
injection, mouse brain develops gliosis due to injection injury as revealed by increased
GFAP staining at the injection site454. By combining thinned skull window and ICA-inj., I
have solved these problems; however, I cannot exclude effects that the procedure may
have on aspects of microglia physiology that were not investigated such as molecular
signaling pathways. In addition, because the cancer cells that are lodged in the brain
after ICA injection are better at reproducing brain metastasis from extracranial tumors
but may not truly recapitulate the early phase of tumor development in primary BTs, a
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better physiological system for studying primary BTs would be one in which thinned
skull windows are combined with spontaneously developing BT in GEMM models in
which resident immune cells such as microglia can be visualized. Nevertheless,
experiments conducted in part II of this chapter reveal the power of the ICA-inj./thinned
skull imaging method in understanding the distribution of both resident and infiltrating
myeloid cells in late stage BTs when ICA-induced tumors have engrafted extensively
into the brain parenchyma.
The novel system established here preserves intact brain vascular structures
and perfusion. In contrast to the direct injection approach which traumatizes blood
vessels and causes leakage of injected dyes into the brain tissue, vessels appeared
normal in the system developed here suggesting an intact BBB442. However, we did not
explore potential molecular changes such as signaling pathways in the cells composing
the BBB145. Previous studies have shown that microglia respond rapidly to secure even
very tiny breaches in the vasculature214. Since I did not observe such protective or
crowding behavior of microglia around the vasculature at early time points, I suspect
that cancer cells engraft into brain tissue by a mechanism that may not damage the
vasculature and maybe undetectable by microglia.
Microglia can potentially transform from a dendritic morphology to an amoeboid
form, one that is strikingly similar to blood-derived monocyte and macrophages455. This
makes it difficult to interpret studies using the conventional approach, as the traumatic
nature of cancer cell deposition causes an increase in the sphericity of the
CX3CR1+/GFP cells around the site of injection. In addition, the cells accumulate in
clusters, making it difficult to assess the morphology of adjacent cells that may retain a
dendritic morphology within the clusters. Increased motility of CX3CR1+/GFP cells
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obscures the early physiologic response and behavior of microglia to cancer cells214.
Therefore, this novel approach may provide better clarity in studying immune cell
response to cancer cells in the brain at the single cell level.
Since BTs in humans are thought to begin from single mutated cells or
disseminated malignant cancer cells from secondary tumors, this approach now opens
an avenue to study the different aspects of immune response to tumor initiation
including the contribution of innate cells such as neutrophils, patrolling monocytes,
dendritic cells, classical monocytes, and NK cells, and the subsequent onset of
adaptive T cell immune response. Although microglia are brain resident and are quick
to respond to pathologies such as brain parenchyma injury, there are other innate
immune cells from the periphery such as neutrophils that are capable of initiating rapid
response to a variety of disease conditions including trauma and even cancer cells261.
However, the impact of the new system developed here on the early phase
homeostasis of other innate cells such as neutrophils was not investigated as previous
studies that utilized an approach similar to the conventional thinned skull method
described here did not observe any recruitment of neutrophils to traumatized site in
brain tissue after direct injection; however, changes in microglia were not investigated
in those studies456.
This new approach developed is not without limitations. With ICA-induced
cancer cell injection, there is markedly reduced power of predicting the location of
cancer cell entrapment and hence increased variability in timing longitudinal intravital
imaging of tumor growth within the brain in different mice. This is especially
pronounced given the small imaging window dimensions in mouse skull and the limits
posed by anatomical skull suture lines in extending such windows. In addition, since
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the intact skull can add to light scattering caused by brain tissue, the extent to which
imaging of immune response in deep brain regions can be accomplished is reduced.
Our approach may also be limited in use due to the requirements of specialized
expertise with manipulating microvessels such as the common or internal carotid artery
during cancer cell injection in mice and the longer duration it takes to complete the
same procedure in several mice as opposed to conventional intracranial injection
approaches. Nevertheless, both ICA and ICr injection systems may be combined to
answer some questions by taking the strengths and limitations of each approach into
consideration. In the future, additional ways of improving these model systems would
include developing lasers or optical adaptors capable of deeper photon penetration
through brain tissue and creation of GEMM BT reporter models.
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Part II: Identification of a cellular mechanism for the regulation of T cell
surveillance in brain tumors
Introduction
Immune surveillance is a critical aspect of tumor progression. Effective immune
surveillance depends on a tightly regulated migration of immune cells between
peripheral organs and secondary lymphoid tissues68,457. However, little is known about
the dynamic behavior and interactions of immune cells in tissues invaded by cancer. In
the brain, the dynamics and regulation of immune response in tumors has been
masked for a long time by the idea of brain immune privilege, and has detracted from a
comprehensive understanding of immune response in BTs and development of
immunotherapy68,69. Further, our present understanding of anti-tumor immune response
through in vivo intravital imaging experiments and analysis has been largely derived
from studies utilizing model tumor antigens, such as ovalbumin, and exogenously
transferred cognate antigen-specific clonal T cell populations. Despite the immense
knowledge on immune cellular dynamics and interactions gained from model antigen
experiments, tumors in humans have great diversity in antigens and the associated
potential T cell response is most likely polyclonal. As such, the true biology in human
patient tumor may not be recapitulated in such experiments.372,375,402. Moreover, in the
brain, intravital visualization and analysis of anti-tumor T cell response is lacking442.
Previous studies have attempted to understand brain tumor immune response
by using brain slices419, thereby isolating the brain from the systemic circulation and
extra-cranial immune response; other attempts at BT in vivo imaging studies have been
limited technically by experimental systems and the range of reporter mouse models
94

available for concrete immune response readout444,446. Here, I have applied an array of
longitudinal intravital imaging systems and reporter mice to visualize endogenous
innate and adaptive immune surveillance in brain tumors. Specifically, I employed
thinned skull window in mice in combination with ICA injection to visualize the innate
and adaptive immune cell response to metastatic tumor types such as MCA and LLC.
In addition, I used the open skull approach to image immune cell response to ICr-inj.
orthotopic GL261 because of the inefficiency of this cancer cell type to engraft into the
brain tissue after ICA injection. Also, this approach aided imaging of GL261 cancer
cells and associated immune cells in deeper brain regions beyond the extent achieved
by the thinned skull/ICA injection approach. The CD11c-YFP mouse strain has been
developed and established for use in dissecting the dynamics of myeloid cells
especially DCs, which have high expression of CD11c. In this study, I used the CD11cYFP mouse strain to visualize a population of innate myeloid cells that I will refer to as
DCs based on their morphology; however, other myeloid cells such as macrophages
can express the YFP fluorophore encoded by the CD11c promoter as elaborated on in
chapter 1. In addition, I have used other myeloid cell reporter mouse strains including
fractalkine and CCL2 chemokine receptors, CX3CR1 and CCR2, encoding GFP and
RFP fluorophores, respectively, to better characterize the myeloid cell repertoire in BT.
hCD2-DsRed mice were used to visualize T cells, which express DsRed that is
encoded by the CD2 promoter. Finally, I have bred the mouse strains above to obtain
double or triple reporter mouse strains to dissect the interactions between the innate
and adaptive immune cells in BTs by intravital imaging.
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Results
3.1b. Longitudinal intravital imaging reveals differential immune response patterns in
different brain tumor types.
It is well established that for a natural immune response to be generated there must be
an effective coordination between myeloid antigen presenting cells (APCs) and T cells
in the lymph node379,397,458,459. At sites of inflammation, T cells are known to undergo a
cyclical process of reactivation between contacting tumor and tumor-associated
APCs301. Therefore, to directly visualize the endogenous immune surveillance in
various brain tumor types in a longitudinal manner, I employed appropriate
experimental intravital imaging systems (Fig. 11). These systems enabled me to
capture longitudinal evolution of endogenous anti-tumor immune response (Figure 15).
As shown in Figure 16 & movie 3, orthotopic GL261 glioma was visualized from about
10 minutes after cancer cell implantation up to a 28-day terminal time point. GL261
tumor progressed lethally, and although CD11c-YFP cells and T cells were robustly
recruited temporally, the pace was slower than tumor growth. GL261 tumor-associated
T cells steadily increased in migration velocity in the tumor microenvironment from
8μm/min up to a peak of 13μm/min) between day 7 and 13, but decreased to ~9um/min
at day 28.
Lewis lung carcinoma (LLC) brain metastasis, which was generated by ICA,
progressed lethally over a 19-day period (Fig. 17 & movie 4). In this model, CD11cYFP cells and T cells were recruited robustly up to day 11, but sharply reduced
afterwards. LLC-associated T cells showed relatively high average velocity at day 5 of
~8μm/min at day 5, and decreased to ~6μm/min at day 11 after cancer injection. The
decrease in T cell velocity continued steadily until day 19 (~4μm/min).
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Figure 15

Figure 15: Schematic and confocal images representing a mouse brain with
anatomical location of late stage brain tumor, and longitudinal appearance of
tumor and immune cells via imaging window.
The continuous blue line schematic above the image panels represents the anatomical
boundaries of a mouse brain, defining the brain into specific regions and is
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superimposed on a representative confocal image of ex vivo whole brain with mosaic of
GL261 tumor (blue), CD11c-YFP cells (white) and T cells (red). The red continuous
circle indicates the region of the brain tissue directly underneath a virtual open skull
window and protected by glass cover slip through which longitudinal intravital imaging
was performed.
The panels below the schema are arranged in a clockwise fashion and show
representative mosaics of tumor (blue), CD11c-YFP cells (green) and T cells (hCD2DsRed) acquired longitudinally by 2-photon microscopy via imaging skull window.
Some regions of mouse skull (white/gray) can be visualized by SHG at late stage time
points when the brain tumor size is near or beyond the edges of the skull window.
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Lastly, in contrast to GL261 and LLC, MCA fibro-sarcoma cancer cells engrafted
and progressed until day 7 (Fig. 18 & movie 5). Interestingly, the recruitment of
CD11c-YFP cells and T cells continued in the tumor region, surpassed tumor coverage
in the imaging field of view, and only began declining after observable tumor regression
between days 10 and 12. MCA-associated T cells did not show any significant change
in average velocity throughout the imaging time points (~9μm/min). These data suggest
that robust anti-tumor immune response is mounted in the brain contrary to the notion
of brain immune privilege, that the recruitment of CD11c-YFP cells and T cells correlate
in a time-dependent manner, and that the average velocity of T cells exhibited during
migration vary in different brain tumor types spanning from relatively high migratory
activity throughout the length of observation in MCA and GL261 tumors to very low
activity in late stage LLC tumors.
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Figure 16

Figure 16. Longitudinal intravital imaging of immune response in GL261 brain
tumor.
Representative still intravital images from time-lapse imaging of DCs (CD11c-YFP;
white) and T cells (hCD2-DsRed) in GL261 brain tumor (blue) from 10 min to 28 days
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after intracranial implantation. The graphs below the image panels show the temporal
dynamics of GL261 tumor growth and infiltration of CD11c-YFP cells and T cells in the
field of view and the mean velocity of T cells over the time period of imaging (n = 1
mouse; represents longitudinal imaging sessions conducted in 5-6 different
experiments; *P < 0.05, ****P < 0.0001; mean velocity was analyzed by using the nonlinear mixed effects regression model). Scale bar represents 50µm.
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Figure 17

Figure 17. Longitudinal intravital imaging of immune response in LLC brain
tumor.
Representative still intravital images from time-lapse imaging of DC (CD11c-YFP;
white) and T cells (hCD2-DsRed) in LLC brain tumor (blue) from 5 days to 19 days after
LLC cancer cell injection via the ICA using the thinned skull window approach. The
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graphs below the image panels show the temporal dynamics of LLC tumor growth and
infiltration of DC cells and T cells in the field of view and the mean velocity of T cells
over the time period of imaging. (n = 1 mouse; represents longitudinal imaging
sessions conducted in 3-4 different experiments ns = not significant; ***P < 0.001, ****P
< 0.0001; mean velocity was analyzed by using the non-linear mixed effects regression
model). Scale bar represents 50µm.
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Figure 18

Figure 18. Longitudinal intravital imaging of immune response in MCA brain
tumor.
Representative still intravital images from time-lapse imaging of CD11c-YFP (white)
and T cells (hCD2-DsRed) in MCA brain tumor from 7 days to 12 days after LLC cancer
cell injection via the ICA using the thinned skull window approach. MCA tumor
regresses at day 10 and is not evident at day 12. The graphs below the image panels
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show the temporal dynamics of MCA tumor growth and infiltration of CD11c-YFP cells
and T cells in the field of view and the mean velocity of T cells over the time period of
imaging. (n = 1 mouse; represents longitudinal imaging sessions conducted in 5 mice
in 3 different experiments; ns = not significant; mean velocity was analyzed by using
the non-linear mixed effects regression model). Scale bar represents 50µm.
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3.2b. CD11c-YFP cells preferentially associate with tumor and T cells relative to
microglia
I reasoned that since CD11c-YFP cells and T cells correlate temporally during
recruitment and population of brain tumor types longitudinally, they may also correlate
in space, in spatially organized niches within the brain tumor microenvironment.
Remarkably, across different brain tumors including GL261, LLC, MCA, and B16-F10, I
observed that tumors that were infiltrated by T cells were those that contained high
densities of CD11c-YFP cells, which unlike the CD11c-negative microglia, are relatively
rare in normal brain (Fig. 19 and 20). T cell densities strikingly correlated with CD11cYFP densities spatially in tumor at both the microscopic (single brain regions acquired
by high-magnification objective) and macroscopic scales (whole brain) (Fig. 19c and
Fig. 21). In macroscopic tumors, both T cells and CD11c+ DCs were found in high
densities around tumor margins (Fig. 21). However, very few CD11c-YFP and T cells
was observed in B16-F10 brain tumor with only a weak correlation between both cell
types (Fig. 19a & b) This was not surprising, as this tumor type is historically known to
be poorly immunogenic.
It is conventionally believed that microglia are the predominant immune cell
population in brain tumors and potentially regulate anti-tumor immune
response191,246,460,461. Based on this, I evaluated the correlation of the area density of
microglia to the area of the image field of view occupied by MCA brain metastatic
tumors, and found only a weak correlation between the density of microglia, MCA
tumor, or MCA tumor-infiltrating T cells. In contrast, the density of CD11c-YFP cells
was strongly correlated with the area occupied by MCA tumor (Fig. 19a & c). This
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suggested a critical role for CD11c-YFP cells in the regulation of T cell immune
response in brain tumors.
Based on such striking spatial correlation between CD11c-YFP cells and T cells,
I next assessed the interaction pattern between these two cell populations by using
intravital two-photon microscopy. In the spontaneously regressive MCA tumor, T cells
migrated preferentially closer to CD11c-YFP cells and adjacent blood vessels than with
the tumor itself (Fig. 22). Similarly, in the progressive GL261 tumor, T cells also
migrated in swarms around CD11c-YFP cells (Fig. 23a & movie 6). Analysis of T cell
motility tracks revealed that the T cells centered around CD11c-YFP cells over a
distance of 8-12µm, which is close to the range obtained in a previous study involving
in vivo intravital imaging studies of lymph node DC/T cell interactions462. However, T
cells maintained a high local migration speed around CD11c-YFP cells over time
despite their proximity, and this contrasts to previous observations in the lymph node
where T cells proximal to DCs showed reduced speed295,379 (Fig. 23b). This would
indicate presumably very transient contacts between the T cells and CD11c-YFP cells
in GL261 brain tumor despite the clustered pattern of T cell swarms that could be easily
presumed for prolonged interaction with CD11c-YFP cells. Further, in GL261, although
T cells appeared confined, the confinement was relatively weak with a confinement
radius of ~73um that became apparent only during long observations. In contrast to
GL261, T cells in MCA brain tumor were more tightly confined around CD11c-YFP cells
with a confinement radius of 33um (Fig. 23c). Together, CD11c-YFP cells and T cells
correlate in brain tumor niches and T cells are organized and motile around CD11cYFP cells.

107

Figure 19

a

b

c
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Figure 19: CD11c-YFP cells preferentially associated with tumor and T cells
relative to microglia.
a. Top: Representative confocal images showing localization of endogenous CD11cYFP cells (white) and T cells (hCD2-DsRed) in different types of brain tumor including
GL261 glioma, LLC, and B16-F10 melanoma (blue) captured between days 13 and 19.
Tumor types were generated by direct intracranial injection (GL261) and ICA injection
(LLC and B16-F10). Bottom: Confocal images show localization of endogenous
CX3CR1 cells (identified as mostly microglia based on distribution and morphology as
described in chapter 3), CD11c-YFP cells, and T cells in MCA brain tumor induced by
ICA injection. Scale bar represents 50 µm.
b. The first three graphs show the correlation between T cells and CD11c-YFP cells in
various tumor types (n = 2-4 mice/tumor type; 9 areas of tumor-associated immune
cells were analyzed from an average of 2 tumor nodules per mouse; each dot
represents a single area analyzed).
c. Graphs show the correlation of CX3CR1-GFP microglia and CD11c-YFP cells to
MCA tumor, and the correlation of T cells to CD11c-YFP cells and CX3CR1-GFP
microglia cells (n = 4 mice; 9 areas of tumor-associated immune cells were analyzed
from an average of 2 tumor nodules per mouse; each dot represents a single area
analyzed).

109

Figure 20

Figure 20. Confocal image of healthy mouse brain
Representative still image from a healthy mouse brain showing brain vasculature
(TRITC-Dextran; red), microglia (green), and CD11c-YFP DCs (white).
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Figure 21

Figure 21. Distribution of CD11c+ DCs and T cells correlate in brain tumor at a
macroscopic level.
Representative image of the axial (left) and coronal (right) planes GL261 brain tumor
(blue) with associated CD11c-YFP DCs (white) and T cells (hCD2-DsRed),
respectively. The cartoon in the middle depicts a mouse brain and the approximate
location of the GL261 brain tumor. The dotted line demonstrates the margin of the brain
and the straight line cuts through the midsection of the tumor. The corresponding line
profile graph to the straight line shows the distribution of CD11c-YFP DCs and T cells
in relation to GL261 brain tumor. (Represents experiments conducted in 5 different
mice)
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Figure 22

Figure 22: T cells preferentially associate with CD11c-YFP cells and the brain
vasculature Graph shows an example of the frequency of T cells migrating at a given
distance relative to vasculature, MCA tumor, and CD11c-YFP cells in intravital timelapse imaging in a day 7 MCA tumor. Individual tumor-infiltrating T cells were tracked,
and the frequency of the distance between the mean positions of T cell tracks to
vasculature, MCA tumor, and CD11c-YFP cells were plotted in the same graph. The
left axis represents frequency of CD11c-YFP+ DC and blood vessel, while the right axis
represents frequency of MCA tumor (n =4).
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Figure 23

a

c

b

Figure 23: Brain tumor infiltrating T cells are organized in clusters around
CD11c-YFP cells.
a. Representative still intravital images of CD11c-YFP and T cellular interactions from 0
– 30 min in a day 10 GL261 brain tumor (blue). The green spots are superimposed on
T cells and represent the positions of T cells in the tumor. The color-coded lines
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represent the tracks of T cells during the duration of acquisition of time-lapse images.
In the bottom right image panel, the T cell track lines are segregated according to
nearness to CD11c-YFP cells. The green lines represent tracks of proximal ( defined as
0-7μm from the CD11c-YFP cell margin) T cells while the blue/violet lines indicate
tracks of distal (defined as 9μm to infinity from CD11c-YFP cell margin) T cells. Scale
bar represents 50µm.
b. Graph shows the average distance of all T cells to CD11c-YFP cells (blue line; left Y
axis) and the average speed of T cells (red line; right Y axis) in relation to the length of
T cell migration time acquired (Represents experiments conducted 5-6 different times).
c. Graphs show the squared average displacement of all T cells in GL261 and MCA
tumor over the length of T cell migration time acquired (represents experiments
conducted separately for ~5-6 different times).
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3.3b. In situ imaging and quantification of myeloid cells in a novel myeloid reporter
mouse reveals distinct localization of myeloid cell subsets in brain tumor.
A better understanding of the myeloid immune cell composition of brain tumors
is complicated by the presence of the brain resident microglia and infiltrating
macrophages and monocytes.There are no reporter mouse models to properly
delineate these two populations appropriately. Therefore, to characterize the myeloid
cells in the brain tumor microenvironment, I generated a novel triple myeloid reporter
mouse in which I could visualize different myeloid cells under the CX3CR1-GFP,
CD11c-YFP, and CCR2-RFP promoters210,212,463. With this new model, five myeloid
cell types including microglia, patrolling monocytes (PMs), classical monocytes (CMs),
mature and immature dendritic cells (DCs) can be potentially identified according to
different combinations of fluorophore expression (Table 2).
To gain insight into the composition and localization of brain tumor-associated
myeloid cells, I then injected MCA cancer cells via the ICA and subsequently imaged
engrafted brain tumors in fixed ex vivo thick brain tissue sections by using confocal
microscopy. Imaging revealed distinct localizations of the different myeloid cells in the
tumor microenvironment (Fig.24a).
Next, I developed a novel method of quantifying the myeloid cell populations
directly from their actual localizations in the tumor and termed this method in situ tumor
immune cytometry (iTIC). This method is detailed in chapter 2 and represents an
advancement in cellular quantification in the field of imaging as it is the first method
employing Imaris imaging software Spot detection tool and the recently developed
Vantage analysis and plotting tool for cytometry purposes. The closest competing
method to iTIC utilizes the colocalization tool on the same Imaris imaging software, but
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has certain technical drawbacks464. For example, the colocalization values calculated
and exported do not efficiently reproduce true fluorophore colocalization from an
arithmetic and computational standpoint. In addition, the exported values have to be
transported to Flowjo software for further analysis and graphing into dot plots. In
contrast, the iTIC method utilizes the mean fluorophore intensity in a cell to calculate
the extent of expression of different fluorophores expressed by the same cell of
interest. Further, the dot plots are generated within the same software by using the
Vantage tool. This allows for back and forth validation of the data as each spot can be
visualized and interrogated by any user. Overall this approach is superior to
conventional flow cytometry because cells are analyzed within retained tissue
architecture and multi-layered tissue and does not involve cell processing as in flow
cytometry tissue preparation, which could result in cell loss. Using the iTIC method, I
was able to identify five distinct myeloid cell populations in the tumor microenvironment
(Table 2) and account for their spatial localization in the tumor (Fig. 24b).
After tissue analysis with iTIC, I identified the same five populations of myeloid
cells outside the tumor and in the tumor regions (Fig. 24c). Interestingly, CD11c-YFP
DCs were highly enriched in the tumor and were composed mainly of CD11c+
CX3CR1- and CD11c+ CX3CR1+ cells. In contrast, CX3CR1+ CD11c- cells were
predominating outside the tumor region (Fig. 25a & b). In an attempt to better
understand the composition of the tumor-infiltrating myeloid cells, I stratified the cells
according to localization in the tumor core or tumor margin. I then analyzed the
populations residing within each of these compartments and found a preferential
enrichment of CD11c-YFP DCs (CD11c+ CX3CR1+ and CD11c+ CX3CR1-) at the
tumor margin, while the CCR2 monocytes (CCR2+ CD11c- and CCR2+ CD11c+) were
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preferentially enriched within the tumor core (Fig. 25c & d). More specifically, both
mature and immature DCs dominated the margin and core of the tumor relative to the
region outside the tumor denoted as the Extratumoral region ((ET); Fig. 24c).
Interestingly, CMs as defined in Table 2, were preferentially enriched in the tumor core
relative to the tumor margin or the region outside the tumor. Patrolling monocytes were
few and were mostly localized in the core of the tumor and outside the tumor region. In
support of our earlier observation (Fig. 19b), microglia were mostly present outside the
tumor region relative to the tumor core and margin; however, there was no change in
the density of microglia in the tumor versus the ET region (Fig.24c), suggesting that the
tumor is not enriched for microglia as opposed to DCs and CMs.

3.4b. CD11c-YFP cells are competent antigen presenting cells and T cell proliferation
occurs in proximity to CD11c-YFP cells
To determine the competence of CD11c-YFP cells to perform professional APC
functions, I stained tumor-bearing brain tissue sections with MHC-II and by confocal
imaging; I found preferential expression of MHC-II in tumor-associated CD11c-YFP
cells compared to the surrounding CX3CR1+ CD11c- microglia (Fig. 26a). In addition,
there were several examples of T cells undergoing proliferation in the brain tumor
microenvironment. In most cases these events occurred in proximity to CD11c-YFP
cells (Fig. 26b & movie 7). These data support the idea that CD11c-YFP cells are a
key professional APC population in the brain tumor microenvironment.
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Figure 24

c.
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Figure 24. In situ imaging and quantification of myeloid cells in a novel myeloid
reporter mouse reveals distinct localization of myeloid cell subsets in brain
tumor.
a. Representative confocal maximum intensity projection of a 3-dimensional image of
MCA brain tumor (blue) induced by ICA injection, CX3CR1-GFP (green), CD11c-YFP
(white), and CCR2-RFP (red) cells.
b. Arithmetic summation of individual myeloid subsets including CX3CR1-GFP, CD11cYFP, and CCR2-RFP cells on Imaris imaging software into a group defined as “parental
group” (white). The parental group cells is split into two compartments, represented by
spots (yellow), relative to the tumor; “in tumor” and “outside tumor”. The cells (spots) in
tumor are further split with respect to the edge or core of the tumor as tumor margin
and tumor core, respectively. CM = classical monocytes, PM = patrolling monocytes,
and DC = dendritic cells.
c. Graphs to the left and right show percentage and density, respectively, of myeloid
cell subsets residing “outside tumor” or extratumoral (ET), “tumor core”, and “tumor
margin.” (n = 4 mice from 2 different experiments).

119

Table 4.

Table 2. Phenotypic myeloid cell markers used in this study. To define myeloid cell
subsets based on these phenotypic markers, novel triple myeloid reporter mice were
created to then define what populations may be operational within our brain tumor
models.
Different combinations of fluorophore marker expression were used to identify distinct
myeloid cell subtypes including microglia, patrolling monocytes (PM), classical
monocytes (CMs), and mature and immature DCs.
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Figure 25

Tumor myeloid cells
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Figure 25. Various myeloid-derived immune populations have differential
distribution in brain tumors.
Vantage mode dot plots were generated using Imaris imaging software. Distinct
myeloid cell subsets were identified based on genetically-tagged fluorophore
expression in a triple myeloid reporter mouse strain based on relative in situ tissue
location to brain tumor. Colors used in the dot plots are pseudo-colors and only indicate
populations identified by the markers on the x and y axis. Representative dot plot to the
left shows the percentage of the various tumor-infiltrating myeloid cells in situ, in (a)
tumor, (b) extratumoral, (c) margin, and (d) core regions of MCA brain tumor. The 4 dot
plots to the right show the percentage expression of CCR2-RFP by individual groups of
myeloid cells in the leftmost panel.
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Figure 26

Figure 26. Confocal image and intravital microscopy reveal the presence of
competent CD11c-YFP APC and T cell proliferation in brain tumor
a. Representative left merged confocal image of MCA brain tumor-associated CD11cYFP cells and CX3CR1-GFP cells, reveals coexpression of CD11c-YFP and MHC-II.
Single panels to the right show MCA tumor, CX3CR1-GFP, CD11c-YFP, and MHC-II
expresson.
b. Representative still images showing intravital time-lapse imaging capture of a T cell
(hCD2-DsRed) undergoing proliferation in association with CD11c-DCs. Yellow sphere
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marks the boundary of a T cell undergoing cell division (Observed in >5 different
experiments).
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3.5b. Localization of BM-derived CD11c-YFP cells and T cells in brain tumor correlate
after adoptive co-transfer
Non-microglial myeloid cells such as monocytes are robustly mobilized from the
BM during tissue inflammation including brain cancer248,419. Therefore, I wanted to test
the idea that BM-derived CD11c-YFP cells localize in brain tumors and serve as
precursors for tumor-associated DCs. In addition, I wanted to determine whether
tumor-infiltrating T cells localize in BM-derived CD11c-YFP cell niches in the brain
tumor microenvironment. To accomplish this, I isolated whole bone marrow (BM) cells
from wild type double reporter mice in which I could visualize CD11c-YFP cells and T
cells, and transferred fresh BM isolates into CX3CR1-Knockout tumor-bearing mice.
BM cells were transferred into animals in two different groups; the first group received
BM cells one day before MCA cancer cells were injected to the brain via the ICA, and
the second group received BM cells fourteen days after cancer cell injection. Upon
imaging of late stage tumor-bearing tissue sections at day twenty after cancer cell
injection, I found that BM-derived CD11c-YFP cells localized in brain tumor and
surprisingly, T cells also localized in tumor-associated CD11c-YFP cell niches within
brain tumor microenvironment in both groups of mice receiving BM cells at an early and
late time point (Fig. 27a). The CD11c-YFP cells also bore striking morphological
resemblance to endogenous brain tumor associated-DCs previously observed.
Quantitatively, the CD11c-YFP cells were specifically localized in tumor in comparison
with non-tumor regions (Fig. 27b). In addition, T cells correlated strongly with CD11cYFP cells in brain tumors from mice that received CD11c-YFP cells and T cells a day
before or 14 days after cancer injection (Fig. 27c). This indicates that BM-derived
CD11c-YFP monocytes populate brain tumors and presumably differentiate into
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competent antigen presenting DCs at different stages of brain tumor growth. In
addition, it supported the idea that CD11c-DCs play a role in the localization of T cells
in brain tumor.
3.6b. CD11c-YFP cells are important for the retention and motility of T cell subsets in
brain tumor
I reasoned that since T cells localize and tend to form clusters around CD11c-YFP cells
in the local tumor milieu that CD11c-YFP cells might be important in regulating T cell
dynamics. To test this idea, I evaluated double reporter mice in which I could both
visualize CD11c-YFP cells and T cells and also manipulate CD11c-YFP cells; this was
possible because the double reporter mouse strain also expressed diphtheria toxin
receptor (DTR) under the CD11c promoter. In CD11c-DTR expressing mice, CD11c
cells can be specifically depleted by consecutive injections of small concentrations
(100ng/day) of diphtheria toxin (DT). I then implanted GL261 cancer cells intra-cranially
into DTR-expressing or DTR-non-expressing control mouse brain, and imaged the
tumor longitudinally. I chose an intermediate tumor growth time point of day 10 to begin
imaging as this time point showed robust CD11c-YFP and T cell recruitment in the
tumor in most mice. I then obtained baseline time-lapse movies of CD11c-YFP cells
and T cells in the tumor at day 10 and this was followed by injecting mice with DT
intraperitoneally (100ng/day) at days 11 and 12, before eventually obtaining post-DT
treatment time-lapse movies at day 13 and day 16. I used 100ng/day of DT because it
produced the most optimal and consistent depletion of CD11c-YFP cells over a short
duration of only two days in my experience. Following treatment with DT, as expected,
CD11c-YFP cells were almost completely eliminated in the tumor (Fig. 28a & movie 8).
The numbers of T cells also decreased sharply (Fig. 28a & b); this was unexpected
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because I had hypothesized that in the GL261 progressive tumor, T cells were “held”
by DCs in presumably unproductive interactions and I anticipated that after elimination
of the DCs, T cells would be released from interacting with CD11c-YFP cells,
redistribute in the tumor and potentially show cytotoxic behavior. I then analyzed the
motility of T cells and found a significant reduction in the mean velocity of T cells postDT treatment when compared to the pre-DT baseline. Correspondingly, T cells showed
more arrest after DT treatment in comparison with the baseline (Fig. 29a-c and movie
9). In contrast, there was no significant change in the motility of T cells in the DTR-nonexpressing control mice between pre-DT and post-DT scenarios. (Fig. 29b-c & movie
9). This indicates that CD11c-YFP cells are important for the retention of T cells in the
tumor microenvironment and in controlling their motility. When I analyzed for FoxP3
Tregs, which are much fewer than non-FoxP3 expressing T cells in brain tumor, I found
that Treg motility was significantly decreased but less affected than T cells (Fig. 30 and
movie 10). Overall, the experiments conducted here showed a critical role for CD11cDCs in retaining T cells and Tregs in GL261 brain tumor and in regulating their motility
behavior.
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Figure 27

Figure 27. Transfer of bone marrow cells into brain tumor-bearing mice reveals
correlation of CD11c-YFP and T cell localization in tumor.
a. Representative images showing the localization of CD11c-YFP cells (white) and T
cells (hCD2-DsRed) in a 21-day MCA brain tumor after BM transfer. The left panel
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represents cell localization in tumor after BM cells were transferred a day before cancer
cell injection via ICA. The right panel represents cell localization in tumor after BM
transfer 14 days after cancer cell injection via ICA.
b. Frequency of CD11c-YFP cells in MCA brain tumor (T) in comparison with nontumor (NT) regions of the brain. A group of colored dots in the graph represent all
metastatic tumor nodules randomly imaged and analyzed from a single mouse. Each
dot represents the number of CD11c-YFP cells localized within a single metastatic
tumor nodule or field of view (n = 3 mice/group; ****P <0.0001; frequency of CD11cYFP cell analysis was done by non-linear mixed effects regression model).
c. Correlation of total T cells per tumor nodule or field of view and CD11c-YFP cells in
the same field of view. Left graph represents cell correlation in tumor in experiments in
which BM was transferred to tumor-bearing mice 1 day before cancer cell injection and
right graph represents cell correlation in tumor from experiment in which BM was
transferred to tumor-bearing mice 14 days after cancer cell injection (n = 3 mice/group).
Different colors represent tumor nodules from different mice. A group of dots of the
same color in the graph represent all metastatic tumor nodules randomly imaged and
analyzed from a single mouse. Each dot represents the correlation of the area of
distribution of CD11c-YFP DC and T cell in a tumor nodule or field of view.
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Figure 28

b.

CD11c-YFP

Figure 28. Longitudinal intravital imaging reveals CD11c-YFP cells are important
for the retention and motility of T cell subsets in brain tumor.
a. Representative still images of longitudinal imaging sessions of endogenous CD11cYFP cells (white), total T cells (red) and Gl261 brain tumor (blue) in CD11c-DTR
transgenic mice at days 10, 13 and 16. Mice were treated with intraperitoneal injections
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of DT at days 11 and 12 (n = 5 mice in 5 different longitudinal experiments). Scale bar
represents 50µm.
b. Percentage of CD11c-YFP cells and T cells in the imaging field of view on days 10
and 13 before and after depletion of CD11c-YFP cells, respectively. Each colored line
represents longitudinal depletion of CD11c-YFP DCs and associated change in T cell
numbers per field of view in a GL261 brain tumor-bearing mouse.
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Figure 29

c

Figure 29. Longitudinal intravital imaging reveals CD11c-YFP cells are important
for the retention and motility of T cell subsets in brain tumor.
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a & b. Representative still images of longitudinal imaging sessions of endogenous
CD11c-YFP cells, total T cells and Gl261-mCerulean glioma tumor in CD11c-DTR
transgenic mice (upper image panels) and wild type mice (lower image panels) at days
10 and 13. Mice were treated with intraperitoneal injections of DT at only days 11 and
12.
c. Graphs show mean velocity and arrest coefficient of T cells at days 10 and 13 before
and after treatment of CD11c-DTR transgenic mice (n = 4 mice accumulated from 4
different longitudinal experiments; experiment was repeated ~8 times and only movies
with trackable T cells were included for analysis; mean velocity and arrest coefficient
analysis were done by non-linear mixed effects regression model and Nested MannWhitney-Wilcoxon Test, respectively; ***P < 0.001, ****P < 0.0001, ns = not significant)
and wild type mice with DT, respectively (n = 2 accumulated from 2 different
longitudinal experiments; experiment was repeated ~6 times). Different colors
represent T cells from different mice.
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Figure 30

Figure 30: Longitudinal intravital imaging reveals CD11c-YFP cells are important
for the retention and motility of Tregs in brain tumor.
Representative still images obtained from longitudinal 2-photon intravital imaging
sessions of GL261-mCerulean tumor, and endogenous Tregs at day 10 and 13.
CD11c-DTR mice were treated by intraperitoneal injection of DT at days 11 and 12.
Graphs show the mean velocity and arrest coefficient of Tregs before and after
depletion of CD11c-YFP cells (n = 2 mice accumulated from 2 different longitudinal
experiments; ns = not significant; **P = 0.01; experiment was conducted ~5 times and
only movies with trackable T cells were included for analysis). Scale bar represents
50μm. (Mean velocity and arrest coefficient analysis were done by Non-linear mixed
effects regression model and Nested Mann-Whitney-Wilcoxon Test)
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3.7b. Batf3 transcription is not important for CD11c-DC-mediated control of brain tumor.
Effective control of tumors generated in peripheral organs has been associated
with efficient cross-presentation of antigens by Batf3-dependent DCs to CD8 T cells in
the tumor bed279. As introduced in chapter 1, Batf3 is a transcription factor that
regulates the development and function of CD8ɑ+/CD103 DCs. In Batf3-KO mice,
CD8ɑ+/CD103 DCs are absent, and antigen cross-presentation is deficient. Therefore,
I sought to test the role of Batf3-dependent CD8ɑ+ DCs in the control of brain tumor
growth. To test this, I injected MCA cancer cells into the brains of WT or Batf3-KO mice
via the internal carotid artery. Following visualization of sections of tumor-bearing brain
tissues and quantification, tumor growth in Batf3-KO mice appeared comparable to
growth in WT mice (Fig. 31a & b), indicating that MCA brain tumor growth is not
dependent on the Batf3 transcriptional network in DCs, at least in the model tested
here. In addition, visualization of CD11c-YFP cells and T cells in Batf3-KO mice
revealed qualitatively comparable infiltration of CD11c-YFP cells and T cells in the
tumor.
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Figure 31
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Figure 31. Batf3 is not important for CD11c-DC-mediated control of brain tumor.
A. Growth of MCA fibrosarcoma in the brains of wild-type and Batf3-KO mice at day 20
following injection of 105 fluorescent-labeled MCA- cells via the internal carotid artery.
Tumor is in glow-scale and indicated by the white arrows. Scale bar represents 1mm.
B. Graph shows percentage of brain tissue covered by tumor and each dot represents
a mouse (n = 3 mice/group; ns = not significant; unpaired t test).
C. Representative confocal images obtained from brain tissue sections from wild type
and Batf3-KO mice at day 20 showing CD11c-YFP and T cells in association with MCA
tumor.
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Discussion
To our knowledge, this is the first documented evidence of real time T cell
dynamics in brain tumors. By applying different methods including direct and indirect
cancer cell injection and longitudinal intravital imaging, I have uncovered a
spatiotemporal relationship between T cells and CD11c DCs in brain tumors.
Interestingly, this was pervasive across different tumor types evaluated, except for the
poorly immunogenic B16-F10 melanoma, which had very few T cells and CD11c DCs
present in the tumor to begin with. Overall, T cells formed clusters around CD11c DCs
but this was not terribly surprising as this finding is consistent with a previous study that
documented the “entrapment” of T cells in CD11c DC network465; however, the fact that
T cells continued to migrate around CD11c DCs in a random pattern in such confined
area was unexpected. Although migration of T cells in clusters or confined spaces
usually reflect decreased velocity and prolonged interactions between T cells and
CD11c DCs in studies utilizing model tumor antigens, I detected few events of longlived contacts between T cells and CD11c DCs in a model presumably involving
polyclonal T cells. This suggests that T cells could be transiently interacting with CD11c
DCs to gather signals for reactivation in the tumor or T cells are only organized in such
patterns by yet unidentified CD11c DC-associated molecules or chemokine gradient(s).
In support of the former, tumor associated CD11c DCs showed preferential expression
of MHC-II and correspondingly, I observed multiple instances of T cell proliferation in
MCA and GL261 tumor ̶ a phenomenon that may be a more common than previously
believed. On the other hand, given the above observations it is also possible that T
cells engaging CD11c DCs in short-lived contacts in the progressive GL261 model may
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be undergoing tolerization in similarity to a DC/T cell interaction pattern previously
detailed in the lymph node379.
A key finding of this study is the demonstration that myeloid cells including
dendritic cells and classical monocytes, rather than microglia, are preferentially
enriched in brain tumors and play a dominant role in T cell tumor surveillance. This is in
contrast with previous studies that have highlighted the predominance of microglia-like
cells in various brain tumor types and their immune suppressive
properties216,232,446,460,461,466-468. This discovery was made possible by the iTIC method,
which I used to delineate and identify major myeloid cell subsets and their spatial
localization in the brain tumor microenvironment. The distinct localization of mature
dendritic cells and classical monocytes to the margin and core of the tumor,
respectively, was particularly striking. These two cell populations have been
documented to play distinct roles in tumor, with mature DCs playing mostly an antitumor role, while the classical monocytes are known to be tumor supportive, at least in
other types of extracranial tumor models28,255,258,356,419. In addition, the revelation of
distinct organization patterns of “mature” and “immature DC” populations at the margin
and core of the tumor by iTIC quantification methodology suggests likely ongoing
differentiation of “immature DCs” or monocytes to mature DCs in the tumor and may
involve cytokine or antigen-dependent differentiation mechanisms. However, it is also
possible that the localization of mature DCs at the tumor margin and CM in the tumor
core represent opposing forces during brain tumor progression, as mature DCs and CM
have been shown to be mostly anti-tumor and pro-tumor258,419, respectively.
Another surprising discovery in this study is that CD11c DCs control T cell
retention and their migratory pattern in brain tumors. Although we nurtured the idea that
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we could eliminate CD11c DCs to “free-up” T cells from CD11c DC “entrapment465,” the
numbers of T cells decreased dramatically, rather than redistribute in the tumor, and
the T cells became relatively less motile when compared to controls. This suggests that
CD11c DCs are necessary for effective T cell surveillance in the tumor. It also suggests
a role for strategies that enhance infiltration of DCs into the tumor microenvironment or
combine DC and T cell for tumor immunotherapy as opposed to conventional strategies
employing either DCs or T cells exclusively. For example, adoptive transfer of TILs or
engineered chimeric antigen receptor (CAR) T cells may profit from an additional
strategy of enhancing DC infiltration into the tumor to potentially aid in the retention and
anti-tumor function of TILs or CAR-T cells at the tumor. This finding also aligns well
with the recent observation of a subset of rare tumor-associated CD103+ DCs
mediating the anti-tumor effects of anti-CTLA4 checkpoint blockade in
melanoma457,469,470. Although we could not implicate the Batf3-dependent CD8α+ DCs,
which shares the same transcription factors as CD103+ DCs, several compensatory
transcriptional pathways such as Irf4 and Irf8 have recently been elucidated that allow
the development of CD8α+ DCs. Importantly, Batf3-dependent CD8α+ DCs are absent
in Batf3-knockout mice on the 129 SvEV mouse background but not the C57Bl6
background, suggesting that mouse background may impact encoding of the Batf3knockout transgene471. In this study, C57Bl6 mice were used and this could further
account for the disparity between our results and published findings279,280,285,286,471.
Future experiments utilizing mice with complete absence of CD8a+/CD103+ in C57Bl6
mice or other Batf3-KO mouse strains will be important in determining the role of this
DC population in the immune control of brain tumors.
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One limitation of this study is the lack of specificity of CD11c expression as a
marker to distinguish DCs from other macrophages. While the CD11c-YFP transgenic
mouse model remains very useful in gaining unprecedented appreciation of the
dynamics of “DCs” and T cells in intravital imaging experiments, better mouse models
that specifically identify only DCs will be important in clarifying the specific functions of
DCs relative to other macrophage subtypes. However, theoretically, it may be
impossible to distinguish all DCs from macrophages, as both cell types arise from a
common macrophage dendritic progenitor (MDP) cell, and these cells utilize very
similar signaling pathways and genetic programs during differentiation472-475. In
addition, given present technology, it is almost impossible to predict MDP differentiation
into specific lineages and may present a challenge for developing a transgenic reporter
mouse that fatefully reveals a single lineage. Also, confounding issues with local tissue
factors such as cytokines altering the plasticity of potentially differentiated cell types
cannot be excluded. This may add to the complexity of achieving a goal of cellular
specificity for DC fluorescent reporter mouse models. Regardless, distinct DC subsets
such as conventional DCs regulated by Zbtb46 transcription factor have been recently
engineered for studies on conventional DCs457,476.
The discovery of distinct myeloid cell organization in different tumor regions by
the iTIC method provides a framework to begin understanding brain tumor-associated
myeloid cells. Although this finding needs to be validated in more tumor types, it calls
into question the long-held notions about myeloid cell types believed to be dominant in
controlling brain tumor immune surveillance. In the literature, methods that appear to
have been confounded by the techniques used to initiate brain tumors (intracranial
injection) and process/analyse brain tumor specimens (flow cytometry procedures) may
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have introduced immune cell artifacts such as trauma-induced inflammation and cell
loss due to tissue processing, respectively, and led to confusion about the composition
of tumor-infiltrating myeloid cells in brain tumor444-446. Presumably due to these
limitations, most studies have pooled different tumor-associated myeloid cells under a
single arc usually coined as the “microglia/macrophages” entity216,477-489. Regardless,
distinguishing myeloid cell populations is still a difficult task as techniques and distinct
surface markers to separate different subsets of myeloid cells infiltrating brain tumor in
their native tumor microenvironment in situ are still being developed. With availability
of more reporter mice tagged with cell lineage-specific fluorophores210,212 myeloid cell
lineages may likely be better teased apart to better understand the composition of
myeloid cell types and their spatial organization in tumor. In fact, when this approach is
potentially combined with conventional gene profiling methods such as in situ
hybridization, a lot of new knowledge may be obtained in terms of associating gene
expression to cellular phenotype, tissue localization, and dynamic cellular behavior.
Based on the findings presented here, the presence of CD11c+ DC in tumor or
similar DCs identified by more robust markers in human tissues may positively impact
the prognosis of brain tumor patients being treated with immunotherapy. In support of
this idea, a recent study showed that high expression of CD11c cells469 or DCs was a
good prognostic factor for patients with different cancer types490,491. However, further
experiments are needed to determine whether CD11c+ DC population is necessary
during immunotherapy in brain tumor models.
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CHAPTER 4: IMMUNE RESPONSE TOWARD BRAIN METASTASIS DEPENDS ON
THE FRACTALKINE- CX3CR1 RECEPTOR AXIS
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Introduction
Immune surveillance of tumor is highly dependent on dynamic cell migration and
cell-cell contact372,379,400,492,493. For effective immune surveillance to occur, T cells must
travel to the site of the tumor after being primed by antigen presenting cells in tumordraining lymph nodes372,375,379,398. In tumor, T cells show migratory patterns that must
be regulated for effective tumor control372. However, little is known about the molecular
mechanisms regulating the dynamics of T cell tumor surveillance in the brain.
Chemokines are widely known to regulate immune cell migration in host homeostasis,
defense, and tolerance294,494. Studies of inflammatory disorders in mouse models have
revealed the importance of chemokines in mediating innate and adaptive immune
responses in autoimmunity, infection, and anti-tumor immune surveillance407,414,495.
There are numerous chemokines that mediate immune responses within
different tissues and they are organized in an organ-specific manner413,496. The stromalderived factor 1 (SDF1) chemokine and its receptors CXCR4/CXCR7 are necessary for
embryonic survival including neuronal migration and vasculogenesis, and has been the
most studied chemokine pathway in brain tumors497. Importantly, SDF1 and CXCR7 are
upregulated in tumor endothelium, microglia, and glioma cancer cells in glioma tissue
while CXCR4 has been shown to be highly expressed in high grade GBM and in glioma
stem-like cells498-500. The SDF1 pathway works by preventing apoptosis in glioma cells
and inducing increased tumor angiogenesis/vasculogenesis501-503; however, inhibition
of CXCR4 or CXCR7 has resulted in increased apoptosis and decreased proliferation
of glioma cells504-506. The monocyte chemoattractant protein 1 (MCP-1/CCL2) is
another chemokine that is produced by microglia in inflammatory conditions or in
glioma tissue and known to attract Tregs, effector T cells, and inflammatory monocytes
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via its receptor CCR2347,419,502,507,508. In addition, the CCL22/CCR4 pathway has been
implicated in recruiting T cells to brain tumor508-510. Microglia express CCR5 and
inhibition

of

CCR5

prevented

transition

to

an

“M2”

immune

suppressive

phenotype511,512. CXCL2-CXCR2 is up-regulated by brain resident perivascular myeloid
cells and inhibition reduced tumor vessel density and glioma size513. Other chemokines
expressed in glioma or implicated in glioma progression include CXCR3, CCL20/CCR6,
CXCL16/CXCR6, CCL27/CCR10514-518.
However, the aforementioned chemokines are inducible in glioma tissue and
presumably operate equally in inflammatory conditions in other mammalian tissues as
in glioma. In contrast, there may be chemokines that operate in an organ-specific
manner even in the brain. Fractalkine is one such chemokine that is highly expressed
by neurons in the healthy brain, and to a lesser extent by epithelia in other tissues such
as the kidney, lung, and uterus411,519. Fractalkine is known to control the migration of
several myeloid cell types and some T cells via its only known receptor, CX3CR1419.
Because of its high expression in the brain, Fractalkine could be a key regulator of antitumor immunity in the brain; however, its involvement in brain tumor T cell immune
surveillance is largely unexplored. Fractalkine is unique as it is the only member of the
fourth class of CX3C- family of chemokines. It is constitutively membrane-bound on
neurons and is produced as a long protein with cytoplasmic, transmembrane, mucinlike stalk, and chemokine domains. In addition, it can assume a soluble form following
cleavage by metalloproteinases such as ADAM10 and 17520. This form accesses the
circulation and is important for the recruitment of CX3CR1-expressing cells412,519,520.
Fractalkine may be released into the tissue and circulation in the setting of CNS
injury521,522. In this regard, brain tumors show striking similarity to CNS injury events as
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they progressively invade the surrounding tissue architecture and potentially induces
responses from the surrounding brain tissue including neurons. Therefore, the
possibility that traumatized neurons surrounding brain tumors could upregulate
expression or release soluble Fractalkine is likely. The process of brain tumor growth
is associated with increased expression of metalloproteinases27,523 . Therefore it is
probable that this process may be utilized in upregulating relevant metalloproteinases
such as ADAM10 and 17, which could then cleave fractalkine into the circulation.
CX3CR1 is a G-protein coupled receptor that is expressed on the surface
membrane of various immune cell types including microglia, macrophages, monocytes,
DCs, and T cells210,413. CX3CR1 is known to be important in cell migration and
adhesion524-526. Using genetically engineered mice, CX3CR1 has been shown to be
important in the pathogenesis of Alzheimer’s disease, atherosclerosis, diabetes
mellitus, atopy, HIV, and cancer414,415,419,527,528. In addition, single nucleotide
polymorphisms of CX3CR1 have been implicated in several inflammatory disease
conditions such as atherosclerosis, HIV/AIDs, and atopic dermatitis529-531. Although
deficiency of CX3CR1 was recently shown to regulate infiltration of immune
suppressive monocytes in glioma progression419, its role in the regulation of brain tumor
immune surveillance is lacking especially with regards to T cell involvement, and in the
regulation of antigen presenting myeloid and T cell dynamics in brain tumor. Therefore,
based on the expression of Fractalkine in the brain, I hypothesized that the FractalkineCX3CR1 axis counteracts brain tumor progression by regulating anti-tumor immune
responses.
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Results
4.1. MCA brain tumor progression is controlled by T cells
Different tumor lines were found to have a differential propensity to grow within
the brain of mice. Specifically, B16 melanoma and Lewis Lung Carcinoma (LLC)
demonstrated engraftment and rapid growth within 14-21 days after in vivo injection. In
contrast, the fibrosarcoma line, MCA, initially demonstrated engraftment in the brain but
failed to grow. This was not an issue of tissue kinetics or cancer cell viability since MCA
demonstrated robust growth in vivo in the lung (Fig 32), indicating that there was a
unique property of the MCA line that allowed immunological recognition and clearance.
To determine whether adaptive immune surveillance is critical for progression of
MCA brain tumor, I injected MCA cancer cells via the ICA to the brain of Rag-KO mice,
which are deficient in T and B cells. After mice were sacrificed at late time points of day
18-20, brain sections visualized by confocal microscopy revealed significantly larger
tumor in brain of Rag-KO mice in comparison to wild type (WT) mice (Fig 33a &b). This
established the role of the adaptive immune system in the control of ICA-induced MCA
brain tumor.
To specifically test the role of T cells in MCA anti-tumor immunity, CD8 cytotoxic
T cells known to play a major role in killing cancer cells were depleted one day before
or 5 days after MCA cancer cells were injected into C57Bl/6 WT mice as described in
chapter 2. After depletion of CD8 T cells one day before cancer cell injection, MCA
brain tumors were found to be significantly larger relative to WT control mice, indicating
that CD8 T cells control MCA brain tumor growth (Figure 33c). However, depletion of
CD8 T cells 5 days after injection of cancer cells resulted only in a trend towards
increased MCA brain tumor growth. Furthermore, intravital microscopy of MCA brain
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tumor in WT reporter mice revealed fragmentation of MCA tumor (Figure 33d and
movie 11). This coincided with persistence of T cells in association with CD11c-YFP
cells in the fragmenting tumor nodule, reminiscent of observations documented in
chapter 4. Although T cells in associating with the tumor exhibited stable engagement,
other T cells within the vicinity of the tumor showed less stable engagement or no
engagement.

4.2. The Fractalkine/CX3CR1 axis is dysregulated in glioblastoma patient myeloid cells
and control of MCA brain metastases in mice depends on the Fractalkine/CX3CR1
pathway
To identify molecular candidates that may regulate brain tumor immune surveillance by
T cells, I mined several databases including BioGPS which I analyzed for mRNA
expression of chemokines in different mammalian tissues. Fractalkine was identified as
a lead candidate based on species conservation and relatively higher expression in the
brain in comparison with other mammalian tissues in mice and humans. (Fig. 34 & 35).
In a bid to explore the role of Fractalkine in regulating brain tumor immune surveillance,
healthy and tumor-bearing mice brain tissue sections were stained with anti-Fractalkine
antibody in order to visualize the expression of Fractalkine. By using confocal
microscopy, I found high expression of Fractalkine at the margin of MCA and GL261
tumor as opposed to its discrete cellular localization in healthy brain tissue, presumably
within neurons as has been previously documented410,519 (Fig. 36a & b).
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Figure 32

a.

b.

Figure 32: MCA brain metastases establish efficiently in lung but not brain.
a. Growth of B16, LLC, and MCA tumors (blue) in the brains or lungs of wild-type mice
after injection of 105 fluorescent-labeled cancer cells via the internal carotid artery or
tail vein, respectively. Panels within the red line rectangle indicate inefficient growth of
MCA in the brains of mice at later time points
b. Percentage of brain parenchyma area in coronal plane infiltrated by tumor. Each dot
represents one mouse [GL261 (n = 5), LLC (n = 7), B16-F10 (n = 2), and MCA (n = 29);
mice were pooled from >2 experiments]. The numbers in parenthesis in the x-axis
represent the range of time points when mice were sacrificed for analysis.
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Figure 33

d

Figure 33: Growth of MCA is controlled by CD8 T cells.
a. Confocal images of coronal brain sections from WT and Rag-KO mice showing
growth of MCA at day 20 following ICA cancer cell injection. Scale bar represents
1mm.
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b. Graph shows the percentage of brain parenchyma infiltrated by tumor in the coronal
plane and each dot represents a mouse (**P < 0.001; n = 7-13 mice/group; pooled from
2 different experiments; Mann-Whitney non-parametric test).
c. Growth of MCA in the brains of control mice or mice injected with anti-CD8α
depleting antibody (100mg/ml; intraperitoneally; Clone #53-6.72, BioXcell, San Diego,
CA) at day 20 following injection of MCA cancer cells via the ICA. Graph shows the
percentage of the brain parenchyma area in coronal plane infiltrated by tumor and each
dot represents a mouse (n = 5-8 mice/group, pooled from 2 different experiments).
Scale bar represents 1mm. D-1 and D5 represent two different groups of mice that
were treated with CD8 depleting antibody beginning one day before they were injected
with cancer cells via the ICA or five days after cancer cells were injected in mice. *P <
0.05, ns = not significant.
d. Representative image panels to the left show MCA-mCerulean fibrosarcoma brain
tumor (blue) undergoing fragmentation in association with CD11c+DCs (white) and T
cells (hCD2-DsRed; time span of active fragmentation is shown in the top left corner of
the upper panels). Representative time-projection image panel in the middle shows
areas of T cell persistence (pink) at the tumor site during a 1-hour time-lapse image
acquisition. In the right panel, time color-coded tracks indicate T cell migration tracks
over 1 hour; T cell migration tracks proximal to tumor/CD11c-YFP DCs appear more
clustered in comparison with distal tracks. Scale bar represents 10μm.
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To test for the relevance of Fractalkine signaling pathway in human brain tumor
patients, NanoString digital color-coded barcode technology was used to measure the
mRNA expression of Fractalkine receptor, CX3CR1. This was done using CD14+
peripheral blood monocytes from healthy donors and GBM patients, and CD14+
myeloid cells from normal post-mortem/epilepsy brain tissue and tumor-infiltrating GBM
myeloid cells. Interestingly, CX3CR1 mRNA levels were significantly reduced in CD14+
PBMCs and GBM tumor-myeloid cells in almost all GBM patient specimens tested in
comparison with control samples (Fig. 36c & d). Therefore, to test for the importance of
Fractalkine signaling via CX3CR1 in brain tumor progression, MCA cancer cells were
injected via the ICA into CX3CR1-KO mice, and wild type (WT) and CX3CR1heterozygous mice were used as controls. This was based on the reasoning that
knockout of CX3CR1 would disrupt Fractalkine signaling and the consequent immune
surveillance, thereby enabling progression of the spontaneously regressing MCA brain
tumor. After confocal imaging of MCA tumor-bearing brain tissue sections and analysis,
significantly larger tumors were found in CX3CR1-KO mice in comparison with WT
mice. Unexpectedly, MCA tumors in CX3CR1 heterozygous mice were also
significantly larger than in WT mice (Fig. 37). This suggested that Fractalkine signaling
via CX3CR1 is important at different levels of its expression in counteracting the
progression of brain tumors, at least in the MCA tumor model.
In line with a role for Fractalkine/CX3CR1 signaling in tumor progression, I
reasoned that absence of fractalkine signaling could impact the dynamics of CD11cYFP cells and T cells. Interestingly, when the density of T cells and CD11c-YFP cells
was quantified in MCA tumor, both populations were highly reduced in CX3CR1heterozygous and CX3CR1-KO mice in comparison with WT mice (Fig. 38a-c). In
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addition, the surface of tumor covered by T cells was reduced in CX3CR1heterozygous and CX3CR1-KO mice relative to WT controls; however, the capacity of
T cells to contact cancer cells was not significantly altered (Fig. 39). This suggested
that the Fractalkine/CX3CR1 signaling pathway supports the recruitment of CD11cYFP cells and T cells to MCA brain tumor.
4.3. CX3CR1 controls T cell motility patterns in the tumor
Finally, I investigated the role of Fractalkine/CX3CR1 signaling in regulation of T
cell motility in brain tumor. To test this, MCA cancer cells were injected via the ICA WT
and CX3CR1-KO mice. By acquiring time-lapse movies of T cells in tumor-bearing WT
or CX3CR1-KO mice between 7-10 days after cancer cell injection and tracking the T
cells (Fig. 40a and movie 12), radial tracking plots of T cells showed that T cells in
CX3CR1-KO mice diverged more from their track origin whereas those in WT mice
were in swarmed or clustered in the tumor region and remained closer to their track
origins (Fig. 40b). No difference in T cell velocity and meandering was found between
CX3CR1-KO and WT mice; however, T cells in CX3CR1-KO mice were more diffuse,
and were less arrested at the tumor (Fig. 40c). These data supports the idea that the
lack of Fractalkine signaling via CX3CR1 leads to altered and inefficient anti-tumor T
cell motility patterns in brain tumor.
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Figure 34: Histogram showing gene expression level of fractalkine in different tissues
and organs in mice (http://biogps.org/#goto=genereport&id=20312).
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Figure 35: Histogram showing gene expression level of fractalkine in different tissues
and organs in human tissue specimens http://biogps.org/#goto=genereport&id=20312).
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Figure 36

Extratumoral region
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Figure 36. Fractalkine is highly expressed at the margin of brain tumors, and
expression of its receptor CX3CR1, is reduced in GBM patients.
a. Representative confocal images of ex vivo brain tumor tissue sections showing
expression of Fractalkine in normal brain, and MCA and GL261 brain tumors. MCA
tumor was generated by ICA injection while GL261 was directly implanted by ICrinjection. Scale bar represents 50μm.
b. Intensity profile of Fractalkine obtained from 10 different MCA tumor nodules (n = 3).
The intensity line profile cuts across the margin of the tumor beginning from inside the
tumor and extending to relatively normal brain tissue.
c. Gene expression level of CX3CR1 on CD14+ monocytes obtained from peripheral
blood of healthy donors and GBM patients (n = 11; unpaired t test).
d. Gene expression level of CD14+ myeloid cells obtained from normal brain tissue
(post mortem/epilepsy patients) and GBM patients. Each dot represents a patient (n =
11; unpaired t test).
*Sungho Lee, MD PhD was helpful in staining normal brain tissues for Fractalkine in
figure a.
*Konrad Gabrusiewicz, PhD and Amy Heimberger, MD, were helpful in conducting and
discussing experiments in figures c and d, and kindly shared the results for this thesis.
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Figure 37

a

b

Figure 37. CX3CR1 deficiency in mice is important for efficient establishment of
brain tumor.
a. Representative confocal images of MCA cancer cell growth in the brains of WT,
CX3CR1-heterozygous, and CX3CR1-KO mice at day 20 after injection via the ICA.
Images are shown in glow-scale; white represents the maximum fluorescence intensity,
red represents the minimum, and black indicates the lack of fluorescent signal. Brain
parenchyma is outlined with red dashed lines for clarity.
b. Graph to the right of the image panel shows the percentage of the brain parenchyma
area in coronal plane infiltrated by tumor and each dot represents a mouse (n = 7-10;
pooled from 3 different experiments; unpaired t test). Scale bar represents 9 mm. *P =
0.04, **P = 0.003, ns = not significant.
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Figure 38

a

b

c

Figure 38. Fractalkine/CX3CR1 signaling is important for recruitment of DCs and
T cells to the tumor.
a. Representative confocal images of endogenous CD11c-YFP cell and T cell
localization in WT, CX3CR1-heterozygous, and CX3CR1-KO mice.
b. Density of CD11c-YFP cells in tumors analyzed in WT, CX3CR1-heterozygous, and
CX3CR1-KO mice (DC index is defined as the volume of CD11c-YFP cells divided by
the volume of the tumor). Each dot represents a tumor nodule (n = 3 mice per group;
Mann-Whitney non-parametric test).
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c. Density of total T cells recruited to tumor nodules in WT, CX3CR1-heterozygous,
and CX3CR1-KO mice (n = 3 mice; Mann-Whitney non-parametric test).
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Figure 39

Figure 39. CX3CR1 controls tumor coverage by T cells but not extent of T cell
surface contact to tumor
a. Extent of tumor surface covered by T cells, and b. Extent of T cell surface contacting
tumor in wild type, CX3CR1-heterozygous, and CX3CR1-KO mice. Each dot
represents the total surface of a single tumor nodule covered by or contacting T cells.
(n = 2-3 mice/group; Mann-Whitney non-parametric test).
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Figure 40

ns
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Figure 40. CX3CR1 is important for T cell motility patterns in brain tumor.
a. Representative still images from intravital time-lapse imaging sessions showing MCA
tumor (blue), blood vessels (hMW TRITC-dextran; cyan), and T cells (CD2-DsRed). T
cell tracks are indicated by lines that are time color-coded.
b. Representative displacement tracks of T cells in MCA brain tumor-bearing WT or
CX3CR1-KO mice. Displacement tracks are time color-coded.
c. T cell motility parameters in MCA brain tumor in WT or CX3CR1-KO mice including
the mean velocity, meandering index, diffusion coefficient, and arrest coefficient. Each
dot represents a T cell (n = 2 mice/ group; mean velocity, meandering index, and
diffusion coefficient were analyzed by non-linear mixed effects regression model and
arrest coefficient was analyzed by nested Mann-Whitney-Wilcoxon test).
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Discussion
In this study, I found that T cell surveillance of brain tumor is controlled by the
Fractalkine/CX3CR1 signaling axis and that this signaling pathway counteracts MCA
brain tumor progression These findings are consistent with the results of a recent study
in which CX3CR1 deficiency was shown to be important in increasing the survival of
brain tumor-bearing mice in which orthotopic brain tumor was generated by using a
GEMM brain tumor-derived cancer cell line419. In addition, lack of CX3CR1 was
associated with increased recruitment of peripheral immune suppressive
monocytes/macrophages increased in brain tumor419. However, they failed to identify
any differences in in situ progression of brain tumor in the brains of CX3CR1-deficient
mice in comparison with WT mice. Fractalkine expression was detected to be low or
not expressed by tumor tissue or cancer cells indicating that fractalkine signaling was
not responsible for recruitment of brain monocytes/macrophages. It appears that their
focus on the accumulation of monocytes/macrophages inside the tumor core and their
inability to identify the localization of DCs or T cells in their tumor model may have
prevented interrogation of fractalkine in the peritumoral compartment as a key player in
brain tumor progression. Here, I show that Fractalkine expression is increased
especially at the margin of the tumor in both the MCA and GL261 model. This would
indicate possible stress or damage to neurons adjacent to brain tumors, as neurons are
known to constitutively express Fractalkine, and presumably upregulate this chemokine
during inflammation. It is important to note that myeloid/T cell tumor infiltration has
been observed in some studies to occur at the margins of tumor types studied532-534,
and consistently in chapter 4, characterization of tumor-infiltrating myeloid cells
revealed that mature DCs expressing CX3CR1 are abundant at the tumor margin.
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Whether this indicates a chemokine-based segregation of myeloid cells into different
tumor compartments is an area of active investigation.
A key issue that was puzzling was that although the brain resident microglia
show high expression of CX3CR1 in both steady state and in brain pathologies, they
did not form clusters or aggregate around brain tumors as has been heavily
documented in the literature446,467,477,486,489,535,536. One explanation for the findings in
this thesis, as opposed to previous observations, may be that Fractalkine does not
diffuse extensively into the brain parenchyma but is only locally upregulated and
secreted around the tumor, and that the engraftment and invasion of tumor, for
example MCA, from within the vasculature into the brain tissue allows for preferential
secretion of Fractalkine into the circulation. This may then lead to the cascade of
preferential recruitment of myeloid cells such as BM-derived monocytes rather than
microglia. In support of this idea, I have observed multiple times that tumor-associated
DCs are usually proximal to the brain vasculature. Another possibility is that steady
state constitutive expression of membrane-bound Fractalkine in neurons and high
expression of CX3CR1 in microglia may exist to tether microglia to neurons in order to
enable an efficient physiologic neuron-pruning function for microglia and to also prevent
potentially “neurotoxic” microglia from roaming free in the brain tissue416,537,538.
Therefore, if this idea holds true, it is possible that relatively distal microglia from the
tumor margins are not recruited because constitutively membrane-bound Fractalkine in
intact neurons retain the capacity to tether microglia and prevent microglia recruitment
to the tumor. In extension, it may be possible that in much larger tumors that have
invaded significant regions of the brain, more microglia are recruited into the tumor, and
that in CX3CR1-KO mice, microglia are untethered and able to infiltrate the tumor and
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contribute to tumor progression; however, more work is needed to test these ideas.
Alternative possibilities may involve the contribution of other chemokines and/or
differences in chemokine signaling pathways between microglia and other myeloid cells
such as DCs.
The decreased density of T cells and CD11c DCs in brain tumor in the absence
of CX3CR1 implicates Fractalkine as a major regulator of DC and T cell surveillance in
the tumor. In fact, analysis of T cell motility behavior in CX3CR1-KO mice showed
altered patterns of T cell movement suggesting that Fractalkine signaling via CX3CR1
is important for the local migration of T cells in the tumor. However, if this pathway were
dominant in deciding the recruitment of DCs and T cells, then such recruitment should
be observed in melanoma brain tumor such as B16-F10 mouse tumor model. As this
was not the case according to my observations in chapter 4, it indicates that there are
other mechanisms that may be necessary for immune cell recruitment. Another
explanation for differences in immune cell infiltration in cancer is their immunogenicity,
which is an area of intense interest. Another possibility is that different cancer cells may
vary in the extent to which they can induce cleavage and secretion of Fractalkine into
the circulation. Therefore, more work is needed to evaluate the role of MMPs such as
ADAM10 and 17 in the different tumor models as a potential mechanism underlying the
differences in immune cell recruitment.
In human brain tumor patient specimens, CX3CR1 expression in CD14+ myeloid
cells was reduced in both brain tumor tissues and in the peripheral blood, suggesting a
similarity to our studies in mice in which CX3CR1-KO enhances brain tumor
progression. However, a role for Fractalkine/CX3CR1 signaling in patient survival was
unclear from preliminary analysis of TCGA datasets as the expression of CX3CR1 in
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patient tissue was conducted in only very few patients and healthy tissues with
insufficient statistical power.

Regardless, there are several possibilities that might

cause a reduction in the expression of CX3CR1 in CD14+ monocytes in human patient
brain

tumor

including

de

novo

genetic

mutations,

chemotherapy-induced

downregulation, or preferential migration and localization of CX3CR1 low-expressing
CD14+ monocytes in brain tumors that could have been preferentially sampled. In
addition, CX3CR1 expression may be downregulated as a mechanism of tumor
immune evasion or it may indicate disruption of fractalkine/CX3CR1 feedback loop.
These possibilities will be dissected in future studies to gain better insight into the
significance of reduced CX3CR1 expression on CD14+ monocytes in brain tumors of
patients with GBM. Although more work needs to be done to elucidate the effect of
reduced CX3CR1 mRNA expression in patients with GBM in functional human studies,
the corresponding decrease in both brain myeloid cells and peripheral blood monocytes
makes CX3CR1 expression an attractive tool for patient stratification for the purposes
of prognostication, treatment, and follow-up.
Given these findings, the fractalkine/CX3CR1 chemokine pathway represents an
attractive immunotherapeutic modulation pathway for guiding endogenous or adoptive
transfer of T cells to brain tumor sites. Development of strategies modulating this
pathway may be crucial in providing new immunotherapeutic strategies aimed at
treating brain tumors.
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CHAPTER 5: SUMMARY, GLOBAL DISCUSSION, AND FUTURE DIRECTIONS
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5.1. Summary
Immune cells residing in tumor microenvironment play a critical role in tumor
progression. In this thesis, I have documented important technical advances in intravital
imaging of brain tumors that enable the visualization of immune cells in a nearphysiological state. I have applied several innovative approaches and tumor models in
elucidating the spatiotemporal dynamics of tumor-infiltrating T cells in relation to CD11c
DCs. The method of in situ immune cell characterization in a novel myeloid cell mouse
model reported here has revealed an unappreciated organization of myeloid cells in
brain tumors. In addition, I have determined a mechanism of cellular control of T cell
dynamics in the brain tumor microenvironment as well as a molecular chemokine cue
that controls brain tumor progression, immune cell recruitment and migratory behavior.
In sum, the data presented here provides a platform from which future studies could
take off and in which multiple areas of cellular and molecular regulation could be better
clarified and applied in the development of novel immunotherapy strategies.
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Figure 41. Model illustrating brain tumor immune surveillance.
The figure depicts a model in which growth of brain tumor causes damage of neurons
and subsequent release of Fractalkine. DCs and T cells are recruited to the tumor, in
part, by Fractalkine. DCs organize around the tumor margin and T cells form clusters
around DCs. Other T cells migrate within the tumor.
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5.2. Future implications of applying a near-physiological brain tumor imaging system
An elusive aspect of brain tumor immunology has been the lack of
understanding of the reactivity of brain resident microglia to brain tumors beginning
from a single cancer cell stage and the differential participation and contribution of
resident and/or infiltrating myeloid immune cells in tumor progression. By using a new
approach, I have clarified that microglia are generally non-reactive to cancer cell growth
in the brain at early time points. Microglia were not recruited to the cancer cells, nor did
they transform their morphology into an “activated” phenotype. In support of this,
microglia somas were observed to remain relatively sessile despite appreciable tumor
growth in brain tissue. Irrespective of the presence of cancer the microglia maintained
probing activity, continuously extending and retracting dendritic processes toward
vasculature and presumably other brain structures including neurons and astrocytes.
Whether the scanning activity of microglia dendrites changes significantly in the
presence of cancer cells in the brain was not apparent in the studies conducted here,
but remains to be investigated. Even at later stages of advanced tumor growth,
appreciable infiltration of microglia into the tumor was not observed. However, it is
possible that a certain range of tumor size or brain tissue compression and/or damage
unidentified here could trigger microglia to infiltrate into the tumor. Therefore, I am not
able to absolutely exclude that microglia are active participants in brain tumor. This
ambivalence is complicated by the fact that there is no appropriate technique available
for the specific depletion of microglia to ascertain its real contribution to tumor
progression. Some techniques that have been tested for depletion of microglia in mice
brain include brain irradiation, Clodronate-liposome, Mac-1-Saporin, Colony Stimulating
Factor 1 Receptor inhibitor (CSF1R; PLX5622), use of ganciclovir-mediated ablation on
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tga20/CD11b Thymidine Kinase of Herpes Simplex Virus (HSVTK) transgenic mice,
CX3CR1-DTR transgenic mice, and IL-34-KO mice225,236,539-543. Some of these systems
have found use in the study of neurodegenerative diseases such as Alzheimer’s or
prion diseases where microglia but not extracranial myeloid cells are believed to play a
major role in disease progression; however, none of these systems eliminate microglia
specifically and most are sub-optimal in depletion efficacy. Also, microglia do not
respond to irradiation strategies as they are radio-resistant221,544. At most, if an
appreciable percentage of microglia is eliminated by any of the listed strategies, the
depletion effect on extracranial myeloid cells in the periphery is disregarded. If the role
of microglia is to be definitively distinguished from incoming myeloid cells in brain tumor
studies, a system that targets only microglia for depletion will need to be established.
Nevertheless, since myeloid cells such as monocytes but not microglia can be depleted
by irradiation, combining this approach with chimeric reporter mouse bone marrow
adoptive transfer experimental systems, in addition to the novel intravital nearphysiological imaging system developed here, may help to partially answer this
question. It is also possible that microglia may regulate brain tumor progression
indirectly by interacting with other tumor immune infiltrates and this is an area of future
study.
5.3. Outstanding questions on DC-T cell interactions
Anti-tumor immunity is known to depend on productive interactions between
DCs and T cells in the lymph node379,457. Recently, however, there has been a
paradigm shift from studying the in vivo dynamic interactions between DCs and T cells
in the lymph node as a standard for understanding anti-tumor immune response to a
new model involving real time visualization and mechanistic probing of DC-T cell
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interactions in the tumor microenvironment 375,402,465,469,476. This thesis has for the first
time extended previous breakthroughs in imaging tumor DC-T cell interactions in
tissues and organs such as the mammary tissue and skin to the brain. I have shown
that there is robust infiltration of endogenous DCs and T cells to brain tumors and that
their dynamics are correlated in space and time. Interestingly, T cells cluster around
foci of DCs, maintain high migratory velocities even when proximal to DCs, and appear
to make transient contacts with DCs. This is in contrast to previous studies that have
employed model antigens such as ovalbumin to model tumor antigens and showed
persistent interactions between DCs and T cells with long-lived contacts, that would
suggest that prolonged DC/T cell interactions in an endogenous setting are infrequent
375,465

. Also, further cell tracking analysis revealed that T cells within clusters around

DCs exhibit random motility when observed for short periods of imaging; however, they
become highly confined around DCs in more prolonged observations especially in
tumors undergoing rejection, which is not a known occurrence in human brain tumors.
Apart from differences in cancer cell immunogenicity that may explain differences in
interaction patterns of T cells with DCs, it will be important to determine whether
migration of T cells around DCs is regulated by adhesion molecules like integrins or
more diffusive molecules such as chemokines. Whether T cells receive differential
levels of stimulation by the DCs or produce varying levels of cytotoxic molecules during
tumor rejection versus progression was not investigated here, but should be examined
in a future study.
Functional studies employing mouse models such as NFAT-GFP, Nurr77-GFP,
or interferon-gamma (IFN-y)-GFP reporter transgenic mice in which the activation
status of T cells can be observed in real time during cellular interactions will be useful
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in determining the effect of DC-T cell interactions in either scenario. In addition, future
application of technologies that visualize intracellular calcium flux in T cells will enable
better understanding of potential DC-T cell immune synapses in tumor393-395,545-548.
Reactivation of T cells in the tumor is a desired outcome in tumor
immunotherapy375. Chronic unproductive activation or exhaustion of T cells in tumor
has been well documented and targeted by checkpoint blockade immunotherapy26,57.
However, little is known about the spatial interactions needed by T cells to integrate full
activation signals for effective functioning in vivo. Even less is known about the
molecular signals required for such interactions. An important question that remains
unanswered is “how do T cells “find” DCs such as CD11c+ DCs to interact with within
the multitude of different potential APCs in the tumor microenvironment and what
factors lead to the formation of T cell clusters around DCs?” This is crucial to
understand because it could guide therapeutic strategies that aim to enhance the
recruitment of endogenous and exogenous transferred T cells to the tumor
microenvironment.
Bear in mind that the novel triple myeloid reporter mouse established and
evaluated here is an attempt to better understand the diverse myeloid cells in situ in
tumor microenvironment; however, it likely does not reveal all myeloid cells that could
potentially infiltrate brain tumor. In addition, although CD11c is highly expressed by
DCs, some monocytes and macrophages express this marker. Therefore, to partly
answer the question stated above, models that are engineered for visualization of
spectrally distinct DC subsets such as conventional DCs in addition to macrophages,
monocytes, and T cells will have to be established in order to delineate the interaction
patterns of T cells within a diverse pool of myeloid cells.
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Another equally pertinent question is how T cells migrate between DCs and the
adjacent tumor and determine which cancer cell(s) to attack or kill; Do T cells kill better
in prolonged interactions with tumor or in repeated on-off brief contacts? Do T cells that
have previously killed continue in a killing “spree” (serial killing) or do they migrate back
to DCs to be re-activated? Are lone T cells enough to effectively kill single cancer cells
or does the killing efficacy increase in a T cell number-dependent manner in which
more than one T cell makes contact with a cancer cell? Are cancer cells being killed
when T cells are simultaneously contacting both DCs and cancer cells or can T cells kill
cancer cells indirectly via DCs while maintaining DC-T cell contact? These are
important questions that must be answered in vivo to better understand ways of
improving T cell killing efficiency.
In observations documented here, active fragmentation of tumor and cancer
cells was observed in association with T cells stably contacting DCs and/or tumor. An
interesting speculation that arises from this is whether a mechanism of tumor killing by
T cells involves initial disruption of adhesion molecules between cancer cells in the
tumor before T cell-derived cytotoxic molecules are released or whether tumor
fragmentation is only sequelae of a killing event. This seems plausible because the
compact architecture of solid tumors may prevent effective T cell infiltration and killing.
Therefore, if T cells are to engage cancer cells effectively, individual cancer cell surface
area may have to be increased by mechanisms that cause disruption of cell-cell
adhesion molecules in a tumor bulk. Whether T cells begin killing by first identifying and
targeting weak links within the tumor is an interesting idea open for exploration.
Another important finding in this study is the dominant control exhibited by
CD11c DCs on T cell retention and motility in brain tumor. This is in contrast with
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previous studies in other tissues suggesting that T cells may be prevented from
performing surveillance function in the tumor by being held in unproductive interactions
with DCs465. In fact, when we adoptively transferred small numbers of T cells and DCs
into brain tumor-bearing mice, T cells surprisingly localized in DC niches in the tumor,
indicating that T cell homing and localization may actually be dependent on DCs. It also
raises questions as to the functions played by specific myeloid cell populations in the
tumor. Do some myeloid cell subsets synergize with DCs in retaining T cells? Do T
cells exist in a Yin Yang situation in which their myeloid interaction partner is
determined by the tumor cytokine milieu? Does the tumor host organ determine what
interaction partners T cells will preferentially engage with? Even within the T cell
population, the difference in the patterns of interaction between individual T cell
subsets with tumor-associated myeloid cells is yet to be determined. It will be critical to
evaluate the interaction patterns of Tregs and its potential myeloid cell partners in the
tumor as this is an attractive T cell target for enhancing the efficacy of immunotherapy.
Future studies should also determine the cellular and molecular regulators of Treg
retention and motility as this may provide insight into potential targets applicable in both
tumor immunology as well as autoimmune studies.
The neuronal chemokine Fractalkine has been implicated in cancer progression
as well as in the regulation of immune cells419. The contextual elucidation of Fractalkine
expression in brain tumor in relation to how tumor-associated myeloid cells are
organized was achieved in this study. In observing robust Fractalkine expression at the
margin of the tumor, it is tempting to speculate that the tumor directed tissue injury; in
particular stress or damage impacted on adjacent neurons that may guide tumor
immune surveillance. The idea that the innate immune system is capable of detecting
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and responding to DAMPs via PRRs in host sterile tissue or noninfectious states lends
support to this speculation112,113,549-552.
There are several types of DAMPs including chromatin-associated high-mobility
group box 1 (HMGB1), heat shock proteins (HSPs), deoxyribonucleotide adenine
triphosphate (DNA), ribonucleotide adenine triphosphate (RNA), S100 molecules,
purine metabolites such as adenosine triphosphate (ATP), and hyaluronan
fragments549,553-555. Examples of PRRs utilized in the detection of DAMPs include Tolllike, RIG-I-like, and NOD-like receptor families. Interestingly, DAMP molecules such as
S100 are expressed by neurons and glial cells and are utilized clinically to assess for
brain injury553-555. In addition, pathways including ATP/purinergic receptors and HSPs
are involved in neuronal and glial physiologic functions such as neurotransmission.
Whether the signaling of these molecules engage innate myeloid cell PRRs at the
margin of brain tumor, initiate innate immune responses and synergize with neuronderived fractalkine to regulate T cell surveillance will be an interesting area to explore.
In partial support of this idea, the data here shows that CX3CR1-GFP+ CD11c DCs
and T cells organize around the margin of brain tumor, and in the absence of
Fractalkine/CX3CR1 signaling, DCs and T cell numbers were decreased, and the
motility of the few tumor-infiltrating T cells was more diffuse. Although it has long been
established that the premise of immune surveillance is based on T cell recognition of
tumor-associated antigens, it will be interesting to explore whether reaction to tissue
injury in and of itself is enough to set off a parallel T cell surveillance mechanism in
tumor. In fact, the immune infiltrates during wound healing bear strong similarity to
those in tumors, and cancer has been suitably termed “a wound that never heals35.” In
this regard, groups of antigen non-specific T cells identified in tumor and named
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“bystander T cells” have unveiled an interesting area in tumor immunology. Whether
“bystander T cells” are recruited due to the tumor or tissue damage remains a matter of
speculation. In support of the latter, a study showed that bystander T cells can be
redirected to kill the stromal component (also a component of wounds) thereby causing
tumor regression556. Nevertheless, one of the goals of future studies should be
focused on elucidating the signals governing the recruitment of “bystander” T cells to
the tumor, determine their interaction partners in the tumor and how they differ from
antigen-experienced T cells, delineate the factors that regulate them, and potentially
manipulate them for therapy.
5.4. Improvement in intravital imaging of immune cell dynamics in tumor
Generally, the extent of visualization during intravital imaging is limited by both
the diffraction index of the tissue being imaged and the numerical aperture of the
imaging objective441,557,558. In particular, intravital imaging in the brain is complicated by
the layers of protective tissue and the high lipid content of brain cells, which increase
light scattering and reduces the depth of tissue that can be sampled441. Although microendoscopes have been used for deep tissue imaging of tumor in mice brain, the
traumatic nature of this approach may confound real immune cell behavior and
function559. In addition, recent development of tissue “clearing”, which is a systematic
process that has been applied to eliminate lipid from the brain and preserves only
cellular architecture, has enabled high-resolution visualization of deep brain regions
that were otherwise unreachable by previous techniques; however, such techniques
can only be applied to non-living fixed brain tissues560,561. Another limitation in imaging
is the numerical aperture of the imaging objective lens561. This limits sampling of
immune cell interactions in large tumors located in a three-dimensional space and the
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extent to which analysis can be done to understand the behavior of T cells in the tumor.
In general, despite the advantage of two-photon microscopes over confocal imaging in
terms of depth and other qualities, imaging large and deep areas of the intact brain still
remains a challenge.
5.5. Significance of this study and implications for cancer immunotherapy
I have developed and applied a novel experimental system in illuminating the
early immune cell events in brain tumor beginning at a single cell level. In combination
with this, I have applied broadly conventional imaging approaches in studying immune
cell dynamics in different brain tumors and elucidated DC-T cell interactions. Given the
differences in immune cell recruitment and tumor progression in the tumor models
used, it will be important to profile tumor cell genes from each tumor type as well as
sequence the antigens presumably recognized by T cells to create a clearer picture of
the differences between experimental tumor types and enhance studies that may be
relevant in better understanding human tumors. GEMM tumor models are the gold
standard for understanding biological phenomena and especially for translating
research findings to the clinic. Therefore, it will be crucial to evaluate DC-T cell
interactions in appropriate GEMM models that harbor genetic mutations that are known
to drive progression of human tumors and possibly contribute to tumor immunogenicity.
I show here that myeloid cells are organized in distinct compartments within
brain tumor microenvironment. Importantly, CD11c+ DCs reside mostly at the tumor
margin. However, present analysis of tumor immune cell infiltration in patients with
brain tumor is done using tumor biopsy specimen obtained from within the core of the
tumor that may not truly reflect the immune infiltrates in the tumor microenvironment.
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Therefore, the findings here should be translated to the clinic to guide neurosurgical
biopsy procedures for immunological evaluation especially when immunotherapy
strategies are being considered. I also show that CD11c+ DCs and T cells are
correlated in space and that CD11c+ DCs control the retention and motility of effector T
cells in brain tumors. Consistently, tissue-resident memory T cells have also been
shown to be preferentially organized around DCs for prolonged periods after clearance
of model viral infections in mice brain371. This has implications for brain tumor
immunotherapy as interactions between T cells and DCs in brain tumors has been
unappreciated as opposed to microglia and macrophages. Identifying and
understanding potential molecular signals that control recruitment, retention, and
survival of DCs in the tumor could present targets for modulating anti-tumor immune
response, for example by specifically eliminating tumor-infiltrating DCs and associated
T cells molecularly, and replacing the tumor microenvironment with “new” immune cells
in addition to therapies that prevent tumor-mediated immune suppression. This strategy
may find relevance in cellular transplantation in which whole body radiation, which
could be injurious to normal tissue, is used to eliminate immune cells such as T cells
before adoptive transfer of exogenous cells. Further, since DCs and T cells appear to
work together during anti-tumor immune response, another strategy for tumor
immunotherapy could entail adoptive transfer of competent antigen-presenting DCs
and cytotoxic T cells serially or simultaneously into patients rather than conventional
approaches employing either DCs of T cells exclusively. This strategy may aid in the
persistence of adoptively transferred T cells in the tumor. Also, in addition to adoptive
transfer of DCs, adjuvants such as Flt3-ligand vaccine (FVAX) may be used to
stimulate increase in endogenous DC numbers in situations where exogenous DC cell
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culture may produce low yield or alterations in DC functions470. Another avenue for
application is in checkpoint blockade immunotherapy. The present goal for this type of
therapy is to increase the percentage of patients that respond to this treatment
strategy. Therefore, based on the data here, there is compelling reason to examine the
composition of DCs in brain tumor or other tumor types in patients before initiating
treatment or in patients who show partial or no response to treatment to determine
whether lack of DCs may play a role in this regard. This could serve as a method of
predicting treatment response. There is also support for combining DC treatment
methods such as adoptive cell transfer or FVAX with T cell checkpoint blockade.
However, more work needs to be done to better understand how DCs may regulate T
cells in tumor during checkpoint blockade immunotherapy in preclinical models.
In addition, I have also demonstrated a role for Fractalkine signaling in brain
tumor progression and in the control of tumor-infiltrating T cell recruitment and
migration. Although I have not directly elaborated on the function of Fractalkine ligand
in tumor progression or immune cell dynamics, this molecular pathway is an attractive
target for modulating immune cells and potentially enhancing cancer immunotherapy. A
major goal in adoptive T cell therapy in which infusion of exogenous T cell infiltrating
lymphocytes or CAR T cells is done in patients with tumor, is to successfully direct the
infused T cells to the tissue of interest. Thus, engineering CAR T cells with chemokine
receptors such as CX3CR1 may help enhance cellular migration to the tumor.
However, further studies are required to understand whether there is a functional
significance to the changes in Fractalkine receptor CX3CR1, in GBM patients, and
whether mouse observations are applicable in human brain tumor. Another aspect of
this pathway that could be potentially modulated is the expression of ADAM10 and 17.
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These MMPs are needed for Fractalkine cleavage and secretion into the circulation.
Therefore, strategies that increase their expression may help maintain the secretion
and levels of soluble Fractalkine in the circulation. This may assist in preventing
downregulation of CX3CR1 expression in anti-tumor myeloid cells562. However, more
work is required to better understand the regulating mechanisms involved in this
process.
In sum, I have elucidated the dynamic behavior of immune cells in brain tumor
and the studies conducted in this thesis have revealed novel cellular and molecular
regulatory mechanisms in immune cell recruitment and interaction. This work paves
way for exploration of other mechanisms involved in the regulation of brain tumor
immune surveillance and potentially other cancer types.
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